WO2019246520A1 - Aminobisphosphonates as latency reversing agents and combination treatments for hiv cure - Google Patents
Aminobisphosphonates as latency reversing agents and combination treatments for hiv cure Download PDFInfo
- Publication number
- WO2019246520A1 WO2019246520A1 PCT/US2019/038469 US2019038469W WO2019246520A1 WO 2019246520 A1 WO2019246520 A1 WO 2019246520A1 US 2019038469 W US2019038469 W US 2019038469W WO 2019246520 A1 WO2019246520 A1 WO 2019246520A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- hiv
- bisphosphonate
- inhibitor
- expanded
- Prior art date
Links
- 238000011284 combination treatment Methods 0.000 title description 2
- 238000000034 method Methods 0.000 claims abstract description 100
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 71
- 229940122361 Bisphosphonate Drugs 0.000 claims abstract description 66
- 150000004663 bisphosphonates Chemical class 0.000 claims abstract description 61
- 239000003112 inhibitor Substances 0.000 claims abstract description 46
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 45
- 102000003964 Histone deacetylase Human genes 0.000 claims abstract description 20
- 108090000353 Histone deacetylase Proteins 0.000 claims abstract description 20
- 210000004027 cell Anatomy 0.000 claims description 304
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 claims description 119
- 239000008194 pharmaceutical composition Substances 0.000 claims description 85
- 230000014509 gene expression Effects 0.000 claims description 55
- 239000000556 agonist Substances 0.000 claims description 49
- 238000011225 antiretroviral therapy Methods 0.000 claims description 45
- 230000037361 pathway Effects 0.000 claims description 33
- 230000003612 virological effect Effects 0.000 claims description 33
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 29
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 claims description 28
- 108090000623 proteins and genes Proteins 0.000 claims description 27
- 208000031886 HIV Infections Diseases 0.000 claims description 25
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 claims description 24
- 229940062527 alendronate Drugs 0.000 claims description 24
- 230000001973 epigenetic effect Effects 0.000 claims description 24
- 239000003607 modifier Substances 0.000 claims description 24
- 208000037357 HIV infectious disease Diseases 0.000 claims description 23
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 23
- 229940046231 pamidronate Drugs 0.000 claims description 22
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 claims description 21
- 101710196623 Stimulator of interferon genes protein Proteins 0.000 claims description 18
- 102100035533 Stimulator of interferon genes protein Human genes 0.000 claims description 18
- 239000000427 antigen Substances 0.000 claims description 18
- 108091007433 antigens Proteins 0.000 claims description 17
- 102000036639 antigens Human genes 0.000 claims description 17
- 108091007065 BIRCs Proteins 0.000 claims description 15
- 102000055031 Inhibitor of Apoptosis Proteins Human genes 0.000 claims description 15
- 239000012190 activator Substances 0.000 claims description 15
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 claims description 13
- 108090000315 Protein Kinase C Proteins 0.000 claims description 13
- 102000003923 Protein Kinase C Human genes 0.000 claims description 13
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 claims description 13
- UGEPSJNLORCRBO-UHFFFAOYSA-N [3-(dimethylamino)-1-hydroxy-1-phosphonopropyl]phosphonic acid Chemical compound CN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O UGEPSJNLORCRBO-UHFFFAOYSA-N 0.000 claims description 13
- 229940015872 ibandronate Drugs 0.000 claims description 13
- PUUSSSIBPPTKTP-UHFFFAOYSA-N neridronic acid Chemical compound NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O PUUSSSIBPPTKTP-UHFFFAOYSA-N 0.000 claims description 13
- 229950010733 neridronic acid Drugs 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- 230000002441 reversible effect Effects 0.000 claims description 13
- 229940089617 risedronate Drugs 0.000 claims description 13
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 claims description 13
- 229960004276 zoledronic acid Drugs 0.000 claims description 13
- 102000038030 PI3Ks Human genes 0.000 claims description 11
- 108091007960 PI3Ks Proteins 0.000 claims description 11
- 230000001939 inductive effect Effects 0.000 claims description 11
- 241000700605 Viruses Species 0.000 claims description 10
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims description 10
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims description 9
- 102100033189 Diablo IAP-binding mitochondrial protein Human genes 0.000 claims description 7
- 101710101225 Diablo IAP-binding mitochondrial protein Proteins 0.000 claims description 7
- 101710156605 Diablo homolog, mitochondrial Proteins 0.000 claims description 7
- HRNLUBSXIHFDHP-UHFFFAOYSA-N N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]benzamide Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC1=NC=CC(C=2C=NC=CC=2)=N1 HRNLUBSXIHFDHP-UHFFFAOYSA-N 0.000 claims description 7
- NCNRHFGMJRPRSK-MDZDMXLPSA-N belinostat Chemical group ONC(=O)\C=C\C1=CC=CC(S(=O)(=O)NC=2C=CC=CC=2)=C1 NCNRHFGMJRPRSK-MDZDMXLPSA-N 0.000 claims description 7
- INVTYAOGFAGBOE-UHFFFAOYSA-N entinostat Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 claims description 7
- FPOHNWQLNRZRFC-ZHACJKMWSA-N panobinostat Chemical compound CC=1NC2=CC=CC=C2C=1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FPOHNWQLNRZRFC-ZHACJKMWSA-N 0.000 claims description 7
- 102000004127 Cytokines Human genes 0.000 claims description 5
- 108090000695 Cytokines Proteins 0.000 claims description 5
- 239000003638 chemical reducing agent Substances 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 210000005259 peripheral blood Anatomy 0.000 claims description 3
- 239000011886 peripheral blood Substances 0.000 claims description 3
- 230000007733 viral latency Effects 0.000 claims description 3
- 230000001024 immunotherapeutic effect Effects 0.000 abstract description 5
- -1 sesterterpenoids Chemical class 0.000 description 55
- 108010002350 Interleukin-2 Proteins 0.000 description 48
- 102000000588 Interleukin-2 Human genes 0.000 description 48
- 239000002552 dosage form Substances 0.000 description 44
- 210000004970 cd4 cell Anatomy 0.000 description 41
- 238000011282 treatment Methods 0.000 description 34
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 33
- 238000004519 manufacturing process Methods 0.000 description 33
- 239000000203 mixture Substances 0.000 description 32
- 150000001875 compounds Chemical class 0.000 description 31
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 30
- 239000004480 active ingredient Substances 0.000 description 29
- 238000003556 assay Methods 0.000 description 26
- 239000012636 effector Substances 0.000 description 25
- 239000013641 positive control Substances 0.000 description 24
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 21
- 208000015181 infectious disease Diseases 0.000 description 21
- 230000006870 function Effects 0.000 description 20
- 229920002301 cellulose acetate Polymers 0.000 description 19
- 238000013270 controlled release Methods 0.000 description 19
- 239000000546 pharmaceutical excipient Substances 0.000 description 19
- 229960000237 vorinostat Drugs 0.000 description 19
- 231100000433 cytotoxic Toxicity 0.000 description 18
- 230000001472 cytotoxic effect Effects 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- 235000002639 sodium chloride Nutrition 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 17
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 17
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 230000004913 activation Effects 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 16
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 16
- 230000005764 inhibitory process Effects 0.000 description 16
- 150000003505 terpenes Chemical class 0.000 description 16
- 230000001154 acute effect Effects 0.000 description 15
- 201000010099 disease Diseases 0.000 description 15
- 239000012071 phase Substances 0.000 description 15
- KJTLQQUUPVSXIM-ZCFIWIBFSA-M (R)-mevalonate Chemical compound OCC[C@](O)(C)CC([O-])=O KJTLQQUUPVSXIM-ZCFIWIBFSA-M 0.000 description 14
- KJTLQQUUPVSXIM-UHFFFAOYSA-N DL-mevalonic acid Natural products OCCC(O)(C)CC(O)=O KJTLQQUUPVSXIM-UHFFFAOYSA-N 0.000 description 14
- 101710149279 Small delta antigen Proteins 0.000 description 14
- 108091008874 T cell receptors Proteins 0.000 description 14
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 14
- 102100022563 Tubulin polymerization-promoting protein Human genes 0.000 description 14
- 230000004044 response Effects 0.000 description 14
- 239000003981 vehicle Substances 0.000 description 14
- 229920002472 Starch Polymers 0.000 description 13
- 239000000839 emulsion Substances 0.000 description 13
- 239000012528 membrane Substances 0.000 description 13
- 150000003839 salts Chemical class 0.000 description 13
- 235000019698 starch Nutrition 0.000 description 13
- 239000000725 suspension Substances 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 238000013459 approach Methods 0.000 description 12
- 229920001577 copolymer Polymers 0.000 description 12
- 239000003937 drug carrier Substances 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- 230000015654 memory Effects 0.000 description 12
- 239000000843 powder Substances 0.000 description 12
- 230000035755 proliferation Effects 0.000 description 12
- 239000003826 tablet Substances 0.000 description 12
- 230000001225 therapeutic effect Effects 0.000 description 12
- 108010010803 Gelatin Proteins 0.000 description 11
- 239000008273 gelatin Substances 0.000 description 11
- 229920000159 gelatin Polymers 0.000 description 11
- 229940014259 gelatin Drugs 0.000 description 11
- 235000019322 gelatine Nutrition 0.000 description 11
- 235000011852 gelatine desserts Nutrition 0.000 description 11
- NUHSROFQTUXZQQ-UHFFFAOYSA-N isopentenyl diphosphate Chemical compound CC(=C)CCO[P@](O)(=O)OP(O)(O)=O NUHSROFQTUXZQQ-UHFFFAOYSA-N 0.000 description 11
- 229920001223 polyethylene glycol Polymers 0.000 description 11
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 11
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 11
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 11
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 10
- 238000003559 RNA-seq method Methods 0.000 description 10
- 102000002689 Toll-like receptor Human genes 0.000 description 10
- 108020000411 Toll-like receptor Proteins 0.000 description 10
- 239000002775 capsule Substances 0.000 description 10
- 238000000684 flow cytometry Methods 0.000 description 10
- 235000011187 glycerol Nutrition 0.000 description 10
- 229960005150 glycerol Drugs 0.000 description 10
- 239000011159 matrix material Substances 0.000 description 10
- 239000003921 oil Substances 0.000 description 10
- 229920000642 polymer Polymers 0.000 description 10
- 230000003389 potentiating effect Effects 0.000 description 10
- 239000003755 preservative agent Substances 0.000 description 10
- 230000029812 viral genome replication Effects 0.000 description 10
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 9
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 9
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 9
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 9
- 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 9
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 9
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 9
- 239000002202 Polyethylene glycol Substances 0.000 description 9
- 239000004372 Polyvinyl alcohol Substances 0.000 description 9
- JGPOSNWWINVNFV-UHFFFAOYSA-N carboxyfluorescein diacetate succinimidyl ester Chemical compound C=1C(OC(=O)C)=CC=C2C=1OC1=CC(OC(C)=O)=CC=C1C2(C1=C2)OC(=O)C1=CC=C2C(=O)ON1C(=O)CCC1=O JGPOSNWWINVNFV-UHFFFAOYSA-N 0.000 description 9
- 239000007891 compressed tablet Substances 0.000 description 9
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 9
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 230000003204 osmotic effect Effects 0.000 description 9
- 229920002451 polyvinyl alcohol Polymers 0.000 description 9
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 230000007420 reactivation Effects 0.000 description 9
- 230000000284 resting effect Effects 0.000 description 9
- 239000000600 sorbitol Substances 0.000 description 9
- 229960002920 sorbitol Drugs 0.000 description 9
- 235000010356 sorbitol Nutrition 0.000 description 9
- 239000008107 starch Substances 0.000 description 9
- 229940032147 starch Drugs 0.000 description 9
- VWFJDQUYCIWHTN-YFVJMOTDSA-N 2-trans,6-trans-farnesyl diphosphate Chemical group CC(C)=CCC\C(C)=C\CC\C(C)=C\CO[P@](O)(=O)OP(O)(O)=O VWFJDQUYCIWHTN-YFVJMOTDSA-N 0.000 description 8
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 8
- 102000006354 HLA-DR Antigens Human genes 0.000 description 8
- 108010058597 HLA-DR Antigens Proteins 0.000 description 8
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 8
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 8
- 239000000499 gel Substances 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 239000008101 lactose Substances 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 7
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 7
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 7
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 7
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 7
- 229930195725 Mannitol Natural products 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 7
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 7
- 208000037581 Persistent Infection Diseases 0.000 description 7
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 7
- 229930006000 Sucrose Natural products 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- YKAYCWPQDPILSA-UHFFFAOYSA-N bromohydrin pyrophosphate Chemical compound BrCC(O)(C)CCOP(O)(=O)OP(O)(O)=O YKAYCWPQDPILSA-UHFFFAOYSA-N 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 239000000969 carrier Substances 0.000 description 7
- 230000010261 cell growth Effects 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 230000001684 chronic effect Effects 0.000 description 7
- 238000007796 conventional method Methods 0.000 description 7
- 239000000975 dye Substances 0.000 description 7
- 239000003995 emulsifying agent Substances 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- 239000008297 liquid dosage form Substances 0.000 description 7
- 239000000594 mannitol Substances 0.000 description 7
- 235000010355 mannitol Nutrition 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 230000013823 prenylation Effects 0.000 description 7
- 239000005720 sucrose Substances 0.000 description 7
- 229960004793 sucrose Drugs 0.000 description 7
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 7
- 231100000331 toxic Toxicity 0.000 description 7
- 230000002588 toxic effect Effects 0.000 description 7
- MDSIZRKJVDMQOQ-GORDUTHDSA-N (2E)-4-hydroxy-3-methylbut-2-en-1-yl diphosphate Chemical compound OCC(/C)=C/COP(O)(=O)OP(O)(O)=O MDSIZRKJVDMQOQ-GORDUTHDSA-N 0.000 description 6
- 229920002125 Sokalan® Polymers 0.000 description 6
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 6
- 230000000840 anti-viral effect Effects 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 6
- 230000000670 limiting effect Effects 0.000 description 6
- 239000006199 nebulizer Substances 0.000 description 6
- 239000002674 ointment Substances 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- CBIDRCWHNCKSTO-UHFFFAOYSA-N prenyl diphosphate Chemical compound CC(C)=CCO[P@](O)(=O)OP(O)(O)=O CBIDRCWHNCKSTO-UHFFFAOYSA-N 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 238000011200 topical administration Methods 0.000 description 6
- 239000001993 wax Substances 0.000 description 6
- 208000030507 AIDS Diseases 0.000 description 5
- 241000416162 Astragalus gummifer Species 0.000 description 5
- 102100027207 CD27 antigen Human genes 0.000 description 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 239000001856 Ethyl cellulose Substances 0.000 description 5
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 5
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 5
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 5
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 5
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 5
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 5
- 238000000585 Mann–Whitney U test Methods 0.000 description 5
- 239000004698 Polyethylene Substances 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 229920001615 Tragacanth Polymers 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 239000011230 binding agent Substances 0.000 description 5
- 230000003915 cell function Effects 0.000 description 5
- 235000010980 cellulose Nutrition 0.000 description 5
- 229920002678 cellulose Polymers 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 235000011180 diphosphates Nutrition 0.000 description 5
- 239000007884 disintegrant Substances 0.000 description 5
- 239000002270 dispersing agent Substances 0.000 description 5
- 230000008029 eradication Effects 0.000 description 5
- 235000019325 ethyl cellulose Nutrition 0.000 description 5
- 229920001249 ethyl cellulose Polymers 0.000 description 5
- 235000003599 food sweetener Nutrition 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 229940093915 gynecological organic acid Drugs 0.000 description 5
- 238000009169 immunotherapy Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 229920000609 methyl cellulose Polymers 0.000 description 5
- 235000010981 methylcellulose Nutrition 0.000 description 5
- 239000001923 methylcellulose Substances 0.000 description 5
- 229960002900 methylcellulose Drugs 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 150000007524 organic acids Chemical class 0.000 description 5
- 235000005985 organic acids Nutrition 0.000 description 5
- 238000007911 parenteral administration Methods 0.000 description 5
- 229920000573 polyethylene Polymers 0.000 description 5
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000008299 semisolid dosage form Substances 0.000 description 5
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 239000000375 suspending agent Substances 0.000 description 5
- 239000003765 sweetening agent Substances 0.000 description 5
- 239000006188 syrup Substances 0.000 description 5
- 235000020357 syrup Nutrition 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 239000000080 wetting agent Substances 0.000 description 5
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 4
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 4
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 4
- 229940045513 CTLA4 antagonist Drugs 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 108010077544 Chromatin Proteins 0.000 description 4
- 229920000858 Cyclodextrin Polymers 0.000 description 4
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 4
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 4
- 239000005977 Ethylene Substances 0.000 description 4
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 208000029725 Metabolic bone disease Diseases 0.000 description 4
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 4
- 208000001132 Osteoporosis Diseases 0.000 description 4
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 4
- 206010042566 Superinfection Diseases 0.000 description 4
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 4
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 4
- 235000010443 alginic acid Nutrition 0.000 description 4
- 229920000615 alginic acid Polymers 0.000 description 4
- 239000004599 antimicrobial Substances 0.000 description 4
- 229940124522 antiretrovirals Drugs 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 229920006217 cellulose acetate butyrate Polymers 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 210000003483 chromatin Anatomy 0.000 description 4
- 238000003501 co-culture Methods 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 238000007906 compression Methods 0.000 description 4
- 230000006835 compression Effects 0.000 description 4
- 235000012343 cottonseed oil Nutrition 0.000 description 4
- 239000002385 cottonseed oil Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 229920001477 hydrophilic polymer Polymers 0.000 description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 4
- 239000004005 microsphere Substances 0.000 description 4
- 210000000822 natural killer cell Anatomy 0.000 description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 239000002357 osmotic agent Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229920001451 polypropylene glycol Polymers 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- 238000000513 principal component analysis Methods 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 239000006215 rectal suppository Substances 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 229960002855 simvastatin Drugs 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 235000007586 terpenes Nutrition 0.000 description 4
- 235000010487 tragacanth Nutrition 0.000 description 4
- 229940116362 tragacanth Drugs 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 239000006216 vaginal suppository Substances 0.000 description 4
- 229940117958 vinyl acetate Drugs 0.000 description 4
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 3
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 3
- 229920001661 Chitosan Polymers 0.000 description 3
- 230000005778 DNA damage Effects 0.000 description 3
- 231100000277 DNA damage Toxicity 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- VWFJDQUYCIWHTN-UHFFFAOYSA-N Farnesyl pyrophosphate Natural products CC(C)=CCCC(C)=CCCC(C)=CCOP(O)(=O)OP(O)(O)=O VWFJDQUYCIWHTN-UHFFFAOYSA-N 0.000 description 3
- 229920002907 Guar gum Polymers 0.000 description 3
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 3
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 3
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- 206010049088 Osteopenia Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000005867 T cell response Effects 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 3
- 229930003316 Vitamin D Natural products 0.000 description 3
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 230000000735 allogeneic effect Effects 0.000 description 3
- 239000008135 aqueous vehicle Substances 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 239000006172 buffering agent Substances 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 229940105329 carboxymethylcellulose Drugs 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 238000002659 cell therapy Methods 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- 239000007910 chewable tablet Substances 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 239000008139 complexing agent Substances 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 238000007908 dry granulation Methods 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 239000002702 enteric coating Substances 0.000 description 3
- 238000009505 enteric coating Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 3
- 150000002170 ethers Chemical class 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000010408 film Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 235000010417 guar gum Nutrition 0.000 description 3
- 239000000665 guar gum Substances 0.000 description 3
- 229960002154 guar gum Drugs 0.000 description 3
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 3
- 239000000017 hydrogel Substances 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 3
- 229960000367 inositol Drugs 0.000 description 3
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 3
- 239000007951 isotonicity adjuster Substances 0.000 description 3
- 239000003589 local anesthetic agent Substances 0.000 description 3
- 229960005015 local anesthetics Drugs 0.000 description 3
- 229960004844 lovastatin Drugs 0.000 description 3
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 3
- 239000007937 lozenge Substances 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 230000011987 methylation Effects 0.000 description 3
- 238000007069 methylation reaction Methods 0.000 description 3
- 239000000693 micelle Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 239000002687 nonaqueous vehicle Substances 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 230000002085 persistent effect Effects 0.000 description 3
- 235000019271 petrolatum Nutrition 0.000 description 3
- 239000004584 polyacrylic acid Substances 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 3
- 229960004063 propylene glycol Drugs 0.000 description 3
- 235000013772 propylene glycol Nutrition 0.000 description 3
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical class CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 3
- 239000003352 sequestering agent Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 3
- 229940001584 sodium metabisulfite Drugs 0.000 description 3
- 235000010262 sodium metabisulphite Nutrition 0.000 description 3
- 235000010199 sorbic acid Nutrition 0.000 description 3
- 239000004334 sorbic acid Substances 0.000 description 3
- 229940075582 sorbic acid Drugs 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 229940044655 toll-like receptor 9 agonist Drugs 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical compound CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 235000019166 vitamin D Nutrition 0.000 description 3
- 239000011710 vitamin D Substances 0.000 description 3
- 150000003710 vitamin D derivatives Chemical class 0.000 description 3
- 229940046008 vitamin d Drugs 0.000 description 3
- 239000008136 water-miscible vehicle Substances 0.000 description 3
- 238000005550 wet granulation Methods 0.000 description 3
- 229920001285 xanthan gum Polymers 0.000 description 3
- 235000010493 xanthan gum Nutrition 0.000 description 3
- 239000000230 xanthan gum Substances 0.000 description 3
- 229940082509 xanthan gum Drugs 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 2
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 2
- ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- AAAQFGUYHFJNHI-SFHVURJKSA-N 2-[(4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-N-ethylacetamide Chemical compound N([C@H](C1=NN=C(C)N1C1=CC=C(OC)C=C11)CC(=O)NCC)=C1C1=CC=C(Cl)C=C1 AAAQFGUYHFJNHI-SFHVURJKSA-N 0.000 description 2
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 2
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 206010000807 Acute HIV infection Diseases 0.000 description 2
- 230000007730 Akt signaling Effects 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 2
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- 229920002498 Beta-glucan Polymers 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- SOGAXMICEFXMKE-UHFFFAOYSA-N Butylmethacrylate Chemical compound CCCCOC(=O)C(C)=C SOGAXMICEFXMKE-UHFFFAOYSA-N 0.000 description 2
- 102000049320 CD36 Human genes 0.000 description 2
- 108010045374 CD36 Antigens Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 102100025470 Carcinoembryonic antigen-related cell adhesion molecule 8 Human genes 0.000 description 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 2
- DQEFEBPAPFSJLV-UHFFFAOYSA-N Cellulose propionate Chemical compound CCC(=O)OCC1OC(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C1OC1C(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C(COC(=O)CC)O1 DQEFEBPAPFSJLV-UHFFFAOYSA-N 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 2
- 229920000896 Ethulose Polymers 0.000 description 2
- 239000001859 Ethyl hydroxyethyl cellulose Substances 0.000 description 2
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 2
- 102100035111 Farnesyl pyrophosphate synthase Human genes 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 102100035716 Glycophorin-A Human genes 0.000 description 2
- 108091005250 Glycophorins Proteins 0.000 description 2
- RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 2
- 102100038719 Histone deacetylase 7 Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 2
- 101000914320 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 8 Proteins 0.000 description 2
- 101001032113 Homo sapiens Histone deacetylase 7 Proteins 0.000 description 2
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 description 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- VDJHFHXMUKFKET-UHFFFAOYSA-N Ingenol mebutate Natural products CC1CC2C(C)(C)C2C2C=C(CO)C(O)C3(O)C(OC(=O)C(C)=CC)C(C)=CC31C2=O VDJHFHXMUKFKET-UHFFFAOYSA-N 0.000 description 2
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 description 2
- 229920000161 Locust bean gum Polymers 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 239000008156 Ringer's lactate solution Substances 0.000 description 2
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 description 2
- 229920001800 Shellac Polymers 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 102000004357 Transferases Human genes 0.000 description 2
- 108090000992 Transferases Proteins 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- SPEUIVXLLWOEMJ-UHFFFAOYSA-N acetaldehyde dimethyl acetal Natural products COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 2
- 150000001241 acetals Chemical class 0.000 description 2
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000000305 astragalus gummifer gum Substances 0.000 description 2
- 229960005370 atorvastatin Drugs 0.000 description 2
- 229960002756 azacitidine Drugs 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 230000037182 bone density Effects 0.000 description 2
- 229940125763 bromodomain inhibitor Drugs 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229960002681 calcium alginate Drugs 0.000 description 2
- 235000010410 calcium alginate Nutrition 0.000 description 2
- 239000000648 calcium alginate Substances 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 229920001727 cellulose butyrate Polymers 0.000 description 2
- 229920006218 cellulose propionate Polymers 0.000 description 2
- WZNRVWBKYDHTKI-UHFFFAOYSA-N cellulose, acetate 1,2,4-benzenetricarboxylate Chemical compound OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O.OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O.CC(=O)OCC1OC(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(COC(C)=O)O1.CC(=O)OCC1OC(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(COC(C)=O)O1.OC(=O)C1=CC(C(=O)O)=CC=C1C(=O)OCC1C(OC2C(C(OC(=O)C=3C(=CC(=CC=3)C(O)=O)C(O)=O)C(OC(=O)C=3C(=CC(=CC=3)C(O)=O)C(O)=O)C(COC(=O)C=3C(=CC(=CC=3)C(O)=O)C(O)=O)O2)OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)C(OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)C(OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)C(OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)O1 WZNRVWBKYDHTKI-UHFFFAOYSA-N 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229950009221 chidamide Drugs 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- QECMENZMDBOLDR-AWEZNQCLSA-N cpi 203 Chemical compound N([C@@H](CC(N)=O)C1=NN=C(N1C=1SC(C)=C(C)C=11)C)=C1C1=CC=C(Cl)C=C1 QECMENZMDBOLDR-AWEZNQCLSA-N 0.000 description 2
- 229960000913 crospovidone Drugs 0.000 description 2
- 238000010614 crotonylation reaction Methods 0.000 description 2
- 239000002577 cryoprotective agent Substances 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000008716 dendritic activation Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 230000004041 dendritic cell maturation Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 239000008355 dextrose injection Substances 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000007907 direct compression Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 229940031098 ethanolamine Drugs 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 235000019326 ethyl hydroxyethyl cellulose Nutrition 0.000 description 2
- 235000010944 ethyl methyl cellulose Nutrition 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229960005167 everolimus Drugs 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000007941 film coated tablet Substances 0.000 description 2
- 238000009501 film coating Methods 0.000 description 2
- 239000007888 film coating Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229960003765 fluvastatin Drugs 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 238000002825 functional assay Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 230000030279 gene silencing Effects 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 235000019314 gum ghatti Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 239000012642 immune effector Substances 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000011261 inert gas Substances 0.000 description 2
- VEBVPUXQAPLADL-POYOOMFHSA-N ingenol Chemical class C1=C(CO)[C@@H](O)[C@]2(O)[C@@H](O)C(C)=C[C@]32[C@H](C)C[C@H]2C(C)(C)[C@H]2[C@H]1C3=O VEBVPUXQAPLADL-POYOOMFHSA-N 0.000 description 2
- VDJHFHXMUKFKET-WDUFCVPESA-N ingenol mebutate Chemical compound C[C@@H]1C[C@H]2C(C)(C)[C@H]2[C@@H]2C=C(CO)[C@@H](O)[C@]3(O)[C@@H](OC(=O)C(\C)=C/C)C(C)=C[C@]31C2=O VDJHFHXMUKFKET-WDUFCVPESA-N 0.000 description 2
- 229960002993 ingenol mebutate Drugs 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000010902 jet-milling Methods 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- IHLWXZNPOVMUFQ-UHFFFAOYSA-N laccaic acid A Chemical compound CC(=O)NCCC1=CC=C(O)C(C=2C(=C3C(=O)C4=C(C(O)=O)C(C(O)=O)=C(O)C=C4C(=O)C3=C(O)C=2O)O)=C1 IHLWXZNPOVMUFQ-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 229950000822 lefitolimod Drugs 0.000 description 2
- 229940095570 lescol Drugs 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 235000010420 locust bean gum Nutrition 0.000 description 2
- 239000000711 locust bean gum Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- GTCAXTIRRLKXRU-UHFFFAOYSA-N methyl carbamate Chemical compound COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 229920003087 methylethyl cellulose Polymers 0.000 description 2
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 description 2
- 229950009116 mevastatin Drugs 0.000 description 2
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 229940066842 petrolatum Drugs 0.000 description 2
- ZQBAKBUEJOMQEX-UHFFFAOYSA-N phenyl salicylate Chemical compound OC1=CC=CC=C1C(=O)OC1=CC=CC=C1 ZQBAKBUEJOMQEX-UHFFFAOYSA-N 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 2
- 229960002797 pitavastatin Drugs 0.000 description 2
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
- 229920002492 poly(sulfone) Polymers 0.000 description 2
- 229920000570 polyether Polymers 0.000 description 2
- 229920006393 polyether sulfone Polymers 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 2
- 229920000098 polyolefin Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 229920002689 polyvinyl acetate Polymers 0.000 description 2
- 239000011118 polyvinyl acetate Substances 0.000 description 2
- 229920000915 polyvinyl chloride Polymers 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 229920001290 polyvinyl ester Polymers 0.000 description 2
- 229920001289 polyvinyl ether Polymers 0.000 description 2
- 229920001291 polyvinyl halide Polymers 0.000 description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 229960002965 pravastatin Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- FECGNJPYVFEKOD-VMPITWQZSA-N resminostat Chemical compound C1=CC(CN(C)C)=CC=C1S(=O)(=O)N1C=C(\C=C\C(=O)NO)C=C1 FECGNJPYVFEKOD-VMPITWQZSA-N 0.000 description 2
- 239000012313 reversal agent Substances 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 2
- 229960003452 romidepsin Drugs 0.000 description 2
- OHRURASPPZQGQM-UHFFFAOYSA-N romidepsin Natural products O1C(=O)C(C(C)C)NC(=O)C(=CC)NC(=O)C2CSSCCC=CC1CC(=O)NC(C(C)C)C(=O)N2 OHRURASPPZQGQM-UHFFFAOYSA-N 0.000 description 2
- 108010091666 romidepsin Proteins 0.000 description 2
- 229960000672 rosuvastatin Drugs 0.000 description 2
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 2
- 229940081974 saccharin Drugs 0.000 description 2
- 235000019204 saccharin Nutrition 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 229940113147 shellac Drugs 0.000 description 2
- 239000004208 shellac Substances 0.000 description 2
- 235000013874 shellac Nutrition 0.000 description 2
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000017550 sodium carbonate Nutrition 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000008137 solubility enhancer Substances 0.000 description 2
- 239000002195 soluble material Substances 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000007940 sugar coated tablet Substances 0.000 description 2
- 238000009495 sugar coating Methods 0.000 description 2
- SUVMJBTUFCVSAD-UHFFFAOYSA-N sulforaphane Chemical compound CS(=O)CCCCN=C=S SUVMJBTUFCVSAD-UHFFFAOYSA-N 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 229940074410 trehalose Drugs 0.000 description 2
- 229940117013 triethanolamine oleate Drugs 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- RPQZTTQVRYEKCR-WCTZXXKLSA-N zebularine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N=CC=C1 RPQZTTQVRYEKCR-WCTZXXKLSA-N 0.000 description 2
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 1
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- HPTXLHAHLXOAKV-INIZCTEOSA-N (2S)-2-(1,3-dioxo-2-isoindolyl)-3-(1H-indol-3-yl)propanoic acid Chemical class O=C1C2=CC=CC=C2C(=O)N1[C@H](C(=O)O)CC1=CNC2=CC=CC=C12 HPTXLHAHLXOAKV-INIZCTEOSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- GYYDPBCUIJTIBM-DYOGSRDZSA-N (2r,3s,4s,5r)-2-(hydroxymethyl)-6-[[(4r,5s)-4-hydroxy-3-methyl-2,6-dioxabicyclo[3.2.1]octan-8-yl]oxy]-4-methoxyoxane-3,5-diol Chemical compound O[C@@H]1[C@@H](OC)[C@@H](O)[C@@H](CO)OC1OC1[C@H]2OCC1OC(C)[C@H]2O GYYDPBCUIJTIBM-DYOGSRDZSA-N 0.000 description 1
- WLMCRYCCYXHPQF-ZVMUOSSASA-N (2s)-1-[(2s)-2-cyclohexyl-2-[[(2s)-2-(methylamino)propanoyl]amino]acetyl]-n-[(1s,2r)-2-[6-[[(1s,2r)-1-[[(2s)-1-[(2s)-2-cyclohexyl-2-[[(2s)-2-(methylamino)propanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-2,3-dihydro-1h-inden-2-yl]oxy]hexa-2,4-diynoxy]- Chemical compound C1([C@H](NC(=O)[C@H](C)NC)C(=O)N2[C@@H](CCC2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2OCC#CC#CCO[C@H]2[C@H](C3=CC=CC=C3C2)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](NC(=O)[C@H](C)NC)C2CCCCC2)CCCCC1 WLMCRYCCYXHPQF-ZVMUOSSASA-N 0.000 description 1
- XMQUEQJCYRFIQS-YFKPBYRVSA-N (2s)-2-amino-5-ethoxy-5-oxopentanoic acid Chemical compound CCOC(=O)CC[C@H](N)C(O)=O XMQUEQJCYRFIQS-YFKPBYRVSA-N 0.000 description 1
- UFPFGVNKHCLJJO-SSKFGXFMSA-N (2s)-n-[(1s)-1-cyclohexyl-2-[(2s)-2-[4-(4-fluorobenzoyl)-1,3-thiazol-2-yl]pyrrolidin-1-yl]-2-oxoethyl]-2-(methylamino)propanamide Chemical compound C1([C@H](NC(=O)[C@H](C)NC)C(=O)N2[C@@H](CCC2)C=2SC=C(N=2)C(=O)C=2C=CC(F)=CC=2)CCCCC1 UFPFGVNKHCLJJO-SSKFGXFMSA-N 0.000 description 1
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 1
- QVCAATSEPLQVBX-FPOVZHCZSA-N (3r,4s)-3,4-bis(4-hydroxyphenyl)-8-methyl-3,4-dihydro-2h-chromen-7-ol Chemical compound C1([C@H]2[C@H](C=3C=CC(O)=C(C=3OC2)C)C=2C=CC(O)=CC=2)=CC=C(O)C=C1 QVCAATSEPLQVBX-FPOVZHCZSA-N 0.000 description 1
- GUAHPAJOXVYFON-ZETCQYMHSA-N (8S)-8-amino-7-oxononanoic acid zwitterion Chemical compound C[C@H](N)C(=O)CCCCCC(O)=O GUAHPAJOXVYFON-ZETCQYMHSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 1
- LAMIXXKAWNLXOC-INIZCTEOSA-N (S)-HDAC-42 Chemical compound O=C([C@@H](C(C)C)C=1C=CC=CC=1)NC1=CC=C(C(=O)NO)C=C1 LAMIXXKAWNLXOC-INIZCTEOSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- PRXXYMVLYKJITB-IZZDOVSWSA-N (e)-n-(2-aminophenyl)-3-[1-[4-(1-methylpyrazol-4-yl)phenyl]sulfonylpyrrol-3-yl]prop-2-enamide Chemical compound C1=NN(C)C=C1C1=CC=C(S(=O)(=O)N2C=C(\C=C\C(=O)NC=3C(=CC=CC=3)N)C=C2)C=C1 PRXXYMVLYKJITB-IZZDOVSWSA-N 0.000 description 1
- AUGCSOFQTDKPSO-RGVLZGJSSA-N (e)-n-[3-(dimethylamino)propyl]-n'-hydroxy-2-(naphthalen-1-yloxymethyl)oct-2-enediamide Chemical compound C1=CC=C2C(OC/C(C(=O)NCCCN(C)C)=C\CCCCC(=O)NO)=CC=CC2=C1 AUGCSOFQTDKPSO-RGVLZGJSSA-N 0.000 description 1
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 1
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
- LJWMTSMUQJNHOC-UHFFFAOYSA-N 1-carbazol-9-yl-3-[2-(1h-indol-3-yl)ethylamino]propan-2-ol Chemical class C12=CC=CC=C2C2=CC=CC=C2N1CC(O)CNCCC1=CNC2=CC=CC=C12 LJWMTSMUQJNHOC-UHFFFAOYSA-N 0.000 description 1
- SVPKNMBRVBMTLB-UHFFFAOYSA-N 2,3-dichloronaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(Cl)=C(Cl)C(=O)C2=C1 SVPKNMBRVBMTLB-UHFFFAOYSA-N 0.000 description 1
- WGIMXKDCVCTHGW-UHFFFAOYSA-N 2-(2-hydroxyethoxy)ethyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCOCCO WGIMXKDCVCTHGW-UHFFFAOYSA-N 0.000 description 1
- OEPOKWHJYJXUGD-UHFFFAOYSA-N 2-(3-phenylmethoxyphenyl)-1,3-thiazole-4-carbaldehyde Chemical compound O=CC1=CSC(C=2C=C(OCC=3C=CC=CC=3)C=CC=2)=N1 OEPOKWHJYJXUGD-UHFFFAOYSA-N 0.000 description 1
- JKNCOURZONDCGV-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-methylprop-2-enoate Chemical compound CN(C)CCOC(=O)C(C)=C JKNCOURZONDCGV-UHFFFAOYSA-N 0.000 description 1
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 1
- FEBUJFMRSBAMES-UHFFFAOYSA-N 2-[(2-{[3,5-dihydroxy-2-(hydroxymethyl)-6-phosphanyloxan-4-yl]oxy}-3,5-dihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-4-yl)oxy]-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl phosphinite Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(OC2C(C(OP)C(O)C(CO)O2)O)C(O)C(OC2C(C(CO)OC(P)C2O)O)O1 FEBUJFMRSBAMES-UHFFFAOYSA-N 0.000 description 1
- LXMGXMQQJNULPR-NTISSMGPSA-N 2-[(4S)-6-(4-chlorophenyl)-1-methyl-4H-[1,2]oxazolo[5,4-d][2]benzazepin-4-yl]acetamide hydrate Chemical compound O.Cc1noc2[C@H](CC(N)=O)N=C(c3ccc(Cl)cc3)c3ccccc3-c12 LXMGXMQQJNULPR-NTISSMGPSA-N 0.000 description 1
- 125000005273 2-acetoxybenzoic acid group Chemical group 0.000 description 1
- CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 description 1
- JRMAQQQTXDJDNC-UHFFFAOYSA-M 2-ethoxy-2-oxoacetate Chemical compound CCOC(=O)C([O-])=O JRMAQQQTXDJDNC-UHFFFAOYSA-M 0.000 description 1
- WROUWQQRXUBECT-UHFFFAOYSA-N 2-ethylacrylic acid Chemical compound CCC(=C)C(O)=O WROUWQQRXUBECT-UHFFFAOYSA-N 0.000 description 1
- 125000003504 2-oxazolinyl group Chemical class O1C(=NCC1)* 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- ODJQKYXPKWQWNK-UHFFFAOYSA-N 3,3'-Thiobispropanoic acid Chemical compound OC(=O)CCSCCC(O)=O ODJQKYXPKWQWNK-UHFFFAOYSA-N 0.000 description 1
- UBLAMKHIFZBBSS-UHFFFAOYSA-N 3-Methylbutyl pentanoate Chemical compound CCCCC(=O)OCCC(C)C UBLAMKHIFZBBSS-UHFFFAOYSA-N 0.000 description 1
- MAUCONCHVWBMHK-UHFFFAOYSA-N 3-[(dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)-oxomethyl]phenoxy]ethyl]-2-benzofurancarboxamide Chemical compound O1C2=CC=CC=C2C(CN(C)C)=C1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 MAUCONCHVWBMHK-UHFFFAOYSA-N 0.000 description 1
- PRDJGNVQBVXXEO-UHFFFAOYSA-N 3-cyanopropyl carbamimidothioate Chemical compound NC(=N)SCCCC#N PRDJGNVQBVXXEO-UHFFFAOYSA-N 0.000 description 1
- MJKVTPMWOKAVMS-UHFFFAOYSA-N 3-hydroxy-1-benzopyran-2-one Chemical class C1=CC=C2OC(=O)C(O)=CC2=C1 MJKVTPMWOKAVMS-UHFFFAOYSA-N 0.000 description 1
- WEQPBCSPRXFQQS-UHFFFAOYSA-N 4,5-dihydro-1,2-oxazole Chemical compound C1CC=NO1 WEQPBCSPRXFQQS-UHFFFAOYSA-N 0.000 description 1
- NZAQRZWBQUIBSF-UHFFFAOYSA-N 4-(4-sulfobutoxy)butane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCCOCCCCS(O)(=O)=O NZAQRZWBQUIBSF-UHFFFAOYSA-N 0.000 description 1
- SUVMJBTUFCVSAD-JTQLQIEISA-N 4-Methylsulfinylbutyl isothiocyanate Natural products C[S@](=O)CCCCN=C=S SUVMJBTUFCVSAD-JTQLQIEISA-N 0.000 description 1
- IDYKCXHJJGMAEV-RRKCRQDMSA-N 4-amino-5-fluoro-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound C1=C(F)C(N)=NC(=O)N1[C@@H]1O[C@H](CO)[C@@H](O)C1 IDYKCXHJJGMAEV-RRKCRQDMSA-N 0.000 description 1
- JDYDEJYIVZNWQU-UHFFFAOYSA-N 4-chloro-n-(4-hydroxynaphthalen-1-yl)-3-nitrobenzenesulfonamide Chemical compound C12=CC=CC=C2C(O)=CC=C1NS(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 JDYDEJYIVZNWQU-UHFFFAOYSA-N 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- GYLDXIAOMVERTK-UHFFFAOYSA-N 5-(4-amino-1-propan-2-yl-3-pyrazolo[3,4-d]pyrimidinyl)-1,3-benzoxazol-2-amine Chemical compound C12=C(N)N=CN=C2N(C(C)C)N=C1C1=CC=C(OC(N)=N2)C2=C1 GYLDXIAOMVERTK-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- VUVUVNZRUGEAHB-CYBMUJFWSA-N 7-(3,5-dimethyl-4-isoxazolyl)-8-methoxy-1-[(1R)-1-(2-pyridinyl)ethyl]-3H-imidazo[4,5-c]quinolin-2-one Chemical compound C1([C@@H](C)N2C3=C4C=C(C(=CC4=NC=C3NC2=O)C2=C(ON=C2C)C)OC)=CC=CC=N1 VUVUVNZRUGEAHB-CYBMUJFWSA-N 0.000 description 1
- PLIVFNIUGLLCEK-UHFFFAOYSA-N 7-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]oxy-n-hydroxyheptanamide Chemical compound C=12C=C(OCCCCCCC(=O)NO)C(OC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 PLIVFNIUGLLCEK-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 102100035709 Acetyl-coenzyme A synthetase, cytoplasmic Human genes 0.000 description 1
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 244000106483 Anogeissus latifolia Species 0.000 description 1
- 235000011514 Anogeissus latifolia Nutrition 0.000 description 1
- 101100506410 Arabidopsis thaliana HDA7 gene Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- PKWRMUKBEYJEIX-DXXQBUJASA-N Birinapant Chemical compound CN[C@@H](C)C(=O)N[C@@H](CC)C(=O)N1C[C@@H](O)C[C@H]1CC1=C(C2=C(C3=CC=C(F)C=C3N2)C[C@H]2N(C[C@@H](O)C2)C(=O)[C@H](CC)NC(=O)[C@H](C)NC)NC2=CC(F)=CC=C12 PKWRMUKBEYJEIX-DXXQBUJASA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102000001805 Bromodomains Human genes 0.000 description 1
- 108050009021 Bromodomains Proteins 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 102100025371 Butyrophilin-like protein 8 Human genes 0.000 description 1
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 108091033409 CRISPR Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- BCZXFFBUYPCTSJ-UHFFFAOYSA-L Calcium propionate Chemical compound [Ca+2].CCC([O-])=O.CCC([O-])=O BCZXFFBUYPCTSJ-UHFFFAOYSA-L 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 229920001747 Cellulose diacetate Polymers 0.000 description 1
- 229920002284 Cellulose triacetate Polymers 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 239000004709 Chlorinated polyethylene Substances 0.000 description 1
- 241000206575 Chondrus crispus Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 244000205754 Colocasia esculenta Species 0.000 description 1
- 235000006481 Colocasia esculenta Nutrition 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical class C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 101710125754 Farnesyl pyrophosphate synthase Proteins 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 1
- GVVPGTZRZFNKDS-YFHOEESVSA-N Geranyl diphosphate Natural products CC(C)=CCC\C(C)=C/COP(O)(=O)OP(O)(O)=O GVVPGTZRZFNKDS-YFHOEESVSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000001922 Gum ghatti Substances 0.000 description 1
- 229920000569 Gum karaya Polymers 0.000 description 1
- 244000043261 Hevea brasiliensis Species 0.000 description 1
- 102000011787 Histone Methyltransferases Human genes 0.000 description 1
- 108010036115 Histone Methyltransferases Proteins 0.000 description 1
- 102100039999 Histone deacetylase 2 Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101000783232 Homo sapiens Acetyl-coenzyme A synthetase, cytoplasmic Proteins 0.000 description 1
- 101000934742 Homo sapiens Butyrophilin-like protein 8 Proteins 0.000 description 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 101001023007 Homo sapiens Farnesyl pyrophosphate synthase Proteins 0.000 description 1
- 101001035011 Homo sapiens Histone deacetylase 2 Proteins 0.000 description 1
- 101001007041 Homo sapiens Keratin-associated protein 4-2 Proteins 0.000 description 1
- 101001125071 Homo sapiens Neuromedin-K receptor Proteins 0.000 description 1
- 101000721034 Homo sapiens Opticin Proteins 0.000 description 1
- 101000583209 Homo sapiens Prokineticin receptor 2 Proteins 0.000 description 1
- 101000651017 Homo sapiens Pulmonary surfactant-associated protein A2 Proteins 0.000 description 1
- 101000619791 Homo sapiens Putative PRAME family member 13 Proteins 0.000 description 1
- 101001092196 Homo sapiens Ret finger protein-like 3 Proteins 0.000 description 1
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- VEBVPUXQAPLADL-UHFFFAOYSA-N Ingenol Natural products C1=C(CO)C(O)C2(O)C(O)C(C)=CC32C(C)CC2C(C)(C)C2C1C3=O VEBVPUXQAPLADL-UHFFFAOYSA-N 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical group CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 1
- DNVXATUJJDPFDM-KRWDZBQOSA-N JQ1 Chemical compound N([C@@H](CC(=O)OC(C)(C)C)C1=NN=C(N1C=1SC(C)=C(C)C=11)C)=C1C1=CC=C(Cl)C=C1 DNVXATUJJDPFDM-KRWDZBQOSA-N 0.000 description 1
- 102100028345 Keratin-associated protein 4-2 Human genes 0.000 description 1
- RFSMUFRPPYDYRD-CALCHBBNSA-N Ku-0063794 Chemical compound C1=C(CO)C(OC)=CC=C1C1=CC=C(C(=NC(=N2)N3C[C@@H](C)O[C@@H](C)C3)N3CCOCC3)C2=N1 RFSMUFRPPYDYRD-CALCHBBNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- CZQHHVNHHHRRDU-UHFFFAOYSA-N LY294002 Chemical compound C1=CC=C2C(=O)C=C(N3CCOCC3)OC2=C1C1=CC=CC=C1 CZQHHVNHHHRRDU-UHFFFAOYSA-N 0.000 description 1
- DJSGRCAKYFXCDH-UHFFFAOYSA-N Laccaic acid A Natural products CC(=O)NCCc1ccc(C)c(c1)c2c(O)c(O)c3C(=O)c4cc(O)c(C(=O)O)c(C(=O)O)c4C(=O)c3c2O DJSGRCAKYFXCDH-UHFFFAOYSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 241000218652 Larix Species 0.000 description 1
- 235000005590 Larix decidua Nutrition 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 241000195947 Lycopodium Species 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 206010027452 Metastases to bone Diseases 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 102000016397 Methyltransferase Human genes 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 229940123379 Methyltransferase inhibitor Drugs 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 101100238610 Mus musculus Msh3 gene Proteins 0.000 description 1
- 108010074246 N,N'-(2,2'-(hexa-2,4-diyne-1,6-diylbis(oxy))bis(2,3-dihydro-1H-indene-2,1-diyl))bis(1-(2-cyclohexyl-2-(2-(methylamino)propanamido)acetyl)pyrrolidine-2-carboxamide) Proteins 0.000 description 1
- DPXJXGNXKOVBJV-YLOPQIBLSA-N N,N'-(hexane-1,6-diyl)bis(1-{(2S)-2-cyclohexyl-2-[(N-methyl-L-alanyl)amino]acetyl}-L-prolyl-beta-phenyl-L-phenylalaninamide) Chemical compound C1([C@H](NC(=O)[C@H](C)NC)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](C(C=2C=CC=CC=2)C=2C=CC=CC=2)C(=O)NCCCCCCNC(=O)[C@@H](NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](NC(=O)[C@H](C)NC)C2CCCCC2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)CCCCC1 DPXJXGNXKOVBJV-YLOPQIBLSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- QGZYDVAGYRLSKP-UHFFFAOYSA-N N-[7-(hydroxyamino)-7-oxoheptyl]-2-(N-phenylanilino)-5-pyrimidinecarboxamide Chemical compound N1=CC(C(=O)NCCCCCCC(=O)NO)=CN=C1N(C=1C=CC=CC=1)C1=CC=CC=C1 QGZYDVAGYRLSKP-UHFFFAOYSA-N 0.000 description 1
- PAWIYAYFNXQGAP-UHFFFAOYSA-N N-hydroxy-2-[4-[[(1-methyl-3-indolyl)methylamino]methyl]-1-piperidinyl]-5-pyrimidinecarboxamide Chemical compound C12=CC=CC=C2N(C)C=C1CNCC(CC1)CCN1C1=NC=C(C(=O)NO)C=N1 PAWIYAYFNXQGAP-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- ZCJHPTKRISJQTN-UHFFFAOYSA-N Nanaomycin A Natural products O=C1C2=C(O)C=CC=C2C(=O)C2=C1C(C)OC(CC(O)=O)C2 ZCJHPTKRISJQTN-UHFFFAOYSA-N 0.000 description 1
- 102100023072 Neurolysin, mitochondrial Human genes 0.000 description 1
- 102100029409 Neuromedin-K receptor Human genes 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- IYBMWBISWZMEOF-UHFFFAOYSA-N O1C2=CC=CC=C2C(=O)C(Cl)C1([N+](=O)[O-])C1=CC=CC=C1 Chemical class O1C2=CC=CC=C2C(=O)C(Cl)C1([N+](=O)[O-])C1=CC=CC=C1 IYBMWBISWZMEOF-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 102100025913 Opticin Human genes 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000005062 Polybutadiene Substances 0.000 description 1
- 229920000148 Polycarbophil calcium Polymers 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 description 1
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 1
- 102100030363 Prokineticin receptor 2 Human genes 0.000 description 1
- 239000004146 Propane-1,2-diol Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 1
- NUQJULCGNZMBEF-UHFFFAOYSA-N Prostratin Natural products COC(=O)C12CC(C)C3(O)C(C=C(CO)CC4(O)C3C=C(C)C4=O)C1C2(C)C NUQJULCGNZMBEF-UHFFFAOYSA-N 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 102100027773 Pulmonary surfactant-associated protein A2 Human genes 0.000 description 1
- 102100022081 Putative PRAME family member 13 Human genes 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 102100037420 Regulator of G-protein signaling 4 Human genes 0.000 description 1
- 101710140404 Regulator of G-protein signaling 4 Proteins 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 241001068263 Replication competent viruses Species 0.000 description 1
- 102100035528 Ret finger protein-like 3 Human genes 0.000 description 1
- 102000004389 Ribonucleoproteins Human genes 0.000 description 1
- 108010081734 Ribonucleoproteins Proteins 0.000 description 1
- 229940044665 STING agonist Drugs 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 229920002305 Schizophyllan Polymers 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
- 240000006474 Theobroma bicolor Species 0.000 description 1
- 239000003490 Thiodipropionic acid Substances 0.000 description 1
- DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 description 1
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- YVPOVOVZCOOSBQ-AXHZAXLDSA-N [(1s,3r,7s,8s,8ar)-8-[2-[(2r,4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] (2s)-2-methylbutanoate;pyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=CN=C1.C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 YVPOVOVZCOOSBQ-AXHZAXLDSA-N 0.000 description 1
- WNWXXAPGHTVCDL-OKDJMAGBSA-N [(1s,3r,7s,8s,8ar)-8-[2-[(2r,4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate;pyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=CN=C1.C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 WNWXXAPGHTVCDL-OKDJMAGBSA-N 0.000 description 1
- NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 description 1
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
- GIWNNMMDOVYUOT-BYKQGDNKSA-N [Na].Nc1ncn([C@H]2C[C@H](OP(O)(=O)OC[C@H]3O[C@H](C[C@@H]3O)n3cnc4c3[nH]c(N)nc4=O)[C@@H](CO)O2)c(=O)n1 Chemical compound [Na].Nc1ncn([C@H]2C[C@H](OP(O)(=O)OC[C@H]3O[C@H](C[C@@H]3O)n3cnc4c3[nH]c(N)nc4=O)[C@@H](CO)O2)c(=O)n1 GIWNNMMDOVYUOT-BYKQGDNKSA-N 0.000 description 1
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 description 1
- 229960004748 abacavir Drugs 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 229920006397 acrylic thermoplastic Polymers 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 229940034653 advicor Drugs 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- 229960000528 amlodipine Drugs 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 229940031955 anhydrous lanolin Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 239000000420 anogeissus latifolia wall. gum Substances 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 230000000798 anti-retroviral effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 229940054051 antipsychotic indole derivative Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000009246 art therapy Methods 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- ZDQSOHOQTUFQEM-PKUCKEGBSA-N ascomycin Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C\C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](O)[C@H](OC)C1 ZDQSOHOQTUFQEM-PKUCKEGBSA-N 0.000 description 1
- ZDQSOHOQTUFQEM-XCXYXIJFSA-N ascomycin Natural products CC[C@H]1C=C(C)C[C@@H](C)C[C@@H](OC)[C@H]2O[C@@](O)([C@@H](C)C[C@H]2OC)C(=O)C(=O)N3CCCC[C@@H]3C(=O)O[C@H]([C@H](C)[C@@H](O)CC1=O)C(=C[C@@H]4CC[C@@H](O)[C@H](C4)OC)C ZDQSOHOQTUFQEM-XCXYXIJFSA-N 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- FQCKMBLVYCEXJB-MNSAWQCASA-L atorvastatin calcium Chemical compound [Ca+2].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1.C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 FQCKMBLVYCEXJB-MNSAWQCASA-L 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 108010063132 birinapant Proteins 0.000 description 1
- 229950004237 birinapant Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229960005520 bryostatin Drugs 0.000 description 1
- MJQUEDHRCUIRLF-TVIXENOKSA-N bryostatin 1 Chemical compound C([C@@H]1CC(/[C@@H]([C@@](C(C)(C)/C=C/2)(O)O1)OC(=O)/C=C/C=C/CCC)=C\C(=O)OC)[C@H]([C@@H](C)O)OC(=O)C[C@H](O)C[C@@H](O1)C[C@H](OC(C)=O)C(C)(C)[C@]1(O)C[C@@H]1C\C(=C\C(=O)OC)C[C@H]\2O1 MJQUEDHRCUIRLF-TVIXENOKSA-N 0.000 description 1
- MUIWQCKLQMOUAT-AKUNNTHJSA-N bryostatin 20 Natural products COC(=O)C=C1C[C@@]2(C)C[C@]3(O)O[C@](C)(C[C@@H](O)CC(=O)O[C@](C)(C[C@@]4(C)O[C@](O)(CC5=CC(=O)O[C@]45C)C(C)(C)C=C[C@@](C)(C1)O2)[C@@H](C)O)C[C@H](OC(=O)C(C)(C)C)C3(C)C MUIWQCKLQMOUAT-AKUNNTHJSA-N 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical class C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- QDHFHIQKOVNCNC-UHFFFAOYSA-N butane-1-sulfonic acid Chemical compound CCCCS(O)(=O)=O QDHFHIQKOVNCNC-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229920005549 butyl rubber Polymers 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 229940022418 caduet Drugs 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 229940023913 cation exchange resins Drugs 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- JROFGZPOBKIAEW-UHFFFAOYSA-N chembl2132692 Chemical compound N1C=2C(OC)=CC=CC=2C=C1C(=C1C(N)=NC=NN11)N=C1C1CCC(C(O)=O)CC1 JROFGZPOBKIAEW-UHFFFAOYSA-N 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- SZMJVTADHFNAIS-BJMVGYQFSA-N chidamide Chemical compound NC1=CC(F)=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)\C=C\C1=CC=CN=C1 SZMJVTADHFNAIS-BJMVGYQFSA-N 0.000 description 1
- 229940089960 chloroacetate Drugs 0.000 description 1
- FOCAUTSVDIKZOP-UHFFFAOYSA-M chloroacetate Chemical compound [O-]C(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-M 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 1
- 229960002286 clodronic acid Drugs 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 150000001896 cresols Chemical class 0.000 description 1
- 229940066901 crestor Drugs 0.000 description 1
- 229960005168 croscarmellose Drugs 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000013211 curve analysis Methods 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 150000001924 cycloalkanes Chemical class 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- GLNWREBYRLDPQP-MHZLTWQESA-N cyclopentyl (2s)-2-[[4-[[8-(hydroxyamino)-8-oxooctanoyl]amino]phenyl]methylamino]-2-phenylacetate Chemical compound C1=CC(NC(=O)CCCCCCC(=O)NO)=CC=C1CN[C@@H](C=1C=CC=CC=1)C(=O)OC1CCCC1 GLNWREBYRLDPQP-MHZLTWQESA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 229940096516 dextrates Drugs 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- FKGKZBBDJSKCIS-UHFFFAOYSA-N diethyl-[[6-[[4-(hydroxycarbamoyl)phenyl]carbamoyloxymethyl]naphthalen-2-yl]methyl]azanium;chloride;hydrate Chemical compound O.[Cl-].C1=CC2=CC(C[NH+](CC)CC)=CC=C2C=C1COC(=O)NC1=CC=C(C(=O)NO)C=C1 FKGKZBBDJSKCIS-UHFFFAOYSA-N 0.000 description 1
- 230000009274 differential gene expression Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- PSHRANCNVXNITH-UHFFFAOYSA-N dimethylamino acetate Chemical compound CN(C)OC(C)=O PSHRANCNVXNITH-UHFFFAOYSA-N 0.000 description 1
- 238000003618 dip coating Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229960002563 disulfiram Drugs 0.000 description 1
- 150000004141 diterpene derivatives Chemical class 0.000 description 1
- 239000012990 dithiocarbamate Substances 0.000 description 1
- 150000004659 dithiocarbamates Chemical class 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000005553 drilling Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 1
- 229960003804 efavirenz Drugs 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 239000007911 effervescent powder Substances 0.000 description 1
- 239000003571 electronic cigarette Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 229920005558 epichlorohydrin rubber Polymers 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- SUPCQIBBMFXVTL-UHFFFAOYSA-N ethyl 2-methylprop-2-enoate Chemical compound CCOC(=O)C(C)=C SUPCQIBBMFXVTL-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 229940009626 etidronate Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 1
- 229960000815 ezetimibe Drugs 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 150000002214 flavonoid derivatives Chemical class 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000001408 fungistatic effect Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000010199 gene set enrichment analysis Methods 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- GVVPGTZRZFNKDS-JXMROGBWSA-N geranyl diphosphate Chemical compound CC(C)=CCC\C(C)=C\CO[P@](O)(=O)OP(O)(O)=O GVVPGTZRZFNKDS-JXMROGBWSA-N 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 239000010903 husk Substances 0.000 description 1
- 229960002474 hydralazine Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 239000008173 hydrogenated soybean oil Substances 0.000 description 1
- 239000008311 hydrophilic ointment Substances 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 229960004337 hydroquinone Drugs 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 239000007946 hypodermic tablet Substances 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000011293 immunotherapeutic strategy Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007915 intraurethral administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229920000554 ionomer Polymers 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 235000010494 karaya gum Nutrition 0.000 description 1
- 229930188348 kazinol Natural products 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000007942 layered tablet Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 229960004873 levomenthol Drugs 0.000 description 1
- 229940059904 light mineral oil Drugs 0.000 description 1
- 229940002661 lipitor Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- INHCSSUBVCNVSK-UHFFFAOYSA-L lithium sulfate Inorganic materials [Li+].[Li+].[O-]S([O-])(=O)=O INHCSSUBVCNVSK-UHFFFAOYSA-L 0.000 description 1
- 229940092923 livalo Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 229940124302 mTOR inhibitor Drugs 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229940057917 medium chain triglycerides Drugs 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 238000007909 melt granulation Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N methyl monoether Natural products COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000003697 methyltransferase inhibitor Substances 0.000 description 1
- 229940099246 mevacor Drugs 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- ODLHGICHYURWBS-FOSILIAISA-N molport-023-220-444 Chemical compound CC(O)COC[C@@H]([C@@H]([C@H]([C@@H]1O)O)O[C@@H]2O[C@H]([C@H](O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O3)[C@@H](O)[C@@H]2O)COCC(O)C)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O)[C@H]3O[C@H]1COCC(C)O ODLHGICHYURWBS-FOSILIAISA-N 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229930003658 monoterpene Natural products 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- WXHHICFWKXDFOW-BJMVGYQFSA-N n-(2-amino-5-fluorophenyl)-4-[[[(e)-3-pyridin-3-ylprop-2-enoyl]amino]methyl]benzamide Chemical compound NC1=CC=C(F)C=C1NC(=O)C(C=C1)=CC=C1CNC(=O)\C=C\C1=CC=CN=C1 WXHHICFWKXDFOW-BJMVGYQFSA-N 0.000 description 1
- RYVLOOXFFIFQEN-UHFFFAOYSA-N n-[4-(1-oxo-3,4-dihydro-2h-pyrido[4,3-b]indol-5-yl)butyl]acetamide Chemical compound C12=CC=CC=C2N(CCCCNC(=O)C)C2=C1C(=O)NCC2 RYVLOOXFFIFQEN-UHFFFAOYSA-N 0.000 description 1
- QSYLKMKIVWJAAK-UHFFFAOYSA-N n-[4-[(2-amino-6-methylpyrimidin-4-yl)amino]phenyl]-4-(quinolin-4-ylamino)benzamide Chemical compound NC1=NC(C)=CC(NC=2C=CC(NC(=O)C=3C=CC(NC=4C5=CC=CC=C5N=CC=4)=CC=3)=CC=2)=N1 QSYLKMKIVWJAAK-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- ZCJHPTKRISJQTN-JGVFFNPUSA-N nanaomycin A Chemical compound O=C1C2=C(O)C=CC=C2C(=O)C2=C1[C@H](C)O[C@@H](CC(O)=O)C2 ZCJHPTKRISJQTN-JGVFFNPUSA-N 0.000 description 1
- QRGHOAATPOLDPF-VQFNDLOPSA-N nanatinostat Chemical compound N1=CC(C(=O)NO)=CN=C1N1C[C@@H]([C@@H]2NCC=3N=C4C=CC(F)=CC4=CC=3)[C@@H]2C1 QRGHOAATPOLDPF-VQFNDLOPSA-N 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 235000019645 odor Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960005184 panobinostat Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229960000969 phenyl salicylate Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- RHGYHLPFVJEAOC-FFNUKLMVSA-L pitavastatin calcium Chemical compound [Ca+2].[O-]C(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1.[O-]C(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 RHGYHLPFVJEAOC-FFNUKLMVSA-L 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229960000540 polacrilin potassium Drugs 0.000 description 1
- 229920001490 poly(butyl methacrylate) polymer Polymers 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920002857 polybutadiene Polymers 0.000 description 1
- 229950005134 polycarbophil Drugs 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229940068886 polyethylene glycol 300 Drugs 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
- 229920001195 polyisoprene Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- WVWZXTJUCNEUAE-UHFFFAOYSA-M potassium;1,2-bis(ethenyl)benzene;2-methylprop-2-enoate Chemical compound [K+].CC(=C)C([O-])=O.C=CC1=CC=CC=C1C=C WVWZXTJUCNEUAE-UHFFFAOYSA-M 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 229940089484 pravachol Drugs 0.000 description 1
- REQCZEXYDRLIBE-UHFFFAOYSA-N procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 description 1
- 229960000244 procainamide Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 229960001309 procaine hydrochloride Drugs 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- 239000000770 propane-1,2-diol alginate Substances 0.000 description 1
- KRIOVPPHQSLHCZ-UHFFFAOYSA-N propiophenone Chemical class CCC(=O)C1=CC=CC=C1 KRIOVPPHQSLHCZ-UHFFFAOYSA-N 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 1
- 229940093625 propylene glycol monostearate Drugs 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- BOJKFRKNLSCGHY-HXGSDTCMSA-N prostratin Chemical compound C1=C(CO)C[C@]2(O)C(=O)C(C)=C[C@H]2[C@@]2(O)[C@H](C)C[C@@]3(OC(C)=O)C(C)(C)[C@H]3[C@@H]21 BOJKFRKNLSCGHY-HXGSDTCMSA-N 0.000 description 1
- 230000026447 protein localization Effects 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 150000005255 pyrrolopyridines Chemical class 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 150000003246 quinazolines Chemical class 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- CZFFBEXEKNGXKS-UHFFFAOYSA-N raltegravir Chemical compound O1C(C)=NN=C1C(=O)NC(C)(C)C1=NC(C(=O)NCC=2C=CC(F)=CC=2)=C(O)C(=O)N1C CZFFBEXEKNGXKS-UHFFFAOYSA-N 0.000 description 1
- 229960004742 raltegravir Drugs 0.000 description 1
- 239000008175 ready-to-use sterile solution Substances 0.000 description 1
- 229940100618 rectal suppository Drugs 0.000 description 1
- 238000005067 remediation Methods 0.000 description 1
- 229950002821 resminostat Drugs 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000009490 roller compaction Methods 0.000 description 1
- LALFOYNTGMUKGG-BGRFNVSISA-L rosuvastatin calcium Chemical compound [Ca+2].CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O.CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O LALFOYNTGMUKGG-BGRFNVSISA-L 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 229950009216 sapanisertib Drugs 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 235000019613 sensory perceptions of taste Nutrition 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 229940103449 simcor Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229940075439 smac mimetic Drugs 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- GOCYQQKRJUGVRU-SQQVDAMQSA-M sodium;(e)-but-2-enoate Chemical compound [Na+].C\C=C\C([O-])=O GOCYQQKRJUGVRU-SQQVDAMQSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000012177 spermaceti Substances 0.000 description 1
- 229940084106 spermaceti Drugs 0.000 description 1
- 238000005563 spheronization Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000003351 stiffener Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229960005559 sulforaphane Drugs 0.000 description 1
- 235000015487 sulforaphane Nutrition 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 230000035923 taste sensation Effects 0.000 description 1
- 229960000235 temsirolimus Drugs 0.000 description 1
- 229920001897 terpolymer Polymers 0.000 description 1
- RBTVSNLYYIMMKS-UHFFFAOYSA-N tert-butyl 3-aminoazetidine-1-carboxylate;hydrochloride Chemical compound Cl.CC(C)(C)OC(=O)N1CC(N)C1 RBTVSNLYYIMMKS-UHFFFAOYSA-N 0.000 description 1
- ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 description 1
- ZUHZGEOKBKGPSW-UHFFFAOYSA-N tetraglyme Chemical compound COCCOCCOCCOCCOC ZUHZGEOKBKGPSW-UHFFFAOYSA-N 0.000 description 1
- 235000019529 tetraterpenoid Nutrition 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 235000019303 thiodipropionic acid Nutrition 0.000 description 1
- 230000009974 thixotropic effect Effects 0.000 description 1
- 229940019375 tiludronate Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000005029 transcription elongation Effects 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000011222 transcriptome analysis Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 229940086542 triethylamine Drugs 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- YFNKIDBQEZZDLK-UHFFFAOYSA-N triglyme Chemical compound COCCOCCOCCOC YFNKIDBQEZZDLK-UHFFFAOYSA-N 0.000 description 1
- 125000005591 trimellitate group Chemical group 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 239000006217 urethral suppository Substances 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229940120293 vaginal suppository Drugs 0.000 description 1
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- PNAMDJVUJCJOIX-XVZWKFLSSA-N vytorin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1.N1([C@@H]([C@H](C1=O)CC[C@@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 PNAMDJVUJCJOIX-XVZWKFLSSA-N 0.000 description 1
- 229940009349 vytorin Drugs 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- 229940072168 zocor Drugs 0.000 description 1
- CGTADGCBEXYWNE-JUKNQOCSSA-N zotarolimus Chemical compound N1([C@H]2CC[C@@H](C[C@@H](C)[C@H]3OC(=O)[C@@H]4CCCCN4C(=O)C(=O)[C@@]4(O)[C@H](C)CC[C@H](O4)C[C@@H](/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C3)OC)C[C@H]2OC)C=NN=N1 CGTADGCBEXYWNE-JUKNQOCSSA-N 0.000 description 1
- 229950009819 zotarolimus Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Definitions
- the present disclosure provides novel methods to cure HIV.
- aminobisphosphonates are disclosed as latency reversing agents (LRAs), and methods to cure HIV by administering to a subject a combination of bisphosphonates and gd T cells are provided.
- these interventions may be combined with other latency reversing agents, e.g., histone deacetylase (HD AC) inhibitors, and other immunotherapeutics for HIV clearance (e.g., broadly HIV-neutralizing antibodies).
- HD AC histone deacetylase
- the latent human immunodeficiency vims (HIV) reservoir within resting memory CD4 + T cells is the major barrier to efforts to eradicate persistent infection (1-4).
- Today the standard of care for patients with HIV is long term antiretroviral therapy (ART) to suppress active viral replication and new infection of cells.
- ART antiretroviral therapy
- therapeutic approaches that allow the clearance of latent but replication-competent HIV are needed.
- Current strategies are based on the use of ongoing ART and concurrently employ latency reversal agents (LRA) to induce viral antigen expression (5, 6) to allow immunological clearance.
- This clearance part has been mainly based on CD8 T cells (7, 8).
- CD8-based therapies can be challenging due to insufficient HIV antigen expression on latently-infected cells, diminished function of specific CD8 T cells (9, 10) and escape HIV variants (7).
- gd T cells In contrast to the majority of ab T cells that recognize antigen peptides bound to major histocompatibility complex (MHC) class I or II, gd T cells, including the most prevalent peripheral subset, V52 cells, mainly recognize non-peptidic phosphorylated metabolites of isoprenoid biosynthesis (11). These metabolites include (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMBPP) (12, 13) and isopentenyl pyrophosphate (IPP) (14), and their recognition does not require conventional MHC-antigen presentation (14, 15).
- HMBPP -4-hydroxy-3-methyl-but-2-enyl pyrophosphate
- IPP isopentenyl pyrophosphate
- Isoprenoids are a class of organic chemicals derived from terpenes. Terpenoids are modified terpenes with added or removed methyl groups or oxygen atoms added. The use terpene can be used more broadly to include terpenoids. These compounds can be classified according to the number of isoprene units that contain the parent terpene in hemiterpenoids, mono terpenoids, sesquiterpenoids, diterpenoids, sesterterpenoids, triterpenoids, tetraterpenoids, poly terpenoids. These chemicals are phosphorylated intermediates of the non-mevalonate (or MEP pathway) and mevalonate pathway of isoprenoid biosynthesis (Figure 1). See Jomaa, H. et al. Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs. Science (New York,
- Bromohydrin pyrophosphate (BrHPP) and 2-methyl-3- butenyl-l -pyrophosphate (2M3B1PP) are examples of synthetic isoprenoids. See Espinosa, E. et al. Chemical synthesis and biological activity of bromohydrin pyrophosphate, a potent stimulator of human gamma delta T cells. The Journal of biological chemistry 276, 18337-18344, doi:l0.l074/jbc.Ml00495200 (2001); and Kobayashi, H. et al. Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study. Cancer immunology, immunotherapy: C// 56, 469-476,
- This disclosure provides a method for inducing expression of HIV viral antigen(s) in latently HIV-infected cells which comprises exposing the latently HIV-infected cells to a bisphosphonate so as to reverse latency and to induce the expression of the HIV viral antigen(s).
- the bisphosphonate may be an aminobisphosphonate.
- the aminobisphosphonate may be an alkyl aminobisphosphonate, a substituted alkyl aminobisphosphonate, a bisphosphonate with a nitrogen containing heterocycle, or a bisphosphonate containing a cyclic alkane or cycloaminoalkane.
- the aminobisphosphonate is Alendronate (FosamaxTM), Ibandronate (BonivaTM or BonvivaTM), Neridronate (NerixiaTM), Olpadronate, Pamidronate (APD/ArediaTM), Risedronate (ActonelTM), or Zoledronate (ZometaTM /AclastaTM).
- the invention also provides a method of inducing expression of HIV viral antigens in latently HIV-infected cells in a subject which comprises administering to the subject a bisphosphonate so as to reverse latency and induce expression of the HIV viral antigens in the cells in the subject.
- the latently infected cells may be rCD4 cells.
- the disclosure also provides a method to boost gd T cell functions and reverse viral latency in a subject infected with HIV which comprises administering to the subject a bisphosphonate.
- the disclosure provides for the use of an aminobisphosphonate as a latency reducing agent.
- the aminobisphosphonate may be Alendronate (FosamaxTM), Ibandronate (BonivaTM or BonvivaTM), Neridronate (NerixiaTM), Olpadronate, Pamidronate (APD/ArediaTM), Risedronate (ActonelTM), or Zoledronate (ZometaTM /AclastaTM).
- the present disclosure also provides a method for eliminating latently infected cells harboring quiescent HIV provirus that comprises reversing HIV latency by exposure to a bisphosphonate, and clearing these infected cells via the direct antiviral activity of gd T cells and/or adjuvant function over other effector cells such as CD8 T cells or Natural Killer (NK) cells.
- a method for eliminating latently infected cells harboring quiescent HIV provirus that comprises reversing HIV latency by exposure to a bisphosphonate, and clearing these infected cells via the direct antiviral activity of gd T cells and/or adjuvant function over other effector cells such as CD8 T cells or Natural Killer (NK) cells.
- the disclosure provides a method of treating/curing a subject infected with HIV that comprises administering to the subject ex vivo expanded gd T cells and a bisphosphonate.
- These methods further may comprise exposing the infected cells to a second HIV latency reversing agent, that may include but are not limited to an epigenetic modifier, an NFkB agonist, a PI3K Akt pathway inhibitor, a protein kinase C agonist, a TCR activator, a TLR agonist, a second mitochondrial-derived activator of caspases (SMAC) mimetic, an inhibitor of IAP (Inhibitor of Apoptosis Protein) family of proteins, or a stimulator of interferon genes protein (STING) agonists.
- a second HIV latency reversing agent may include but are not limited to an epigenetic modifier, an NFkB agonist, a PI3K Akt pathway inhibitor, a protein kinase C agonist, a TCR activator, a TLR agonist, a second mitochondrial-derived activator of caspases (SMAC) mimetic, an inhibitor of IAP (Inhibitor of Apopto
- the disclosure provides a method of treating HIV infection in a subject, comprising: (a) isolating peripheral blood mononuclear (PBMC) cells from the subject; (b) culturing the isolated PBMC cells ex vivo with an effective amount of a bisphosphonate or antibodies and suitable cytokines/chemokines so as to expand gd T cells; (c) optionally genetically modifying the gd T cells before or after expansion, e.g., CAR T cells; (d) infusing the expanded gd T cells into the subject; and (e) administering to the subject a bisphosphonate so as to activate quiescent HIV pro virus, allowing elimination of HIV infection.
- PBMC peripheral blood mononuclear
- the method further may comprise administering to the subject in step (e) a second HIV latency reversing agent such as an epigenetic modifier, an NFkB agonist, a PI3K/Akt pathway inhibitor, a protein kinase C agonist, SMAC mimetic, a TCR activator, a STING agonist or a TLR agonist.
- a second HIV latency reversing agent such as an epigenetic modifier, an NFkB agonist, a PI3K/Akt pathway inhibitor, a protein kinase C agonist, SMAC mimetic, a TCR activator, a STING agonist or a TLR agonist.
- an epigenetic modifier LRA is a histone deacetylase (HD AC) inhibitor.
- the subject is receiving ongoing, standard antiretroviral therapy (ART).
- ART standard antiretroviral therapy
- the PBMCs are expanded in the presence of the bisphosphonate for 5 to 30 days or 7 to 21 days.
- the bisphosphonate may be washed off after initial exposure of the cells to the drug.
- the expanded gd T cells and the bisphosphonate are administered concurrently or sequentially.
- the bisphosphonate may be Alendronate (FosamaxTM), Ibandronate (BonivaTM or BonvivaTM), Neridronate (NerixiaTM), Olpadronate, Pamidronate (APD/ArediaTM), Risedronate (ActonelTM), or Zoledronate (ZometaTM /AclastaTM).
- the HDAC inhibitor may be belinostat (PXD101), entinostat (MS-275), mocetinostat (MGCD0103), panobinostat (LBH589), romidepsin or vorinostat (SAHA).
- the bisphosphonate may be used in conjunction with a TLR agonist, such as the TLR9 agonist Lefitolimod/MGNl703.
- N-BPs are structurally related to pyrophosphates generated in the isoprenoid biosynthesis pathways and are shown herein to be both HIV latency reversing agents to reactivate latency and induce activation of gd T cell functions, including direct cytotoxic capacity and adjuvant functions over other effector cell populations. Other inhibitors of the mevalonate pathway may also be effective.
- terpenoids examples include but are not limited to (E)-4-hydroxy-3-methyl-but-2- enyl pyrophosphate (HMBPP), isopentenyl pyrophosphate (IPP), dimethyl-allyl-pyrophosphate (DMAPP), bromohydrin pyrophosphate (BrHPP) and 2-methyl-3-butenyl-l -pyrophosphate (2M3B1PP).
- HMBPP -4-hydroxy-3-methyl-but-2- enyl pyrophosphate
- IPP isopentenyl pyrophosphate
- DMAPP dimethyl-allyl-pyrophosphate
- bromohydrin pyrophosphate BrHPP
- 2-methyl-3-butenyl-l -pyrophosphate 2M3B1PP
- statins include atorvastatin, Lipitor ®; fluvastatin, Lescol®, Lescol® XL; lovastatin, Mevacor®; mevastatin; pitavastatin, Livalo®; pravastatin, Pravachol®; rosuvastatin, Crestor®; simvastatin, Zocor®; simvastatin & ezetimibe, Vytorin®; lovastatin + niacin extended- release, Advicor®; atorvastatin + amlodipine, Caduet®; and simvastatin + niacin extended-release, Simcor®.
- the disclosure also provides pharmaceutical compositions and uses as HIV latency reversing agents of a bisphosphonate and a second HIV latency reversing agent.
- Known HIV reversing agents are enumerated in the application, for example a histone deacetylase inhibitor such as vorinostat (SAHA).
- SAHA vorinostat
- compositions comprising an HMG- CoA reductase inhibitor and an HIV latency reversing agent such as a histone deacetylase.
- the disclosure also provides for pharmaceutical compositions comprising either (i) a synthetic analogue of a component of the mevalonate pathway, (ii) an inhibitor of the mevalonate pathway (beyond bisphosphonates or HMG-CoA reductase inhibitors), or (iii) an intermediate from the mevalonate pathway in combination with HIV latency reversing agent such as a histone deacetylase.
- FIG. 1 The mevalonate pathway produces famesyl pyrophosphate.
- Nitrogen- containing bisphosphonates (N-BP) inhibit the enzyme famesyl pyrophosphate synthase preventing farnesyl pyrophosphate groups to be synthesized. These groups are used by Famesyl transferase enzymes for prenylation downstream. Inhibition of the farnesyl pyrophosphate synthase induces accumulation of geranyl pyrophosphate and isopentenyl pyrophosphate, which are specifically recognized by gd T cells that become activated.
- FIG.2A Quantification of HIV gag RNA levels in HIV-infected suppressed donors.
- FIG. 2B Normalized levels of HIV gag RNA copies to the media condition.
- FIG. 2C-2D N-BPs reactivate HIV from latency. N-BPs were used at concentrations that are comparable to the in vivo plasma concentrations reported for their use to treat bone-related diseases (PAM at 2.5pg/mL and Zol at ImM). Isolated rCD4 cells from nine HIV-infected donors on stable ART and suppressed for at least one year were assayed. Each dot represents one donor, which is the mean of 6-15 replicates of lxlO 6 cells.
- FIG. 2D Fold change induction of HIV caRNA copies normalized to the untreated condition was comparable between the positive control (PHA and IL-2) and the conditions treated with PAM and Zol (p>0.05, Wilcoxon paired signed rank test).
- FIG. 3A PAM induces production of replication-competent HIV in cultures of isolated rCD4 cells.
- PHA reactivated latent HIV in 9 of the 10 patients analyzed by QVOA.
- SAHA induced HIV production in six of nine patients and finally PAM at 25pg/mL reactivated latent HIV in seven of the 10 patients while VOR (SAHA) reactivated in 6 out of 9 individuals.
- FIG. 3B PAM at 2.5pg/mL induce production of replication-competent HIV comparable to the positive control PHA and IL-2.
- FIG. 4A-4B Toxicity of N-BPs to cell populations.
- Total PBMC or isolated rCD4 cells from HIV-infected participants were exposed to different concentrations of PAM. In parallel, controls with lOOU/mL IL-2 were ran.
- FIG. 4A Percentage of 7-AAD in total PBMCs. No significant differences between media and increasing concentrations of PAM (DL-2415) were detected in any of the cell populations analyzed: total CD4 cells, CD8 cells, NK cells or gd T cells.
- FIG. 4B Expression of CD95 in isolated rCD4 cells. PAM (DL-2415) is not toxic to rCD4 cells.
- FIG. 5A Effect of PAM (DL-2415) on cell proliferation. Representative histograms of one donor is shown. PAM does not promote proliferation of isolated rCD4 cells. PAM does not promote proliferation of total CD4 or CD8 T cells. As expected, V52 cells proliferated in response to PAM and IL-2 (bottom histograms).
- FIG. 5B N-BPs do not induce proliferation of CD4, CD8 or gd T cells. Percentage of proliferation measured by carboxyfluorescein diacetate succinimidyl ester (CFSE) for varying concentration of PAM (upper graph) and Zol (lower graph). Percentage of CFSE positive cells (non proliferated) was comparable to the untreated condition for all concentrations analyzed. PAM at 2.5pg/mL and Zol at lOng/mL an lOOU/mL IL-2 were used as the positive control for V52 cell expansion. Bars represent the mean ⁇ SEM of three to 5 different donors.
- CFSE carboxyfluorescein diacetate succinimidyl ester
- FIG. 5C N-BPs do not promote activation of lymphocyte populations. Isolated PBMC were exposed to different concentrations of PAM (graphs on the left) and Zol (graphs on the right). PHA was used as the positive control, and untreated cells (media alone) were used as the negative control. Expression of activation markers CD69 and HLA-DR by flow cytometry was increased in the positive control, but activation levels remained comparable to the untreated condition in all other experimental conditions. Cells from three to five individuals were assayed in triplicate. Multiple t-test Holm-Sidak analysis p>0.05.
- FIG. 6A-6C N-BPs mechanism of action. RNA from isolated rCD4 cells was extracted and RNA-seq performed.
- FIG. 6A The principal component analysis represents a multidimensional association showing that the greatest source of variation in gene expression is due to the treatment. A heatmap showed differentially expressed genes in the treated and the untreated conditions. Upregulated and downregulated were split according to the treatment (data not shown).
- FIG. 6B Examples of pathways altered by PAM treatment analyzed by gene set enrichment using GSVA and curated gene modules (C2). Genes involved in the positive control, cholesterol biosynthesis pathway were upregulated in the untreated condition compared to the PAM-treated condition.
- FIG. 7A-7B N-BPs reverse latency in vivo.
- ART-treated patients received the N-BP alendronate (Arm A) or placebo (Arm B).
- FIG.7A Seven of the ten patients in arm A who received alendronate, showed an effect on HIV caRNA. In four of them the effect was a decrease compared to baseline, and in the other three, there was an increase compared to baseline.
- FIG. 7B In the five patients analyzed that received placebo, HIV caRNA was comparable between all the time points analyzed. Wilcoxon signed rank test.
- FIG. 8A-8C Expansion of V52 cells after six days of culture.
- FIG.8A Greater V52 cell frequency in uninfected donors.
- FIG. 8B Representative histograms showing V52 cell expansion. PBMC from uninfected (left histogram) or ART- suppressed HIV-infected donors (right panel) were incubated for six days using HMBPP+IL-2, PAM+IL-2, or IL-2 alone.
- V52 cells from HIV-infected individuals expand in response to Pamidronate (PAM) and IL-2.
- V52 cell fold change relative to basal cell numbers is represented.
- FIG. 9A-9B Percentage of V52 cells after six days of culture.
- FIG. 9A Basal and expanded V52 cell frequency. V52 cells frequencies from ART-suppressed HIV-infected donors achieve greater values when expanded with pamidronate (PAM)+IL-2.
- FIG. 9B Detailed comparison of V52 cell numbers after exposure to HMBPP and PAM in HIV-infected donors. Each symbol shape represents one condition and each individual donor is represented by a different color. Mann Whitney U-test. *p ⁇ 0.05, **p ⁇ 0.005, ***p ⁇ 0.0005.
- FIG. 10A-10C Expansion of V52 cells from ART -suppressed HIV-infected donors in response to pamidronate (PAM)
- FIG. 10A PAM exposure significantly increase V52 cell frequency.
- V52 cells from suppressed HIV+ donors (N 2l) significantly expandeded in response to PAM.
- FIG. 10B Decreased V52 cell numbers in donors treated in the chronic phase of the infection.
- FIG. 10C Comparable expansion capacity between patients who initiated ART in the acute or chronic phase of HIV infection.
- FIG. 11A-11C Phenotype of pamidronate (PAM)-expanded V52 cells in ART- suppressed HIV-infected donors. Phenotype of V 52 cells was analyzed by flow cytometry in eight HIV-infected individuals after expansion. Mean ⁇ SEM is represented.
- FIG. 11A Memory populations defined as central memory (TCM): CD45-/CD27+/CCR7+); transitional memory (TTM: CD45-/CD27+/CCR7-); effector memory (TEM: CD45-/CD27-/CCR7-).
- FIG. 11B Expression of cytotoxic markers CD8, CD56 and CD16
- FIG. 11C Expression of activation markers CD69, CD25 and HLA-DR, and exhaustion markers PD-l and CTLA-4.
- FIG. 12A-12C V52 T cells inhibit active HIV replication.
- FIG. 12B Pamidronate (PAM)-expanded V52 T cells retain their capacity to inhibit viral replication. After 14 days of exposure to PAM, gd T cells were cocultured with autologous superinfected CD4 cells.
- PAM Pamidronate
- FIG. 13A Examples of individual HIV p24 production by isolated V52 T cells expanded with pamidronate (PAM) compared to CD4 cells cultured alone.
- FIG. 14A-14B Cytotoxic assays.
- FIG. 14A V52 cells degranulate in response to
- FIG. 14B MHC-blocking experiments. Expanded V52 cells were incubated with a pan- HLA monoclonal antibody prior to coculture with autologous HIV- superinfected CD4 cells.
- FIG. 15A-15C V52 cells degranulate in the presence of autologous HIV-infected
- FIG. 15A Flow cytometry plots showing an example of CD107a detection in cocultures of expanded V52 cells with autologous CD4 cells (left) and with autologous JR-CSF- superinfected CD4 cells (right).
- FIG. 15B Greater CD107a production in the presence of HIV- infected cells.
- FIG. 15C Comparable degranulation capacity of V52 cells between donors treated in acute and chronic HIV infection. CDl07a production was not statistically different between acute and chronic patients. Both groups of patients showed statistically higher CDl07a expression in cocultures of V52 cells and superinfected CD4 target cells than in cultures of V52 cells cocultured with ex vivo isolated CD4 cells. Effector: target ratio (1:1). Mann Whitney U-test.
- FIG. 16 gd T cells clear latently infected cells after latency reversal with vorinostat (VOR).
- Isolated resting CD4 (r-CD4) cells from ART-suppressed HIV-infected donors were reactivated with 0.5mM VOR. After washing, r-CD4 cells were cultured alone or with gd T cells, which were removed from the culture after 24 hours. The same number of replicate cultures of lxlO 6 from each condition were then cultured in parallel for 19 days.
- VOR efficiently reactivated latent HIV in six (represented in the graph) of the eight patients analyzed in the condition where r- CD4 cells were cultured alone.
- the terms“about” and/or“approximately” may be used in conjunction with numerical values and/or ranges.
- the term“about” is understood to mean those values near to a recited value.
- “about 40 [units]” may mean within ⁇ 25% of 40 (e.g., from 30 to 50), within ⁇ 20%, ⁇ 15%, ⁇ 10%, ⁇ 9%, ⁇ 8%, ⁇ 7%, ⁇ 6%, ⁇ 5%, ⁇ 4%, ⁇ 3%, ⁇ 2%, ⁇ 1%, less than ⁇ 1%, or any other value or range of values therein or there below.
- the term“about” may mean ⁇ one half a standard deviation, ⁇ one standard deviation, or ⁇ two standard deviations.
- the phrases“less than about [a value]” or“greater than about [a value]” should be understood in view of the definition of the term “about” provided herein.
- the terms “about” and “approximately” may be used interchangeably.
- Nonlimiting examples of bisphosphonates are non-nitrogenous bisphosphonates are Etidronate (DidronelTM), Clodronate (BonefosTM, LoronTM) or Tiludronate (SkelidTM).
- nitrogenous bisphosphonates are Alendronate (FosamaxTM), Ibandronate (BonivaTM or BonvivaTM), Neridronate (NerixiaTM), Olpadronate, Pamidronate (APD/ArediaTM), Risedronate (ActonelTM), or Zoledronate (ZometaTM /AclastaTM).
- Disease refers to any disease, disorder, condition, symptom, or indication.
- “Host” preferably refers to a human. It also includes other mammals including the equine, porcine, bovine, feline, and canine families.
- Non-limiting examples of latency reversing agents are an epigenetic modifier, an NFkB agonist, a PI3K/Akt pathway inhibitor, a protein kinase C agonist, a TCR activator or a TLR agonist. See Darcis et ah, 2017, Trends Immun 38(3) 217-228; Rasmussen and Lewin 2016 Curr Opin HIV AIDS 11:394-401; and Kim et al. 2018 Cell Host Microbe 23 14-26.
- the epigenetic modifier may be (i) a bromodomain or BET inhibitor (e.g., CPI- 203, CPI-0610, 1-BET 151 (GSK1210151A), I-BET 762 (GSK525762), JQ1, LY294002, olinone, OTX- 015, TEN-010); (ii) a crotonylation agent, e.g., sodium crotonate or PEP005, see Jiang et al.
- a bromodomain or BET inhibitor e.g., CPI- 203, CPI-0610, 1-BET 151 (GSK1210151A), I-BET 762 (GSK525762), JQ1, LY294002, olinone, OTX- 015, TEN-010
- a crotonylation agent e.g., sodium crotonate or PEP005, see Jiang et al.
- a histone deacetylase inhibitor e.g., 4SC-202, Abexinostat (PCI-24781), ACY-1215, AR-42, Belinostat (PXD101), CG200745, Chidamide, CHR-2845 , CHR-3996, CUDC-101, Entinostat (MS-275), Givinostat (ITF2357), HBI- 8000, (a benzamide HDI), Kevetrin (selective for HDAC2), ME-344, Mocetinostat (MGCD0103), Panobinostat, Quisinostat (JNJ-26481585), Resminostat (4SC-201), Romidepsin, sulforaphane, Valproic acid, Vorinostat); (iv) a methyl
- Biochem Pharmacol 129 1-13 (e.g., 5-Aza-2'-deoxycytidine (5azadC), 5-Azacytidine (5azaC), DC_05 analogues, Dichlone, Flavonoid derivatives (Kazinol Q, chloro-nitroflavanones), Guadecitabine (SGI- 110), Indole derivatives, Isoxazoline and oxazoline derivatives, Laccaic acid A, MG98, Nanaomycin A, Procainamide conjugates, Propiophenone derivatives, Pyrrolopyridine derivatives, Quinazoline derivatives, RG108 analogues, SGI-1027, SW155246, Zebularine); (vi) a pTEF-b activator, see
- Nonlimiting examples of NFkB agonists are the SMAC (second mitochondria-derived activator of caspases) mimetics (e.g., AZD5582 (Sampey et al. 2018, bioRxiv May 2, 2018), BV6, birinapant, LCL161).
- Nonlimiting examples of a PI3K/Akt pathway inhibitors are disulfiram, mTor inhibitors (e.g., RAD rapamycin (sirolimus) and derivatives/analogs thereof such as everolimus or RAD001; ABT578, AP23573, AP23841, ascomycin (an ethyl analog of FK506), AZD08055, CCI-779, EX2044, EX3855, EX7518, INK-128, KU-0063794, OSI027, SAR543).
- mTor inhibitors e.g., RAD rapamycin (sirolimus) and derivatives/analogs thereof such as everolimus or RAD001; ABT578, AP23573, AP23841, ascomycin (an ethyl analog of FK506), AZD08055, CCI-779, EX2044, EX3855, EX7518, INK-128, KU-00
- Nonlimiting examples of protein kinase C agonists are bryostatin, ingenol B/PEP005, prostratin).
- TLR7 and TLR9 agonists are TLR7 and TLR9 agonists (e.g., TLR9 agonist, Lefitolimod/MGNl703 or 1V270 or SD-101, see Sato-Kaneko et ah, 2017 JCI Insight 2(18) e93397).
- gd T cells represent a small subset of T cells that possess a distinct T cell receptor (TCR) on their surfaces.
- TCR T cell receptor
- a majority of T cells have a TCR composed of two glycoprotein chains called a- and b- TCR chains.
- the TCR is made up of one g-chain and one d-chain. In humans they represent under 10% of total T cells)
- gd T cells are not MHC-restricted.
- the gd T cells may be endogenous cells, e.g., native cells or expanded native cells from a patient.
- the gd T cells may be genetically engineered, e.g., CCR5 and/or CXCR4 knockouts. See Delhove and Qasim, 2017,“Genome-Edited T Cell Therapies” Curr Stem Cell Rep 3:124-136; Schumann et ah, 2015, "Generation of knock-in primary human T cells using Cas9 ribonucleoproteins". Proceedings of the National Academy of Sciences USA. 112 (33): 10437-10442; Zhang et al. 2017,“Gene editing in T cell therapy” J Genetics and Genomics 44 (2017) 415-422.
- the gd T cells are adopted T cells.
- “Pharmaceutically acceptable salts” refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof.
- Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of the basic residues.
- the pharmaceutically acceptable salts include the conventional quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids.
- such conventional non-toxic salts include, but are not limited to, those derived from inorganic and organic acids selected from l,2-ethanedisulfonic, 2-acetoxybenzoic, 2- hydroxyethanesulfonic, acetic, ascorbic, benzenesulfonic, benzoic, bicarbonic, carbonic, citric, edetic, ethane disulfonic, ethane sulfonic, fumaric, glucoheptonic, gluconic, glutamic, glycolic, glycollyarsanilic, hexylresorcinic, hydrabamic, hydrobromic, hydrochloric, hydroiodide, hydroxymaleic, hydroxy naphthoic, isethionic, lactic, lactobionic, lauryl sulfonic, maleic, malic, mandelic, methanesulfonic, napsylic, nitric, oxalic, pamoic, pantothenic
- Such conventional and non-toxic salts also include inorganic or organic bases such as lithium, magnesium, sodium, potassium, calcium, aluminum, zinc, arginine, lysine, benzathine, chloroprocaine, choline, diethanolamine, ethanolamine, ethylenediame, histadine, meglumine, procaine, and triethylamine.
- inorganic or organic bases such as lithium, magnesium, sodium, potassium, calcium, aluminum, zinc, arginine, lysine, benzathine, chloroprocaine, choline, diethanolamine, ethanolamine, ethylenediame, histadine, meglumine, procaine, and triethylamine.
- Therapeutically effective amount includes an amount of a compound of the present invention that is effective when administered alone or in combination to treat the desired condition or disorder.
- “Therapeutically effective amount” includes an amount of the combination of compounds claimed that is effective to treat the desired condition or disorder.
- the combination of compounds is preferably a synergistic combination. Synergy, as described, for example, by Chou and Talalay, Adv. Enzyme Regul. 1984, 22:27-55, occurs when the effect of the compounds when administered in combination is greater than the additive effect of the compounds when administered alone as a single agent. In general, a synergistic effect is most clearly demonstrated at sub-optimal concentrations of the compounds. Synergy can be in terms of lower cytotoxicity, increased antiviral effect, or some other beneficial effect of the combination compared with the individual components.
- Treating covers the treatment of a disease-state in a mammal, and includes: (a) preventing the disease-state from occurring in a mammal, in particular, when such mammal is predisposed to the disease-state but has not yet been diagnosed as having it; (b) inhibiting the disease-state, e.g., arresting its development; and/or (c) relieving the disease-state, e.g., causing regression of the disease state until a desired endpoint is reached. Treating also includes the amelioration of a symptom of a disease (e.g., lessen the pain or discomfort), wherein such amelioration may or may not be directly affecting the disease (e.g., cause, transmission, expression, etc.).
- compositions comprising a compound disclosed herein as an active ingredient, or a pharmaceutically acceptable salt, solvate or hydrate thereof in combination with a pharmaceutically acceptable vehicle, carrier, diluent, or excipient, or a mixture thereof.
- the compound provided herein may be administered alone, or in combination with one or more other compounds provided herein.
- the pharmaceutical compositions that comprise a compound disclosed herein can be formulated in various dosage forms for oral, parenteral, and topical administration.
- the pharmaceutical compositions can also be formulated as modified release dosage forms, including delayed-, extended-, prolonged-, sustained-, pulsatile-, controlled-, accelerated- and fast-, targeted-, programmed-release, and gastric retention dosage forms.
- These dosage forms can be prepared according to conventional methods and techniques known to those skilled in the art (see, Remington: The Science and Practice of Pharmacy.
- the pharmaceutical compositions are provided in a dosage form for oral administration, which comprise a compound provided herein, e.g., a compound disclosed herein or a pharmaceutically acceptable salt, solvate or hydrate thereof; and one or more pharmaceutically acceptable excipients or carriers.
- compositions are provided in a dosage form for parenteral administration, which comprise a compound disclosed herein or a pharmaceutically acceptable salt, solvate or hydrate thereof; and one or more pharmaceutically acceptable excipients or carriers.
- compositions are provided in a dosage form for topical administration, which comprise a compound disclosed herein or a pharmaceutically acceptable salt, solvate or hydrate thereof; and one or more pharmaceutically acceptable excipients or carriers.
- the pharmaceutical compositions provided herein can be provided in a unit-dosage form or multiple-dosage form.
- a unit-dosage form refers to physically discrete a unit suitable for administration to a human and animal subject, and packaged individually as is known in the art. Each unit-dose contains a predetermined quantity of an active ingredient(s) sufficient to produce the desired therapeutic effect, in association with the required pharmaceutical carriers or excipients. Examples of a unit-dosage form include an ampoule, syringe, and individually packaged tablet and capsule. A unit-dosage form may be administered in fractions or multiples thereof.
- a multiple-dosage form is a plurality of identical unit-dosage forms packaged in a single container to be administered in segregated unit-dosage form.
- Examples of a multiple-dosage form include a vial, bottle of tablets or capsules, or bottle of pints or gallons.
- the pharmaceutical compositions provided herein can be administered at once, or multiple times at intervals of time. It is understood that the precise dosage and duration of treatment may vary with the age, weight, and condition of the patient being treated, and may be determined empirically using known testing protocols or by extrapolation from in vivo or in vitro test or diagnostic data. It is further understood that for any particular individual, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the formulations.
- the therapeutically effective dose is from about 0.1 mg to about 2,000 mg per day of a compound provided herein.
- the pharmaceutical compositions therefore should provide a dosage of from about 0.1 mg to about 2000 mg of the compound.
- pharmaceutical dosage unit forms are prepared to provide from about 1 mg to about 2000 mg, from about 10 mg to about 1000 mg, from about 20 mg to about 500 mg or from about 25 mg to about 250 mg of the essential active ingredient or a combination of essential ingredients per dosage unit form.
- the pharmaceutical dosage unit forms are prepared to provide about 10 mg, 20 mg, 25 mg, 50 mg, 100 mg, 250 mg, 500 mg, 1000 mg or 2000 mg of the essential active ingredient.
- compositions provided herein can be administered parenterally by injection, infusion, or implantation, for local or systemic administration ⁇
- Parenteral administration include intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular, intrasynovial, intravesical, and subcutaneous administration ⁇
- compositions provided herein can be formulated in any dosage forms that are suitable for parenteral administration, including solutions, suspensions, emulsions, micelles, liposomes, microspheres, nanosystems, and solid forms suitable for solutions or suspensions in liquid prior to injection.
- dosage forms can be prepared according to conventional methods known to those skilled in the art of pharmaceutical science (see, Remington: The Science and Practice of Pharmacy, supra).
- compositions intended for parenteral administration can include one or more pharmaceutically acceptable carriers and excipients, including, but not limited to, aqueous vehicles, water-miscible vehicles, non-aqueous vehicles, antimicrobial agents or preservatives against the growth of microorganisms, stabilizers, solubility enhancers, isotonic agents, buffering agents, antioxidants, local anesthetics, suspending and dispersing agents, wetting or emulsifying agents, complexing agents, sequestering or chelating agents, cryoprotectants, lyoprotectants, thickening agents, pH adjusting agents, and inert gases.
- aqueous vehicles water-miscible vehicles
- non-aqueous vehicles non-aqueous vehicles
- antimicrobial agents or preservatives against the growth of microorganisms stabilizers, solubility enhancers, isotonic agents, buffering agents, antioxidants, local anesthetics, suspending and dispersing agents, wetting or emuls
- Suitable aqueous vehicles include, but are not limited to, water, saline, physiological saline or phosphate buffered saline (PBS), sodium chloride injection, Ringers injection, isotonic dextrose injection, sterile water injection, dextrose and lactated Ringers injection.
- Non-aqueous vehicles include, but are not limited to, fixed oils of vegetable origin, castor oil, com oil, cottonseed oil, olive oil, peanut oil, peppermint oil, safflower oil, sesame oil, soybean oil, hydrogenated vegetable oils, hydrogenated soybean oil, and medium-chain triglycerides of coconut oil, and palm seed oil.
- Water- miscible vehicles include, but are not limited to, ethanol, l,3-butanediol, liquid polyethylene glycol (e.g., polyethylene glycol 300 and polyethylene glycol 400), propylene glycol, glycerin, N- methyl-2-pyrrolidone, N,N-dimethylacetamide, and dimethyl sulfoxide.
- Suitable antimicrobial agents or preservatives include, but are not limited to, phenols, cresols, mercurials, benzyl alcohol, chlorobutanol, methyl and propyl p-hydroxybenzoates, thimerosal, benzalkonium chloride (e.g., benzethonium chloride), methyl- and propyl-parabens, and sorbic acid.
- Suitable isotonic agents include, but are not limited to, sodium chloride, glycerin, and dextrose.
- Suitable buffering agents include, but are not limited to, phosphate and citrate.
- Suitable antioxidants are those as described herein, including bisulfite and sodium metabisulfite.
- Suitable local anesthetics include, but are not limited to, procaine hydrochloride.
- Suitable suspending and dispersing agents are those as described herein, including sodium carboxymethylcelluose, hydroxypropyl methylcellulose, and polyvinylpyrrolidone.
- Suitable emulsifying agents include those described herein, including polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan monooleate 80, and triethanolamine oleate.
- Suitable sequestering or chelating agents include, but are not limited to EDTA.
- Suitable pH adjusting agents include, but are not limited to, sodium hydroxide, hydrochloric acid, citric acid, and lactic acid.
- Suitable complexing agents include, but are not limited to, cyclodextrins, including a-cyclodextrin, b-cyclodextrin, hydroxypropyl-b- cyclodextrin, sulfobutylether ⁇ -cyclodextrin, and sulfobutylether 7 ⁇ -cyclodextrin (CAPTISOL®, CyDex, Lenexa, Kans.).
- cyclodextrins including a-cyclodextrin, b-cyclodextrin, hydroxypropyl-b- cyclodextrin, sulfobutylether ⁇ -cyclodextrin, and sulfobutylether 7 ⁇ -cyclodextrin (CAPTISOL®, CyDex, Lenexa, Kans.).
- compositions provided herein can be formulated for single or multiple dosage administration ⁇
- the single dosage formulations are packaged in an ampoule, a vial, or a syringe.
- the multiple dosage parenteral formulations must contain an antimicrobial agent at bacteriostatic or fungistatic concentrations. All parenteral formulations must be sterile, as known and practiced in the art.
- the pharmaceutical compositions are provided as ready-to-use sterile solutions.
- the pharmaceutical compositions are provided as sterile dry soluble products, including lyophilized powders and hypodermic tablets, to be reconstituted with a vehicle prior to use.
- the lyophilized nanoparticles are provided in a vial for reconstitution with a sterile aqueous solution just prior to injection.
- the pharmaceutical compositions are provided as ready-to-use sterile suspensions.
- the pharmaceutical compositions are provided as sterile dry insoluble products to be reconstituted with a vehicle prior to use.
- the pharmaceutical compositions are provided as ready-to-use sterile emulsions.
- the pharmaceutical compositions provided herein can be formulated as immediate or modified release dosage forms, including delayed-, sustained, pulsed-, controlled, targeted-, and programmed-release forms.
- compositions can be formulated as a suspension, solid, semi-solid, or thixotropic liquid, for administration as an implanted depot.
- oral administration also includes buccal, lingual, and sublingual administration ⁇ Suitable oral dosage forms include, but are not limited to, tablets, fastmelts, chewable tablets, capsules, pills, troches, lozenges, pastilles, cachets, pellets, medicated chewing gum, bulk powders, effervescent or non-effervescent powders or granules, solutions, emulsions, suspensions, wafers, sprinkles, elixirs, and syrups.
- the pharmaceutical compositions can contain one or more pharmaceutically acceptable carriers or excipients, including, but not limited to, binders, fillers, diluents, disintegrants, wetting agents, lubricants, glidants, coloring agents, dye-migration inhibitors, sweetening agents, and flavoring agents.
- pharmaceutically acceptable carriers or excipients including, but not limited to, binders, fillers, diluents, disintegrants, wetting agents, lubricants, glidants, coloring agents, dye-migration inhibitors, sweetening agents, and flavoring agents.
- Binders or granulators impart cohesiveness to a tablet to ensure the tablet remaining intact after compression.
- Suitable binders or granulators include, but are not limited to, starches, such as corn starch, potato starch, and pre-gelatinized starch (e.g., STARCH 1500); gelatin; sugars, such as sucrose, glucose, dextrose, molasses, and lactose; natural and synthetic gums, such as acacia, alginic acid, alginates, extract of Irish moss, panwar gum, ghatti gum, mucilage of isabgol husks, carboxymethylcellulose, methylcellulose, polyvinylpyrrolidone (PVP), Veegum, larch arabogalactan, powdered tragacanth, and guar gum; celluloses, such as ethyl cellulose, cellulose acetate, carboxymethyl cellulose calcium, sodium carboxymethyl cellulose, methyl cellulose, hydroxye
- Suitable fillers include, but are not limited to, talc, calcium carbonate, microcrystalline cellulose, powdered cellulose, dextrates, kaolin, mannitol, silicic acid, sorbitol, starch, pre-gelatinized starch, and mixtures thereof.
- the binder or filler may be present from about 50 to about 99% by weight in the pharmaceutical compositions provided herein.
- Suitable diluents include, but are not limited to, dicalcium phosphate, calcium sulfate, lactose, sorbitol, sucrose, inositol, cellulose, kaolin, mannitol, sodium chloride, dry starch, and powdered sugar.
- Certain diluents, such as mannitol, lactose, sorbitol, sucrose, and inositol when present in sufficient quantity, can impart properties to some compressed tablets that permit disintegration in the mouth by chewing. Such compressed tablets can be used as chewable tablets.
- Suitable disintegrants include, but are not limited to, agar; bentonite; celluloses, such as methylcellulose and carboxymethylcellulose; wood products; natural sponge; cation-exchange resins; alginic acid; gums, such as guar gum and Veegum HV; citrus pulp; cross-linked celluloses, such as croscarmellose; cross-linked polymers, such as crospovidone; cross-linked starches; calcium carbonate; microcrystalline cellulose, such as sodium starch glycolate; polacrilin potassium; starches, such as com starch, potato starch, tapioca starch, and pre-gelatinized starch; clays; aligns; and mixtures thereof.
- the amount of a disintegrant in the pharmaceutical compositions provided herein varies upon the type of formulation, and is readily discernible to those of ordinary skill in the art.
- the pharmaceutical compositions provided herein may contain from about 0.5 to about 15% or from about 1 to about 5% by weight of a disintegrant.
- Suitable lubricants include, but are not limited to, calcium stearate; magnesium stearate; mineral oil; light mineral oil; glycerin; sorbitol; mannitol; glycols, such as glycerol behenate and polyethylene glycol (PEG); stearic acid; sodium lauryl sulfate; talc; hydrogenated vegetable oil, including peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, com oil, and soybean oil; zinc stearate; ethyl oleate; ethyl laureate; agar; starch; lycopodium; silica or silica gels, such as AEROSIL® 200 (W. R. Grace Co., Baltimore, Md.) and CAB-O-SIL® (Cabot Co. of Boston, Mass.); and mixtures thereof.
- the pharmaceutical compositions provided herein may contain about 0.1 to about 5% by weight of a lubricant.
- Suitable glidants include colloidal silicon dioxide, CAB-O-SIL® (Cabot Co. of Boston, Mass.), and asbestos-free talc.
- Coloring agents include any of the approved, certified, water soluble FD&C dyes, and water insoluble FD&C dyes suspended on alumina hydrate, and color lakes and mixtures thereof.
- a color lake is the combination by adsorption of a water-soluble dye to a hydrous oxide of a heavy metal, resulting in an insoluble form of the dye.
- Flavoring agents include natural flavors extracted from plants, such as fruits, and synthetic blends of compounds which produce a pleasant taste sensation, such as peppermint and methyl salicylate.
- Sweetening agents include sucrose, lactose, mannitol, syrups, glycerin, and artificial sweeteners, such as saccharin and aspartame.
- Suitable emulsifying agents include gelatin, acacia, tragacanth, bentonite, and surfactants, such as polyoxyethylene sorbitan monooleate (TWEEN® 20), polyoxyethylene sorbitan monooleate 80 (TWEEN® 80), and triethanolamine oleate.
- Suspending and dispersing agents include sodium carboxymethylcellulose, pectin, tragacanth, Veegum, acacia, sodium carbomethylcellulose, hydroxypropyl methylcellulose, and polyvinylpyrrolidone.
- Preservatives include glycerin, methyl and propylparaben, benzoic add, sodium benzoate and alcohol.
- Wetting agents include propylene glycol monostearate, sorbitan monooleate, diethylene glycol monolaurate, and polyoxyethylene lauryl ether.
- Solvents include glycerin, sorbitol, ethyl alcohol, and syrup. Examples of non- aqueous liquids utilized in emulsions include mineral oil and cottonseed oil.
- Organic acids include citric and tartaric acid.
- Sources of carbon dioxide include sodium bicarbonate and sodium carbonate.
- compositions provided herein can be provided as compressed tablets, tablet triturates, chewable lozenges, rapidly dissolving tablets, multiple compressed tablets, or enteric-coating tablets, sugar-coated, or film-coated tablets.
- Enteric-coated tablets are compressed tablets coated with substances that resist the action of stomach acid but dissolve or disintegrate in the intestine, thus protecting the active ingredients from the acidic environment of the stomach.
- Enteric-coatings include, but are not limited to, fatty acids, fats, phenyl salicylate, waxes, shellac, ammoniated shellac, and cellulose acetate phthalates.
- Sugar-coated tablets are compressed tablets surrounded by a sugar coating, which may be beneficial in covering up objectionable tastes or odors and in protecting the tablets from oxidation.
- Film-coated tablets are compressed tablets that are covered with a thin layer or film of a water-soluble material.
- Film coatings include, but are not limited to, hydroxyethylcellulose, sodium carboxymethylcellulose, polyethylene glycol 4000, and cellulose acetate phthalate.
- Hydrophilic polymer formulations have been widely used for improved oral availability such as ethylene oxides, hydroxy propyl methyl cellulose (HPC), poly (ethylene oxide) (PEO), polyvinyl alcohol (PVA), poly(hydroxyethylmethyl acrylate) methyl methacrylate (PHEMA), or vinyl acetate (PCT Pub. No. WO1999/37302 (Alvarez et al. ); Dimitrov & Lambov, 1999, Int J Pharm 189 105-111; Zhang et al., 1990, Proc Int. Symp Controlled Release Bioact. Mater. 17, 333, the contents of which are hereby incorporated by reference in their entirety).
- Film coating imparts the same general characteristics as sugar coating. Multiple compressed tablets are compressed tablets made by more than one compression cycle, including layered tablets, and press- coated or dry-coated tablets.
- the tablet dosage forms can be prepared from the active ingredient in powdered, crystalline, or granular forms, alone or in combination with one or more carriers or excipients described herein, including binders, disintegrants, controlled-release polymers, lubricants, diluents, and/or colorants. Flavoring and sweetening agents are especially useful in the formation of chewable tablets and lozenges.
- the pharmaceutical compositions provided herein can be provided as soft or hard capsules, which can be made from gelatin, methylcellulose, starch, or calcium alginate.
- the hard gelatin capsule also known as the dry-filled capsule (DFC)
- DFC dry-filled capsule
- the soft elastic capsule is a soft, globular shell, such as a gelatin shell, which is plasticized by the addition of glycerin, sorbitol, or a similar polyol.
- the soft gelatin shells may contain a preservative to prevent the growth of microorganisms.
- Suitable preservatives are those as described herein, including methyl- and propyl parabens, and sorbic acid.
- the liquid, semisolid, and solid dosage forms provided herein may be encapsulated in a capsule.
- Suitable liquid and semisolid dosage forms include solutions and suspensions in propylene carbonate, vegetable oils, or triglycerides. Capsules containing such solutions can be prepared as described in U.S. Pat. Nos. 4,328,245; 4,409,239; and 4,410,545, the contents of which are hereby incorporated by reference in their entirety.
- the capsules may also be coated as known by those of skill in the art in order to modify or sustain dissolution of the active ingredient.
- compositions provided herein can be provided in liquid and semisolid dosage forms, including emulsions, solutions, suspensions, elixirs, and syrups.
- An emulsion is a two-phase system, in which one liquid is dispersed in the form of small globules throughout another liquid, which can be oil-in-water or water-in-oil.
- Emulsions may include a pharmaceutically acceptable non-aqueous liquid or solvent, emulsifying agent, and preservative.
- Suspensions may include a pharmaceutically acceptable suspending agent and preservative.
- Aqueous alcoholic solutions may include a pharmaceutically acceptable acetal, such as a di(lower alkyl) acetal of a lower alkyl aldehyde, e.g., acetaldehyde diethyl acetal; and a water-miscible solvent having one or more hydroxyl groups, such as propylene glycol and ethanol.
- Elixirs are clear, sweetened, and hydroalcoholic solutions.
- Syrups are concentrated aqueous solutions of a sugar, for example, sucrose, and may also contain a preservative.
- a solution in a polyethylene glycol may be diluted with a sufficient quantity of a pharmaceutically acceptable liquid carrier, e.g., water, to be measured conveniently for administration.
- Other useful liquid and semisolid dosage forms include, but are not limited to, those containing the active ingredient(s) provided herein, and a dialkylated mono- or poly-alkylene glycol, including, l,2-dimethoxymethane, diglyme, triglyme, tetraglyme, polyethylene glycol-350- dimethyl ether, polyethylene glycol-550-dimethyl ether, polyethylene glycol-750-dimethyl ether, wherein 350, 550, and 750 refer to the approximate average molecular weight of the polyethylene glycol.
- a dialkylated mono- or poly-alkylene glycol including, l,2-dimethoxymethane, diglyme, triglyme, tetraglyme, polyethylene glycol-350- dimethyl ether, polyethylene glycol-550-dimethyl ether, polyethylene glycol-750-dimethyl ether, wherein 350, 550, and 750 refer to the approximate average molecular weight of the polyethylene glycol
- These formulations can further comprise one or more antioxidants, such as butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), propyl gallate, vitamin E, hydroquinone, hydroxycoumarins, ethanolamine, lecithin, cephalin, ascorbic acid, malic acid, sorbitol, phosphoric acid, bisulfite, sodium metabisulfite, thiodipropionic acid and its esters, and dithiocarbamates.
- antioxidants such as butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), propyl gallate, vitamin E, hydroquinone, hydroxycoumarins, ethanolamine, lecithin, cephalin, ascorbic acid, malic acid, sorbitol, phosphoric acid, bisulfite, sodium metabisulfite, thiodipropionic acid and its esters, and dithiocarbamates.
- antioxidants such as
- compositions provided herein for oral administration can be also provided in the forms of liposomes, micelles, microspheres, or nanosystems.
- Micellar dosage forms can be prepared as described in U.S. Pat. No. 6,350,458, the content of which is hereby incorporated by reference in its entirety.
- compositions provided herein can be provided as non-effervescent or effervescent, granules and powders, to be reconstituted into a liquid dosage form.
- Pharmaceutically acceptable carriers and excipients used in the non-effervescent granules or powders may include diluents, sweeteners, and wetting agents.
- Pharmaceutically acceptable carriers and excipients used in the effervescent granules or powders may include organic acids and a source of carbon dioxide.
- Coloring and flavoring agents can be used in all of the above dosage forms.
- the pharmaceutical compositions provided herein can be formulated as immediate or modified release dosage forms, including delayed-, sustained, pulsed-, controlled, targeted-, and programmed- release forms.
- the pharmaceutical compositions provided herein can be co-formulated with other active ingredients which do not impair the desired therapeutic action, or with substances that supplement the desired action.
- compositions provided herein can be administered topically to the skin, orifices, or mucosa.
- topical administration includes (intra)dermal, conjunctival, intracorneal, intraocular, ophthalmic, auricular, transdermal, nasal, vaginal, urethral, respiratory, and rectal administration ⁇
- compositions provided herein can be formulated in any dosage forms that are suitable for topical administration for local or systemic effect, including emulsions, solutions, suspensions, creams, gels, hydrogels, ointments, dusting powders, dressings, elixirs, lotions, suspensions, tinctures, pastes, foams, films, aerosols, irrigations, sprays, suppositories, bandages, dermal patches.
- the topical formulation of the pharmaceutical compositions provided herein can also comprise liposomes, micelles, microspheres, nanosystems, and mixtures thereof.
- Pharmaceutically acceptable carriers and excipients suitable for use in the topical formulations provided herein include, but are not limited to, aqueous vehicles, water-miscible vehicles, non-aqueous vehicles, antimicrobial agents or preservatives against the growth of microorganisms, stabilizers, solubility enhancers, isotonic agents, buffering agents, antioxidants, local anesthetics, suspending and dispersing agents, wetting or emulsifying agents, complexing agents, sequestering or chelating agents, penetration enhancers, cryoprotectants, lyoprotectants, thickening agents, and inert gases.
- compositions can also be administered topically by electroporation, iontophoresis, phonophoresis, sonophoresis, or microneedle or needle-free injection, such as POWDERJECTTM (Chiron Corp., Emeryville, CA), and BIOJECTTM (Bioject Medical Technologies Inc., Tualatin, OR).
- electroporation iontophoresis, phonophoresis, sonophoresis, or microneedle or needle-free injection
- BIOJECTTM Bioject Medical Technologies Inc., Tualatin, OR
- Suitable ointment vehicles include oleaginous or hydrocarbon vehicles, including lard, benzoinated lard, olive oil, cottonseed oil, and other oils, white petrolatum; emulsifiable or absorption vehicles, such as hydrophilic petrolatum, hydroxystearin sulfate, and anhydrous lanolin; water-removable vehicles, such as hydrophilic ointment; water-soluble ointment vehicles, including polyethylene glycols of varying molecular weight; emulsion vehicles, either water-in-oil (W/O) emulsions or oil-in-water (O/W) emulsions, including cetyl alcohol, glyceryl monostearate, lanolin, and stearic acid (see, Remington: The Science and Practice of Pharmacy.
- Suitable cream base can be oil-in-water or water-in-oil.
- Cream vehicles may be water-washable, and contain an oil phase, an emulsifier, and an aqueous phase.
- the oil phase is also called the“internal” phase, which is generally comprised of petrolatum and a fatty alcohol such as cetyl or stearyl alcohol.
- the aqueous phase usually, although not necessarily, exceeds the oil phase in volume, and generally contains a humectant.
- the emulsifier in a cream formulation may be a nonionic, anionic, cationic, or amphoteric surfactant.
- Gels are semisolid, suspension-type systems. Single -phase gels contain organic macromolecules distributed substantially uniformly throughout the liquid carrier. Suitable gelling agents include crosslinked acrylic acid polymers, such as carbomers, carboxypolyalkylenes, CARBOPOL®; hydrophilic polymers, such as polyethylene oxides, polyoxyethylene- polyoxypropylene copolymers, and polyvinylalcohol; cellulosic polymers, such as hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose phthalate, and methylcellulose; gums, such as tragacanth and xanthan gum; sodium alginate; and gelatin.
- dispersing agents such as alcohol or glycerin can be added, or the gelling agent can be dispersed by trituration, mechanical mixing, and/or stirring.
- compositions provided herein can be administered rectally, urethrally, vaginally, or perivaginally in the forms of suppositories, pessaries, bougies, poultices or cataplasm, pastes, powders, dressings, creams, plasters, contraceptives, ointments, solutions, emulsions, suspensions, tampons, gels, foams, sprays, or enemas.
- These dosage forms can be manufactured using conventional processes as described in Remington: The Science and Practice of Pharmacy, supra.
- Rectal, urethral, and vaginal suppositories are solid bodies for insertion into body orifices, which are solid at ordinary temperatures but melt or soften at body temperature to release the active ingredient(s) inside the orifices.
- Pharmaceutically acceptable carriers utilized in rectal and vaginal suppositories include bases or vehicles, such as stiffening agents, which produce a melting point in the proximity of body temperature, when formulated with the pharmaceutical compositions provided herein; and antioxidants as described herein, including bisulfite and sodium metabisulfite.
- Suitable vehicles include, but are not limited to, cocoa butter (theobroma oil), glycerin- gelatin, carbowax (polyoxyethylene glycol), spermaceti, paraffin, white and yellow wax, and appropriate mixtures of mono-, di- and triglycerides of fatty acids, hydrogels, such as polyvinyl alcohol, hydroxyethyl methacrylate, polyacrylic acid; glycerinated gelatin. Combinations of the various vehicles may be used. Rectal and vaginal suppositories may be prepared by the compressed method or molding. The typical weight of a rectal and vaginal suppository is about 2 to about 3 g. [00106]
- the pharmaceutical compositions provided herein can be administered ophthalmically in the forms of solutions, suspensions, ointments, emulsions, gel-forming solutions, powders for solutions, gels, ocular inserts, and implants.
- the pharmaceutical compositions provided herein can be administered intranasally or by inhalation to the respiratory tract.
- the pharmaceutical compositions can be provided in the form of an aerosol or solution for delivery using a pressurized container, pump, spray, atomizer, such as an atomizer using electrohydrodynamics to produce a fine mist, or nebulizer, alone or in combination with a suitable propellant, such as 1,1,1, 2-tetrafluoroethane or 1, 1,1, 2, 3,3,3- heptafluoropropane.
- a suitable propellant such as 1,1,1, 2-tetrafluoroethane or 1, 1,1, 2, 3,3,3- heptafluoropropane.
- the pharmaceutical compositions can also be provided as a dry powder for insufflation, alone or in combination with an inert carrier such as lactose or phospholipids; and nasal drops.
- an inert carrier such as lactose or phospholipids
- Many pulmonary drugs are delivered by dry powder inhalers (DPIs) with differing arrangements such as single dose, multi-dose with the pharmaceutical composition in bulk, or multi-dose with individual blister packs. See Kleinstreuer et al. 2015; Weer and Miller 2015 J Pharm Sci 104 3259- 3288.
- the powder can comprise a bioadhesive agent, including chitosan or cyclodextrin.
- the pharmaceutical composition may be delivered by nebulizer such as an atomizer (jet nebulizer), an ultrasonic wave nebulizer, or a vibrating mesh nebulizer.
- nebulizer such as an atomizer (jet nebulizer), an ultrasonic wave nebulizer, or a vibrating mesh nebulizer. See Kleinstreuer et al. 2015.
- the pharmaceutical composition may be dissolved in glycerol, propane 1,2 diol gycol (PG), water or a mixture thereof and vaporized at relatively low temperature (>100 °C, typically 40-65 °C) in an e-cigarette.
- glycerol propane 1,2 diol gycol
- PG propane 1,2 diol gycol
- relatively low temperature >100 °C, typically 40-65 °C
- Solutions or suspensions for use in a pressurized container, pump, spray, atomizer, or nebulizer can be formulated to contain ethanol, aqueous ethanol, or a suitable alternative agent for dispersing, solubilizing, or extending release of the active ingredient provided herein, a propellant as solvent; and/or a surfactant, such as sorbitan trioleate, oleic acid, or an oligolactic acid.
- compositions provided herein can be micronized to a size suitable for delivery by inhalation, such as about 50 micrometers or less, or about 10 micrometers or less.
- Particles of such sizes can be prepared using a comminuting method known to those skilled in the art, such as spiral jet milling, fluid bed jet milling, supercritical fluid processing to form nanoparticles, high pressure homogenization, or spray drying.
- Capsules, blisters and cartridges for use in an inhaler or insufflator can be formulated to contain a powder mix of the pharmaceutical compositions provided herein; a suitable powder base, such as lactose or starch; and a performance modifier, such as l-leucine, mannitol, or magnesium stearate.
- the lactose may be anhydrous or in the form of the monohydrate.
- Other suitable excipients or carriers include dextran, glucose, maltose, sorbitol, xylitol, fructose, sucrose, and trehalose.
- the pharmaceutical compositions provided herein for inhaled/intranasal administration can further comprise a suitable flavor, such as menthol and levomenthol, or sweeteners, such as saccharin or saccharin sodium.
- compositions provided herein for topical administration can be formulated to be immediate release or modified release, including delayed-, sustained-, pulsed-, controlled-, targeted, and programmed release.
- modified release dosage form refers to a dosage form in which the rate or place of release of the active ingredient(s) is different from that of an immediate dosage form when administered by the same route.
- Modified release dosage forms include delayed-, extended-, prolonged-, sustained-, pulsatile-, controlled-, accelerated- and fast-, targeted-, programmed-release, and gastric retention dosage forms.
- compositions in modified release dosage forms can be prepared using a variety of modified release devices and methods known to those skilled in the art, including, but not limited to, matrix controlled release devices, osmotic controlled release devices, multi-particulate controlled release devices, ion- exchange resins, enteric coatings, multilayered coatings, microspheres, liposomes, and combinations thereof
- the release rate of the active ingredient(s) can also be modified by varying the particle sizes and polymorphism of the active ingredient(s).
- modified release examples include, but are not limited to, those described in U.S. Pat. Nos. 3,845,770; 3,916,899; 3,536,809; 3,598,123; 4,008,719; 5,674,533; 5,059,595; 5,591,767; 5,120,548; 5,073,543; 5,639,476; 5,354,556; 5,639,480; 5,733,566; 5,739,108; 5,891,474;
- compositions provided herein in a modified release dosage form can be fabricated using a matrix controlled release device known to those skilled in the art (see, Takada et al. in“Encyclopedia of Controlled Drug Delivery,” Vol.2, Mathiowitz Ed., Wiley, 1999).
- the pharmaceutical compositions provided herein in a modified release dosage form is formulated using an erodible matrix device, which is water- swellable, erodible, or soluble polymers, including synthetic polymers, and naturally occurring polymers and derivatives, such as polysaccharides and proteins.
- an erodible matrix device which is water- swellable, erodible, or soluble polymers, including synthetic polymers, and naturally occurring polymers and derivatives, such as polysaccharides and proteins.
- Materials useful in forming an erodible matrix include, but are not limited to, chitin, chitosan, dextran, and pullulan; gum agar, gum arabic, gum karaya, locust bean gum, gum tragacanth, carrageenans, gum ghatti, guar gum, xanthan gum, and scleroglucan; starches, such as dextrin and maltodextrin; hydrophilic colloids, such as pectin; phosphatides, such as lecithin; alginates; propylene glycol alginate; gelatin; collagen; and cellulosics, such as ethyl cellulose (EC), methylethyl cellulose (MEC), carboxymethyl cellulose (CMC), CMEC, hydroxyethyl cellulose (HEC), hydroxypropyl cellulose (HPC), cellulose acetate (CA), cellulose propionate (CP), cellulose butyrate (CB),
- EC
- the pharmaceutical compositions are formulated with a non- erodible matrix device.
- the active ingredient(s) is dissolved or dispersed in an inert matrix and is released primarily by diffusion through the inert matrix once administered.
- Materials suitable for use as a non-erodible matrix device included, but are not limited to, insoluble plastics, such as polyethylene, polypropylene, polyisoprene, polyisobutylene, polybutadiene, polymethylmethacrylate, polybutylmethacrylate, chlorinated polyethylene, polyvinylchloride, methyl acrylate-methyl methacrylate copolymers, ethylene-vinyl acetate copolymers, ethylene/propylene copolymers, ethylene/ethyl acrylate copolymers, vinyl chloride copolymers with vinyl acetate, vinylidene chloride, ethylene and propylene, ionomer polyethylene terephthalate, butyl rubber epichlorohydr
- the desired release kinetics can be controlled, for example, via the polymer type employed; the polymer viscosity; the particle sizes of the polymer and/or the active ingredient(s); the ratio of the active ingredient(s) versus the polymer, and other excipients or carriers in the compositions.
- compositions provided herein in a modified release dosage form can be prepared by methods known to those skilled in the art, including direct compression, dry or wet granulation followed by compression, melt-granulation followed by compression.
- compositions provided herein in a modified release dosage form can be fabricated using an osmotic controlled release device, including one-chamber system, two- chamber system, asymmetric membrane technology (AMT), and extruding core system (ECS).
- AMT asymmetric membrane technology
- ECS extruding core system
- such devices have at least two components: (a) the core which contains the active ingredient(s); and (b) a semipermeable membrane with at least one delivery port, which encapsulates the core.
- the semipermeable membrane controls the influx of water to the core from an aqueous environment of use so as to cause drug release by extrusion through the delivery port(s).
- the core of the osmotic device optionally includes an osmotic agent, which creates a driving force for transport of water from the environment of use into the core of the device.
- osmotic agents water-swellable hydrophilic polymers, which are also referred to as“osmopolymers” and“hydrogels,” including, but not limited to, hydrophilic vinyl and acrylic polymers, polysaccharides such as calcium alginate, polyethylene oxide (PEO), polyethylene glycol (PEG), polypropylene glycol (PPG), poly (2-hydroxy ethyl methacrylate), poly(acrylic) acid, poly(methacrylic) acid, polyvinylpyrrolidone (PVP), crosslinked PVP, polyvinyl alcohol (PVA), PVA/PVP copolymers, PVA/PVP copolymers with hydrophobic monomers such as methyl methacrylate and vinyl acetate, hydrophilic polyurethan
- the other class of osmotic agents is osmogens, which are capable of imbibing water to affect an osmotic pressure gradient across the barrier of the surrounding coating.
- Suitable osmogens include, but are not limited to, inorganic salts, such as magnesium sulfate, magnesium chloride, calcium chloride, sodium chloride, lithium chloride, potassium sulfate, potassium phosphates, sodium carbonate, sodium sulfite, lithium sulfate, potassium chloride, and sodium sulfate; sugars, such as dextrose, fructose, glucose, inositol, lactose, maltose, mannitol, raffinose, sorbitol, sucrose, trehalose, and xylitol, organic acids, such as ascorbic acid, benzoic acid, fumaric acid, citric acid, maleic acid, sebacic acid, sorbic acid, adipic acid, edetic
- Osmotic agents of different dissolution rates can be employed to influence how rapidly the active ingredient(s) is initially delivered from the dosage form.
- amorphous sugars such as MANNOGEMTM EZ (SPI Pharma, Lewes, DE) can be used to provide faster delivery during the first couple of hours to promptly produce the desired therapeutic effect, and gradually and continually release of the remaining amount to maintain the desired level of therapeutic or prophylactic effect over an extended period of time.
- the active ingredient(s) is released at such a rate to replace the amount of the active ingredient metabolized and excreted.
- the core can also include a wide variety of other excipients and carriers as described herein to enhance the performance of the dosage form or to promote stability or processing.
- Materials useful in forming the semipermeable membrane include various grades of acrylics, vinyls, ethers, polyamides, polyesters, and cellulosic derivatives that are water-permeable and water-insoluble at physiologically relevant pHs, or are susceptible to being rendered water- insoluble by chemical alteration, such as crosslinking.
- Suitable polymers useful in forming the coating include plasticized, unplasticized, and reinforced cellulose acetate (CA), cellulose diacetate, cellulose triacetate, CA propionate, cellulose nitrate, cellulose acetate butyrate (CAB), CA ethyl carbamate, CAP, CA methyl carbamate, CA succinate, cellulose acetate trimellitate (CAT), CA dimethylaminoacetate, CA ethyl carbonate, CA chloroacetate, CA ethyl oxalate, CA methyl sulfonate, CA butyl sulfonate, CA p-toluene sulfonate, agar acetate, amylose triacetate, beta glucan acetate, beta glucan triacetate, acetaldehyde dimethyl acetate, triacetate of locust bean gum, hydroxylated ethylene-vinylacetate, EC, PEG, PPG, PEG/PPG copo
- Semipermeable membrane can also be a hydrophobic microporous membrane, wherein the pores are substantially filled with a gas and are not wetted by the aqueous medium but are permeable to water vapor, as disclosed in U.S. Pat. No. 5,798,119.
- Such hydrophobic but water- vapor permeable membrane are typically composed of hydrophobic polymers such as polyalkenes, polyethylene, polypropylene, polytetrafluoroethylene, polyacrylic acid derivatives, polyethers, polysulfones, polyethersulfones, polystyrenes, polyvinyl halides, polyvinylidene fluoride, polyvinyl esters and ethers, natural waxes, and synthetic waxes.
- hydrophobic polymers such as polyalkenes, polyethylene, polypropylene, polytetrafluoroethylene, polyacrylic acid derivatives, polyethers, polysulfones, polyethersulfones, polystyrenes, polyvinyl halides, polyvinylidene fluoride, polyvinyl esters and ethers, natural waxes, and synthetic waxes.
- the delivery port(s) on the semipermeable membrane can be formed post-coating by mechanical or laser drilling. Delivery port(s) can also be formed in situ by erosion of a plug of water-soluble material or by rupture of a thinner portion of the membrane over an indentation in the core. In addition, delivery ports can be formed during coating process, as in the case of asymmetric membrane coatings of the type disclosed in U.S. Pat. Nos. 5,612,059 and 5,698,220, the contents of which are hereby incorporated by reference in their entirety.
- the total amount of the active ingredient(s) released and the release rate can substantially by modulated via the thickness and porosity of the semipermeable membrane, the composition of the core, and the number, size, and position of the delivery ports.
- compositions in an osmotic controlled-release dosage form can further comprise additional conventional excipients or carriers as described herein to promote performance or processing of the formulation.
- the osmotic controlled-release dosage forms can be prepared according to conventional methods and techniques known to those skilled in the art. See, Remington: The Science and Practice of Pharmacy, supra ; Santus and Baker, J. Controlled Release 1995, 35, 1-21; Verma et ak, Drug Development and Industrial Pharmacy 2000, 26, 695-708; Verma et ak, J. Controlled Release 2002, 79, 7-27, the contents of which are hereby incorporated by reference in their entirety.
- the pharmaceutical compositions provided herein are formulated as AMT controlled-release dosage form, which comprises an asymmetric osmotic membrane that coats a core comprising the active ingredient(s) and other pharmaceutically acceptable excipients or carriers.
- AMT controlled-release dosage forms can be prepared according to conventional methods and techniques known to those skilled in the art, including direct compression, dry granulation, wet granulation, and a dip-coating method.
- the pharmaceutical compositions provided herein are formulated as ESC controlled-release dosage form, which comprises an osmotic membrane that coats a core comprising the active ingredient(s), a hydroxylethyl cellulose, and other pharmaceutically acceptable excipients or carriers.
- compositions provided herein in a modified release dosage form can be fabricated as a multiparticulate controlled release device, which comprises a multiplicity of particles, granules, or pellets, ranging from about 10 pm to about 3 mm, about 50 pm to about 2.5 mm, or from about 100 pm to about 1 mm in diameter.
- multiparticulates can be made by the processes known to those skilled in the art, including wet-and dry-granulation, extrusion/spheronization, roller-compaction, melt-congealing, and by spray-coating seed cores. See, for example, Multiparticulate Oral Drug Delivery: Marcel Dekker: 1994; and Pharmaceutical Pelletization Technology; Marcel Dekker: 1989.
- excipients or carriers as described herein can be blended with the pharmaceutical compositions to aid in processing and forming the multiparticulates.
- the resulting particles can themselves constitute the multiparticulate device or can be coated by various film forming materials, such as enteric polymers, water-swellable, and water-soluble polymers.
- the multiparticulates can be further processed as a capsule or a tablet.
- an “effective amount” refers generally to an amount that is a sufficient, but non- toxic, amount of the active ingredient (i.e., a compound disclosed herein) to achieve the desired effect, which is a reduction or elimination in the severity and/or frequency of symptoms and/or improvement or remediation of damage.
- a “therapeutically effective amount” refers to an amount that is sufficient to remedy a disease state or symptoms, or otherwise prevent, hinder, retard or reverse the progression of a disease or any other undesirable symptom.
- a “prophylactically effective amount” refers to an amount that is effective to prevent, hinder or retard the onset of a disease state or symptom.
- toxicity and therapeutic efficacy of the compound disclosed herein can be determined according to standard pharmaceutical procedures in cell cultures and/or experimental animals, including, for example, determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population).
- the dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50/ED50.
- Compositions that exhibit large therapeutic indices are preferred.
- the data obtained from cell culture and/or animal studies can be used in formulating a range of dosages for humans.
- the dosage of the active ingredient typically lines within a range of circulating concentrations that include the ED50 with little or no toxicity.
- the dosage can vary within this range depending upon the dosage form employed and the route of administration utilized.
- a pharmaceutical composition comprising a compound disclosed herein to be employed therapeutically or prophylactically will depend, for example, upon the therapeutic context and objectives.
- dosage levels for treatment will thus vary depending, in part, upon the molecule delivered, the indication for which the compound disclosed herein is being used, the route of administration, and the size (body weight, body surface or organ size) and/or condition (the age and general health) of the patient.
- a clinician may titer the dosage and modify the route of administration to obtain the optimal therapeutic effect.
- Typical dosages range from about 0.1 pg/kg to up to about 100 mg/kg or more, depending on the factors mentioned above.
- the dosage may range from 0.1 pg/kg up to about 150 mg/kg; or 1 pg/kg up to about 100 mg/kg; or 5 pg/kg up to about 50 mg/kg.
- the dosing frequency will depend upon the pharmacokinetic parameters of the compound disclosed herein in the formulation. For example, a clinician will administer the composition until a dosage is reached that achieves the desired effect.
- the composition may therefore be administered as a single dose or as two or more doses (which may or may not contain the same amount of the desired molecule) over time, or as a continuous infusion via an implantation device or catheter. Treatment may be continuous over time or intermittent. Further refinement of the appropriate dosage is routinely made by those of ordinary skill in the art and is within the ambit of tasks routinely performed by them. Appropriate dosages may be ascertained through use of appropriate dose-response data.
- gd T cells from HIV-infected virologically suppressed donors were expanded with the bisphosphonate pamidronate (PAM) and cells were used in autologous cellular systems ex vivo. These cells are i) are potent cytotoxic effectors able to efficiently inhibit HIV replication ex vivo, ii) degranulate in the presence of autologous infected CD4 T cells and iii) specifically clear latently infected cells after latency reversal with VOR.
- PAM bisphosphonate pamidronate
- the human immunodeficiency virus infects CD4+ cells and integrates its viral genome into the host cell genome. Some of these cells enter a resting state where latent but replication-competent HIV remains invisible to current antiretroviral therapy (ART) and the immune system. This quiescent provirus within long-lived resting CD4 (rCD4) cells represent the main barrier to cure HIV infection, as demonstrated by HIV rebound when ART is interrupted. Current research efforts to cure HIV infection aim to get HIV out of latency using small molecule
- LRAs HIV latency-reversing agents
- HD AC Histone deacetylase
- FTi farnesyl transferase inhibitors
- SAHA HDAC inhibitor vorinostat
- the enzyme famesyl transferase is required for prenylation, which transfers the farnesyl pyrophosphate (FPP) groups to proteins.
- FPP groups are essential for several protein post- translational modifications such as prenylation.
- Protein prenylation is critical to the functions of a select group of proteins that have crucial functions in biological regulation, such as protein localization and regulatory capacity of cell signaling (Wang and Casey, 2016).
- FTi inhibit protein prenylation.
- These FPP groups are synthesized in the isoprenoid biosynthesis pathway also called the mevalonate pathway.
- BP statins and bisphosphonates
- BP are a class of drugs currently approved for the treatment of several diseases involving bone density loss including treatment of osteoporosis, multiple myeloma, bone metastases lesions, and Paget’s disease, among others.
- BP can be divided into two classes: non-nitrogen-containing (Non-N-BP) class and nitrogen-containing class or aminobisphosphonates (N-BPs).
- N-BPs nitrogen-containing class or aminobisphosphonates
- N-BPs are not metabolized, are more potent than their non-nitrogen containing counterparts, and function by inhibiting the enzyme famesyl pyrophosphate synthase (FDPS) in the mevalonate pathway (FIG.
- FDPS famesyl pyrophosphate synthase
- IPP isopentenyl pyrophosphate
- V52 cells can be largely expanded in vitro using N-BPs to become potent cytotoxic effectors against tumor cell lines (Poonia and Pauza, 2012).
- expanded V52 cells from ART- suppressed HIV-infected patients can be expanded in vitro using PAM.
- These expanded cells are i) potent cytotoxic effectors that inhibit active viral replication ex vivo, ii) degranulate in the presence of autologous infected CD4 T cells and iii) specifically target and eliminate latent HIV-infected cells after latency reversal with SAHA (Garrido et al., JCI Insight 2018 published June 21, 2018).
- N-BP inhibits the formation of FPP groups that are essential for protein prenylation
- N-BP may also reactivate HIV from latency.
- Induction of latent HIV by N- BP was analyzed using two different approaches: i) quantitation of HIV gag RNA copies in real time quantitative reverse PCR and ii) quantification of replication-competent HIV in quantitative viral outgrowth assays (QVOA).
- QVOA quantitative viral outgrowth assays
- gd T cells Once activated, gd T cells also exert critical adjuvant functions to induce proper adaptive immune responses including induction of dendritic cell maturation and activation of HIV-specific T cell responses (Lafont et ak, 2014). Therefore, our strategy includes the novel use of N-BPs as LRAs and take advantage of the specific activation of gd T cell functions to eradicate persistent HIV infection.
- PBMC from uninfected individuals will be isolated and gd T cells expanded in vitro using N-BPs and a combination of cytokines that will generate potent cytotoxic effector gd T cells, as per previously optimized protocols. Expansions will last at least 14 days, to obtain sufficient number of cells to analyze phenotype and ex vivo function.
- N-BP administration ART-suppressed HIV-infected individuals will receive a dose of N-BPs alone or in combination with other LRAs, according to standard procedures to reactivate the latent virus.
- the methods and compositions may be used for treatment of acute HIV infection or patients that have not received ART therapy.
- gd T cells Previously expanded gd T cells will be infused concomitant to LRAs administration or as a two-step approach.
- the gd T cells may be administered with external cytokines such as IL-2, IL-7 or IL-15.
- the expanded gd T cells may be genetically engineered.
- N-BPs induce HIV gag RNA production from isolated rCD4 cells.
- 18 patients were analyzed. In each patient, a total of 24-72 million isolated rCD4 cells were studied using between 6-15 million cells per condition, depending on cell availability.
- PAM protein-binding protein
- HIV gag RNA copies/lxlO 5 cells were significantly quantified above the untreated control, the same patients whom showed positive HIV gag RNA copies using the positive control PHA and IL-2 (FIG. 2A).
- HIV RNA expression levels induced by PAM were comparable to PHA control.
- the HDACi SAHA was also used as a control at the physiological concentration of 335nM in seven patients showing significant gag HIV expression in one patient.
- HIV gag RNA was quantifiable at a mean level of 70 HIV gag RNA copies, compared to 901 HIV gag RNA copies after PHA stimulation, 174 HIV gag RNA after VOR stimulation and 260 HIV gag RNA copies after 25pg/mL PAM stimulation.
- RNA data to the untreated condition from 11 HIV-infected donors showed the capacity of PAM to induce latency reversal, measured as HIV gag RNA copies, from latent HIV in isolated rCD4 cells from durable suppressed individuals (FIG. 2B).
- N-BPs are capable of inducing the production of HIV gag RNA from isolated rCD4 cells from HIV-infected donors on suppressive ART.
- N-BPs induce replication-competent HIV production from isolated rCD4 cells in QVOA
- rCD4 cells were isolated, plated in limiting dilution and incubated in parallel with 2pg/mL PHA and lOOU/mL IL-2, 25pg/mL PAM, 335nM SAHA or 5U/mL IL-2 to perform QVOA. HIV latency was reversed and replication-competent vims produced in nine of 10 patients with a mean value of IUPM rCD4 cells of 0.426. SAHA induced viral production in six of nine patients tested with a mean IUPM value of 0.159. Finally, in cultures of rCD4 cells incubated with PAM, HIV was induced to produce replication-competent virus in seven of 10 patients with a mean IUPM rCD4 cells value of 0.180. The results are shown in FIG. 3A.
- N-BPs are not toxic to immune cells
- N-BPs are toxic to immune cells
- dose response curves using PAM concentrations from 25pg/mL to 200pg/mL were performed to analyze the expression of 7- AAD in total CD4, CD8, gd and NK cells (FIG. 4A), and CD95 expression was used in rCD4 cells (FIG. 4B).
- Results show that N-BPs are not toxic even at the highest concentration of 200pg/mL to any of the populations analyzed.
- N-BPs do not promote proliferation of rCD4 cells, total CD4 cells or CD8 cells
- Proliferation analysis using CFSE assays demonstrate that N-BPs used at different concentrations, from 25mg/mL to 200pg/mL do not promote proliferation of rCD4 cells.
- PHA and IL-2 were used as the positive control, media alone as the negative control and 335nM SAHA as a comparator, as this HDACi do not promote proliferation either.
- Our results show that PAM did not induce proliferation of rCD4 cells at any of the concentrations analyzed (FIG. 5A-5B).
- As an additional control we tested the effect of PAM on V52 cells, that specifically induces expansion of V52 cells.
- our results demonstrate that PAM in combination with IL-2 significantly induces expansion of V52 cells. The results are shown in FIG. 5A-5B.
- N-BPs do not promote activation of lymphocyte populations
- N-BPs impact mRNA expression of genes implicated in chromatin regulation
- RNA-seq was performed on total RNA isolated from rCD4 cells from four of the same patients in whom caRNA experiments were assayed.
- Whole-transcriptome analysis with total RNA sequencing was performed in PAM-treated samples and compared to the untreated conditions.
- the principal component analysis demonstrated that treatment with PAM was the responsible for the largest source of gene expression variation (FIG. 6A).
- Results showed that 3,953 genes were differentially expressed (q- value ⁇ 0.1 and base mean >10) showing a good split of downregulated and upregulated genes according to treatment (data not shown).
- Gene set enrichment analysis was performed using GSVA and curated modules (C2).
- N-BPS cholesterol biosynthesis pathway
- Example pathways regulated by N-BPs included DNA damage, cell cycle, metabolism and epigenetics. Comparison between untreated and PAM-treated conditions in DNA damage, methylation targets and HDAC7 targets are shown in figure 6B as examples.
- FIG. 6C we found a positive correlation between the genes that are altered during HIV infection and those impacted by treatment with N-BPs. This result show that pathways are altered similarly and strongly suggest that N-BPs may have a specific function over HIV reactivation.
- N-BPs may be acting at the chromatin level to reverse HIV latency.
- HDACs histone deacetylases
- FIG. 6B an example of the impact at the chromatin level is the downregulation of the expression of HDA7 targets and methyltransferases
- alendronate induced the activation of gd T cells.
- Activated gd T cells may have exerted a direct cytotoxic function eliminating HIV-infected reactivated cells and/or adjuvant functions that included the induction of dendritic cells, and anti-HIV specific responses helping in the clearance of the infected cells.
- N-BPs are novel LRAs capable of inducing HIV expression from latency.
- N-BPs are not toxic to immune cells, i.e., CD4 cells, CD8 cells, gd cells or NK cells, do not induce proliferation of infected cells and do not alter CD4 cell subpopulations, i.e., naive, TCM, TTM, TD (data not shown).
- N-BPs as LRAs to be used as a novel tool in HIV cure strategies.
- N-BPs can be used to reactivate latent HIV and these compounds may be used alone, in combination with other LRAs, or combined with immunotherapeutic strategies to augment immune capacity to eliminate the reactivated HIV.
- V52 cells are potent effectors capable of targeting and eliminating infected cells (Garrido et al, JCI Insight 2018).
- the data disclosed herein also confirm the beneficial specific activation of V52 cells after incubation with N-BPs.
- N-BP can be safely used in combination with ART.
- N-BPs are novel latency reversing agents and we propose their novel use in the field of HIV latency and persistence.
- N-BP pamidronate (PAM, Sigma- Aldrich) at two different concentrations: 25pg/mL and 2.5pg/mL to induce HIV reactivation from latency.
- the lower concentration translates into what has been predicted in plasma of cancer patients (2.6lpg/mL).
- Phytohaemagglutinin (PHA) was used as a positive control at a concentration of 2pg/mL for QVOA and at 5pg/mL for PCR experiments.
- VOR was used at the clinically relevant concentration of 335-500nM.
- Donors HIV-infected donors under suppressive antiretroviral treatment (ART) with undetectable plasma viral load ( ⁇ 50 copies/mL) for at least one consecutive year before inclusion were analyzed. Patients had initiated ART either in the acute or in the chronic phase of HIV infection.
- ART antiretroviral treatment
- qPCR constitutes the gold standard method to test latency reversal capacity.
- Isolated rCD4 cells are cultured in bulk using positive and negative controls: in the presence of positive controls PHA and IL-2 and VOR, untreated cells, or in the presence of the experimental condition: PAM at 25pg/mL or 2.5pg/mL for six hours. After six hours cells are washed and plated in replicates of lxlO 6 cells. After further washes, cells are pelleted and stored at -80°C until RNA is extracted. Then, cDNA is synthesized using well-standardized protocols and gag HIV PCR performed using specific and validated primers to amplify Gag (Archin et al., 2012).
- HIV p24 protein production (replication-competent vims as measure of infectious particles production) in quantitative viral outgrowth assays (QVOA) after 24 hours of rCD4 cells exposure to PAM was analyzed.
- QVOA quantitative viral outgrowth assays
- isolated rCD4 cells are maintained 24 hours in antiretrovirals to avoid de novo infection of potentially spontaneous reactivation. Then, cells are washed, they are counted and plated in limiting dilution. We performed 8 replicates at lxlO 6 , 8 replicates at 0.5xl0 6 and 10 replicates at O.lxlO 6 of isolated rCD4 cells.
- the viability dye 7-Aminoactinomycin D (7-AAD) is a non-permanent dye that can be used to identify non- viable cells as it can penetrate in cells with non-intact membranes. Once inside the cell, 7-AAD binds to the DNA producing fluorescence that identifies cells as non-viable. 7- AAD was used to identify the toxic effect of PAM using the above-mentioned concentrations on PBMC after 6 and 24 hours of incubation. To analyze toxicity of PAM in rCD4 cells we used the expression of CD95 as a marker of apoptosis.
- rCD4 cells and PBMC were incubated with different PAM concentrations for 6 or 24 hours, harvested, washed, stained with monoclonal antibodies and analyzed by flow cytometry.
- the expression of the activation markers CD69 and HLA-DR was analyzed in subpopulations of PBMC (total CD4 cells and CD8 cells).
- CD69, HLA-DR and CD25 were used.
- CFSE carboxyfluorescein diacetate succinimidyl ester
- Controls for proliferation assays included 2pg/mL or 5pg/mL PHA and lOOU/mL IL-2, and 335nM VOR as positive controls, and 5U/mL and lOOU/mL as negative controls.
- T cell subpopulations include: Total Lymphocytes (CD3+ cells), CD3+CD4+ cells, CD3+CD8+ cells, CD3+y5TCR+ cells, and CD3-CD56+ (NK) cells.
- This set of experiments included dose-response curve analysis using increasing PAM concentrations ranging from 0.5pg/mL to 200pg/mL (0.5, 1.5, 2.5, 5, 10, 12.5, 25, 50,100 and 200 pg/mL).
- RNA Integrity Number RIN
- RNA6000 assay Agilent
- lpg of total RNA was converted to RNAseq libraries using the KAPA Stranded mRNA-Seq Kit (Illumina) and sequenced on an Illumina HiSeq 4000 using a 2x50bp configuration.
- Quality-control-passed reads were aligned to the human reference genome CGRh38/hg38 using STAR. See Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, and Gingeras TR.
- Aminobisphosphonates such as pamidronate (PAM) and zoledronate (Zol) are drugs that modulate the isoprenoid metabolism indirectly augmenting IPP production and activating V52 cells (16). Once activated, V52 cells are potent cytotoxic effectors (20) against malignancies (17, 18) and HIV-infected cells (19-23). We and others have previously demonstrated that V52 T cells can inhibit active viral replication (20, 24).
- expanded V52 T cell immune adjuvant functions include induction of dendritic cell maturation and activation of HIV-specific T cell responses (25), which are of special interest as a future complementary use of gd T cells in adoptive cell transfer strategies.
- HMBPP was a more potent inducer of nd2 cell expansion compared to PAM, while cells from HIV-infected donors expanded better after PAM treatment
- FIG.8B, FIG. 8C and FIG. 9A the fold change expansion induced by PAM in HIV- infected donors was comparable to uninfected donors (FIG.8B, FIG. 8C).
- a mean of 5.3% of the total CD3 cells present in the culture were V52 cells after HMBPP treatment, compared to 11.0% after PAM treatment (FIG 9B).
- PAM allows efficient V52 cell expansion in HIV-infected donors.
- V52 T cells from ART-treated HIV-infected individuals successfully expand after exposure to PAM
- mean fold expansion was 28.4, ranging from 1.7-fold to more than 124-fold increase.
- V52 memory cell populations were defined as follows: Central Memory (TCM, CD45RA-/CD27+/CCR7+),
- TTM Transitional Memory
- TEM Effector Memory
- V52+CD56+ 50% of the expanded V52 cells displayed a cytotoxic phenotype (V52+CD56+) and around 30% displayed an ADCC-like phenotype characterized by the expression of CD16.
- Activation markers CD69, CD25 and HLA-DR were expressed in a mean of 37.2%, 14.8% and
- V52 cells 16.6% V52 cells, respectively.
- the expression of the exhaustion markers PD-1 was observed in a mean of 19.8% and CTLA-4 was observed in 4.3% of the expanded V52 cells (FIG. 11C).
- PAM-expanded V52 cells inhibit active HIV replication
- V52 T cells degranulate in the presence of HIV-infected CD4 cells
- CD107a expression Total CD4 T cells from nine ART-suppressed HIV-infected individuals were isolated and superinfected with the HIV strain JR-CSF to act as targets in cocultures with autologous expanded nd2 cells. In preliminary experiments, isolated CD4 cells were activated with PHA prior to superinfection with JR-CSF. However, we observed that cytotoxic nd2 cells were activated when
- gd T cells can efficiently clear latently HIV-infected cells upon latency disruption
- gd T cells reduce the recovery of replication-competent HIV after reactivation of r-CD4 T cells with VOR.
- Our modification of the assay consisted on depleting gd T cells after 24 hours of coculture, and it is critical to allow evaluation of the specific clearance by gd T cells. This modification avoids measurement of unspecific effects over allogeneic uninfected cells added later to outgrowth the virus.
- r-CD4 cells from eight ART- suppressed donors were isolated, exposed to VOR and co-cultured with or without autologous isolated expanded V52 T cells. After 24 hours of culture, gd T cells were depleted from the cultures, plated in replicates, and uninfected allogeneic CD4 cells were added to amplify replication-competent HIV. After 15/19 days of culture, viral outgrowth from r-CD4 cells cultured alone was detected in six out of eight HIV-infected donors, as measured by the number of HIV p24 positive wells.
- gd T cells kill autologous HIV-infected CD4 T cells.
- V52 T cells were able to expand up to 120 fold in response to PAM/IL2 ex vivo and reduce up to 80% viral replication in autologous co-culture systems.
- this disclosure supports the important finding that gd T cell possess antiviral capabilities that are maintained in virologically-suppressed individuals. Further, such antiviral gd T cells can be expanded ex vivo to target latently infected cells induced to express HIV.
- PAM-expanded nd2 cells showed increased CD107a production after coculture with autologous HIV-superinfected CD4 cell targets compared to cocultures of autologous CD4 cells without superinfection, demonstrating specific degranulation triggered by HIV infection.
- CD107a production although statistically significant, was not very high, suggesting the involvement of other pathways in HIV recognition (42).
- CDl07a production may be potentially diminished compared to an assay were 100% of targets were activating gd T cells.
- Antigen recognition by the gd TCR is generally not restricted to major MHC molecules (14, 15), although gd T cell recognition of peptides loaded on MHC molecules has been reported (43).
- gd T cells from HIV-infected individuals retain their functionality after expansion and constitute an attractive immunotherapeutic alternative or complementary tool to current approaches aimed to cure HIV.
- Our work has opened novel and interesting questions regarding the basic biology, function and specificities of gd T cells.
- HIV-infected donors included were on ART and virologically suppressed ( ⁇ 50 copies/mL) for at least one year prior to inclusion. Characteristics and inclusion criteria of these donors have been previously described (24, 48). HIV-infected donors treated in the acute phase of HIV infection started therapy within 45 days of the estimated date of infection. Buffy coats from uninfected donor volunteers were obtained from the New York Blood Center (Long Island City, NY, USA).
- PBMC Peripheral blood mononuclear cells
- nd2 cells and CD8 T cells were isolated by fluorescent activated cell sorting (FACS) using a FACSAria II (BD).
- FACS fluorescent activated cell sorting
- PBMC were stained with monoclonal antibodies against CD3 (clone SK7), V52 (clone B6), CD4 (clone SK3), and CD8 (clone SK1) (all from Biolegend, San Diego, CA).
- nd2 T cells were defined as CD3 + nd2 + and CD8 T cells were defined by CD3 + ndT nd2 CD4 CD8 + .
- CD4 T cells were isolated from the same donor using a commercially available enrichment kit that contains antibodies against CD8, CD14, CD16, CD19, CD20, CD36, CD56, CD66b, CD123, TCR-g/d and glycophorin A (StemCell Technologies, Vancouver). Resting CD4 (r-CD4) cells were isolated using a custom StemCell Technologies cocktail that contained the following antibodies: CD8, CD14, CD16, CD19, CD20, CD36, CD56, CD123, ybTCR, Glycophorin A, CD66b, CD25, HLADR and CD69. Purity of the FACS-isolated populations and resting CD4 T cells was >99%, and magnetically isolated CD4 T cells showed a purity >96%.
- HMBPP E-4-hydroxy-3- methyl-but-2-enyl pyrophosphate
- Isolated CD4 T cells from HIV-infected donors were super- infected with the viral strain JR-CSF using two different approaches i) CD4 cells were activated with 4pg/mL PHA and lOOU/mL IL-2 for 24h, washed twice and super-infected by spinoculation at 2500rpm for 2 hours. Cells were then extensively washed to remove free virions and then used for further experiments ii) Isolated CD4 cells were spinoculated at 2500rpm for 4 hours in the presence of 8 pg/mL polybrene.
- Viral inhibition assays using V52 cells from HIV-infected individuals as effectors were performed as previously described for uninfected individuals (24), with some modifications. Fifty thousand infected CD4 T cells were co-cultured in triplicate at different effector: target ratios of 1 : 1 , 1:10 and 1:100, unless otherwise noted. Infected CD4 cells alone were also cultured in triplicate as control of HIV production. In some experiments, ex vivo isolated CD8 T cells were used as effector cells. Supernatants were harvested at day 7 and stored at -20°C until HIVp24 ELISA quantification (ABLinc., Rockville, MA, USA) was performed. Results are expressed as percent of viral inhibition normalized to HIV p24 production when target CD4 T cells were cultured alone.
- CD 107 a was used as a functional marker of cytotoxicity.
- FACS -sorted expanded V52 T cells were co-cultured with JR-CSF-infected autologous CD4 cells as targets.
- CD4 T cells were infected following the two different approaches described above. At least 100,000 effector cells were co-cultured at a 1 : 1 ratio with CD4 target cells in 96-well plates for 5 hours in the presence of GolgiStop (BD) and the monoclonal antibody CDl07a (clone H4A3, BD). In some experiments, MHC expression was blocked by incubating the cells with a pan-HLA monoclonal antibody (clone W6/32, Biolegend).
- Tanaka Y Morita CT
- Tanaka Y Tanaka Y
- Nieves E Brenner MB
- Bloom BR Natural and synthetic non-peptide antigens recognized by human gamma delta T cells. Nature.
- Tumor-Infiltrating gammadelta T Lymphocytes Pathogenic Role, Clinical Significance, and Differential Programing in the Tumor Microenvironment. Frontiers in immunology. 2014;5(607.
- Van Acker HH, Anguille S, Willemen Y, Smits EL, and Van Tendeloo VF Van Acker HH, Anguille S, Willemen Y, Smits EL, and Van Tendeloo VF.
- Bisphosphonates for cancer treatment Mechanisms of action and lessons from clinical trials. Pharmacology & therapeutics. 20l6;l58(24-40.
- Vgamma9Vdelta2 T cell activation and differentiation.
- ⁇ gamma ⁇ ⁇ delta ⁇ T lymphocytes display potent antitumor activity toward human squamous cell carcinoma.
- Clinical cancer research an official journal of the American Association for Cancer Research. 2008;l4(l3):4232-40.
- Statement 1 A method for inducing expression of HIV viral antigen(s) in latently HIV- infected cells which comprises exposing the latently HIV-infected cells to a bisphosphonate so as to reverse latency and to induce the expression of the HIV viral antigen(s).
- Statement 2 The method of Statement 1, wherein the bisphosphonate is an aminobisphosponate.
- Statement 3 The method of Statement 2, wherein the aminobisphosphonate is Alendronate (FosamaxTM), Ibandronate (BonivaTM or BonvivaTM), Neridronate (NerixiaTM), Olpadronate, Pamidronate (APD/ArediaTM), Risedronate (ActonelTM), or Zoledronate (ZometaTM /AclastaTM).
- Statement 4 A method of inducing expression of HIV viral antigens in latently HIV- infected cells in a subject which comprises administering to the subject a bisphosphonate so as to reverse latency and induce expression of the HIV viral antigens in the cells in the subject.
- Statement 5 The method of Statement 4, wherein the latently infected cells are rCD4 cells.
- Statement 6 The method of any of Statements 1-5, wherein the subject is receiving antiretroviral therapy (ART).
- Statement 7 A method to boost gd T cell expression and reverse viral latency in a subject infected with HIV which comprises administering to the subject a bisphosphonate.
- Statement 8 The method of Statement 7, wherein the subject is receiving antiretroviral therapy (ART).
- Statement 10 The use of Statement 9, wherein the aminobisphosphonate is Alendronate (FosamaxTM), Ibandronate (BonivaTM or BonvivaTM), Neridronate (NerixiaTM), Olpadronate, Pamidronate (APD/ArediaTM), Risedronate (ActonelTM), or Zoledronate (ZometaTM /AclastaTM).
- Statement 11 A method for eliminating latently infected cells harboring quiescent HIV provirus that comprises exposing the infected cells with gd T cells and a bisphosphonate.
- Statement 12 The method of Statement 11, further comprising exposing latently infected cells to a second HIV latency reversing agent.
- Statement 13 The method of Statement 12, wherein the second HIV latency reversing agent is an epigenetic modifier, an NFkB agonist, a PI3K Akt pathway inhibitor, a protein kinase C agonist, a SMAC (second mitochondria-derived activator of caspases) mimetic, a TCR activator or a TLR agonist.
- the second HIV latency reversing agent is an epigenetic modifier, an NFkB agonist, a PI3K Akt pathway inhibitor, a protein kinase C agonist, a SMAC (second mitochondria-derived activator of caspases) mimetic, a TCR activator or a TLR agonist.
- Statement 14 The method of Statement 13, wherein the epigenetic modifier is a histone deacetylase (HD AC) inhibitor.
- the epigenetic modifier is a histone deacetylase (HD AC) inhibitor.
- Statement 15 A method of treating/curing a subject infected with HIV which comprises administering to the subject ex vivo expanded gd T cells and a bisphosphonate.
- Statement 16 The method of Statement 15, further comprising administering to the subject a second HIV latency reversing agent.
- Statement 17 The method of Statement 16, wherein the HIV latency reversing agent is an epigenetic modifier, an NFkB agonist, a PI3K/Akt pathway inhibitor, a protein kinase C agonist, a SMAC (second mitochondria-derived activator of caspases) mimetic, a TCR activator, a TLR agonist, an inhibitor of LAP (Inhibitor of Apoptosis Protein) family of proteins, or a stimulator of interferon genes protein (STING) agonist.
- the HIV latency reversing agent is an epigenetic modifier, an NFkB agonist, a PI3K/Akt pathway inhibitor, a protein kinase C agonist, a SMAC (second mitochondria-derived activator of caspases) mimetic, a TCR activator, a TLR agonist, an inhibitor of LAP (Inhibitor of Apoptosis Protein) family of proteins, or a stimulator of interferon genes protein (STING) agonist
- Statement 18 The method of Statement 17, wherein the epigenetic modifier is histone deacetylase (HD AC) inhibitor.
- the epigenetic modifier is histone deacetylase (HD AC) inhibitor.
- Statement 19 The method of any of Statements 11-18, wherein the expanded gd T cells and the bisphosphonate are administered concurrently.
- Statement 20 The method of any of Statements 11-18, wherein the expanded gd T cells and the bisphosphonate are administered sequentially.
- Statement 21 The method of Statement 20, wherein the expanded gd T cells and the bisphosphonate are administered over a 24 hour period.
- Statement 22 The method of any of Statements 11-21, wherein the ex vivo expanded gd T cells are nd ⁇ T-cells.
- Statement 23 The method of any of Statements 11-21, wherein the ex vivo expanded gd T cells are nd2 T-cells.
- Statement 24 The method of any of Statements 11-23, wherein the ex vivo expanded gd T cells are autologous cells.
- Statement 25 The method of any of Statements 11-23, wherein the ex vivo expanded gd T cells are heterologous cells.
- Statement 26 The method of any of Statements 11-25, wherein the bisphosphonate is Alendronate (FosamaxTM), Ibandronate (BonivaTM or BonvivaTM), Neridronate (NerixiaTM), Olpadronate, Pamidronate (APD/ArediaTM), Risedronate (ActonelTM), or Zoledronate (ZometaTM /AclastaTM).
- the HDAC inhibitor is belinostat (PXD101), entinostat (MS-275), mocetinostat (MGCD0103), panobinostat (LBH589), or vorinostat (SAHA).
- Statement 28 A method of treating HIV infection in a subject, comprising: (a) isolating peripheral blood mononuclear (PBMC) cells from the subject; (b) culturing the isolated PBMC cells ex vivo with an effective amount of a bisphosphonate or antibodies and suitable cytokines so as to expand gd T cells; (c) or optionally genetically modifying the expanded gd T cells; (d) infusing the expanded gd T cells into the subject; and (e) administering to the subject a bisphosphonate so as to activate quiescent HIV provirus and treat the subject with HIV.
- PBMC peripheral blood mononuclear
- Statement 29 The method of Statement 28, further comprising administering to the subject in step (e) a second HIV latency reversing agent.
- Statement 30 The method of Statement 29, wherein the second HIV latency reversing agent is an epigenetic modifier, an NFkB agonist, a PI3K/Akt pathway inhibitor, a protein kinase C agonist, a TCR activator, a TLR agonist, an inhibitor of LAP (Inhibitor of Apoptosis Protein) family of proteins, or a stimulator of interferon genes protein (STING) agonist.
- the second HIV latency reversing agent is an epigenetic modifier, an NFkB agonist, a PI3K/Akt pathway inhibitor, a protein kinase C agonist, a TCR activator, a TLR agonist, an inhibitor of LAP (Inhibitor of Apoptosis Protein) family of proteins, or a stimulator of interferon genes protein (STING) agonist.
- LAP Inhibitor of Apoptosis Protein
- Statement 31 The method of Statement 30, wherein the epigenetic modifier is a histone deacetylase (HDAC) inhibitor.
- HDAC histone deacetylase
- Statement 32 The method of any of Statements 28-31 , wherein the subject was receiving antiretroviral therapy (ART).
- Statement 33 The method of any of Statements 28-32, wherein the PBMCs are expanded in the presence of the bisphosphonate for 5 to 30 days.
- Statement 34 The method of any of Statements 28-33, wherein the PBMCs are expanded for 7 to 21 days.
- Statement 35 The method of any of Statements 28-34, wherein the expanded gd T cells and the bisphosphonate are administered concurrently.
- Statement 36 The method of any of Statements 28-34, wherein the expanded gd T cells and the bisphosphonate are administered sequentially.
- Statement 37 The method of any of Statements 28-36, wherein the bisphosphonate is Alendronate (FosamaxTM), Ibandronate (BonivaTM or BonvivaTM), Neridronate (NerixiaTM), Olpadronate, Pamidronate (APD/ArediaTM), Risedronate (ActonelTM), or Zoledronate (ZometaTM /AclastaTM).
- Statement 38 The method of Statement 31, wherein the HDAC inhibitor is belinostat (PXD101), entinostat (MS-275), mocetinostat (MGCD0103), panobinostat (LBH589), or vorinostat (SAHA).
- HDAC inhibitor is belinostat (PXD101), entinostat (MS-275), mocetinostat (MGCD0103), panobinostat (LBH589), or vorinostat (SAHA).
- SAHA vorinostat
- Statement 40 The pharmaceutical composition of Statement 39, wherein the second HIV latency reversing agent is an epigenetic modifier, an NFkB agonist, a PI3K/Akt pathway inhibitor, a protein kinase C agonist, a TCR activator, a TLR agonist, an inhibitor of IAP (Inhibitor of Apoptosis Protein) family of proteins, or a stimulator of interferon genes protein (STING) agonist.
- the second HIV latency reversing agent is an epigenetic modifier, an NFkB agonist, a PI3K/Akt pathway inhibitor, a protein kinase C agonist, a TCR activator, a TLR agonist, an inhibitor of IAP (Inhibitor of Apoptosis Protein) family of proteins, or a stimulator of interferon genes protein (STING) agonist.
- IAP Inhibitor of Apoptosis Protein
- STING stimulator of interferon genes protein
- Statement 41 The pharmaceutical composition of Statement 40, wherein the epigenetic modifier is a histone deacetylase (HD AC) inhibitor.
- the epigenetic modifier is a histone deacetylase (HD AC) inhibitor.
- Statement 42 A pharmaceutical composition comprising an HMG CoA inhibitor and an HIV latency reversing agent.
- Statement 45 The pharmaceutical composition of Statement 42, wherein the HMG CoA inhibitor is a statin.
- Statement 45 The pharmaceutical composition of Statement 44, wherein the statin is torvastatin, fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin or a combination thereof.
- Statement 46 A pharmaceutical composition comprising either (i) a synthetic analogue of a component of the mevalonate pathway, (ii) an inhibitor of the mevalonate pathway (beyond bisphosphonates or HMG-CoA reductase inhibitors), or (iii) an intermediate from the mevalonate pathway, and an HIV latency reversing agent.
- Statement 47 The pharmaceutical composition of Statement 46, wherein the synthetic analogue, inhibitor, or intermediate is (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMBPP), isopentenyl pyrophosphate (IPP), dimethyl-allyl-pyrophosphate (DMAPP), bromohydrin pyrophosphate (BrHPP) or 2-methyl-3-butenyl-l-pyrophosphate (2M3B1PP).
- HMBPP isopentenyl pyrophosphate
- IPP isopentenyl pyrophosphate
- DMAPP dimethyl-allyl-pyrophosphate
- BrHPP bromohydrin pyrophosphate
- 2M3B1PP 2-methyl-3-butenyl-l-pyrophosphate
- Statement 48 The pharmaceutical composition of any of Statements 42-47, wherein the HIV latency reversing agent is an epigenetic modifier, an NFkB agonist, a PI3K/Akt pathway inhibitor, a protein kinase C agonist, a TCR activator, a TLR agonist, an inhibitor of IAP (Inhibitor of Apoptosis Protein) family of proteins, or a stimulator of interferon genes protein (STING) agonist.
- the HIV latency reversing agent is an epigenetic modifier, an NFkB agonist, a PI3K/Akt pathway inhibitor, a protein kinase C agonist, a TCR activator, a TLR agonist, an inhibitor of IAP (Inhibitor of Apoptosis Protein) family of proteins, or a stimulator of interferon genes protein (STING) agonist.
- IAP Inhibitor of Apoptosis Protein
- STING stimulator of interferon genes protein
- Statement 49 The pharmaceutical composition of Statement 48, wherein the epigenetic modifier is a histone deacetylase (HD AC) inhibitor.
- the epigenetic modifier is a histone deacetylase (HD AC) inhibitor.
- Statement 50 The pharmaceutical composition of Statement 49, wherein the HDAC inhibitor is belinostat (PXD101), entinostat (MS-275), mocetinostat (MGCD0103), panobinostat (LBH589), or vorinostat (SAHA).
- HDAC inhibitor is belinostat (PXD101), entinostat (MS-275), mocetinostat (MGCD0103), panobinostat (LBH589), or vorinostat (SAHA).
- SAHA vorinostat
- Statement 52 The use of the pharmaceutical composition of any of Statements 39-50 as an HIV latency reversing agent when administered to a subject.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present disclosure provides novel methods to cure HIV. In particular aminobisphosphonates are disclosed as latency reversing agents (LRAs), and methods to cure HIV by administering to a subject a combination of bisphosphonates and γδ T cells are provided. In some embodiments, these interventions may be combined with other latency reversing agents, e.g., histone deacetylase (HD AC) inhibitors, and other immunotherapeutics for HIV clearance (e.g., broadly HIV -neutralizing antibodies).
Description
AMINOBISPHOSPHONATES AS LATENCY REVERSING AGENTS AND
COMBINATION TREATMENTS FOR HIV CURE
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. Serial No. 62/687,936 filed June 21, 2018, Natalia Soriano-Sarabia, Atty. Dkt. 150-30-PROV, which is hereby incorporated by reference in its entirety.
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
[0002] This invention was made with government support under Grant Number AI125097, AI126619, AI50410, and CA016086 awarded by the National Institutes of Health. The government has certain rights in the invention.
1. FIELD
[0003] The present disclosure provides novel methods to cure HIV. In particular aminobisphosphonates are disclosed as latency reversing agents (LRAs), and methods to cure HIV by administering to a subject a combination of bisphosphonates and gd T cells are provided. In some embodiments, these interventions may be combined with other latency reversing agents, e.g., histone deacetylase (HD AC) inhibitors, and other immunotherapeutics for HIV clearance (e.g., broadly HIV-neutralizing antibodies).
2. BACKGROUND
2.1. Introduction
[0004] The“background” description provided herein is for the purpose of generally presenting the context of the disclosure. Work of the presently named inventors, to the extent it is described in this background section, as well as aspects of the description which may not otherwise qualify as prior art at the time of filing, are neither expressly or impliedly admitted as prior art against the present disclosure.
[0005] The latent human immunodeficiency vims (HIV) reservoir within resting memory CD4+ T cells is the major barrier to efforts to eradicate persistent infection (1-4). Today the standard of care for patients with HIV is long term antiretroviral therapy (ART) to suppress active viral replication and new infection of cells. However, therapeutic approaches that allow the clearance of latent but replication-competent HIV are needed. Current strategies are based on the use of ongoing ART and concurrently employ latency reversal agents (LRA) to induce viral antigen expression (5,
6) to allow immunological clearance. This clearance part has been mainly based on CD8 T cells (7, 8). However, CD8-based therapies can be challenging due to insufficient HIV antigen expression on latently-infected cells, diminished function of specific CD8 T cells (9, 10) and escape HIV variants (7).
[0006] In contrast to the majority of ab T cells that recognize antigen peptides bound to major histocompatibility complex (MHC) class I or II, gd T cells, including the most prevalent peripheral subset, V52 cells, mainly recognize non-peptidic phosphorylated metabolites of isoprenoid biosynthesis (11). These metabolites include (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMBPP) (12, 13) and isopentenyl pyrophosphate (IPP) (14), and their recognition does not require conventional MHC-antigen presentation (14, 15).
[0007] Isoprenoids are a class of organic chemicals derived from terpenes. Terpenoids are modified terpenes with added or removed methyl groups or oxygen atoms added. The use terpene can be used more broadly to include terpenoids. These compounds can be classified according to the number of isoprene units that contain the parent terpene in hemiterpenoids, mono terpenoids, sesquiterpenoids, diterpenoids, sesterterpenoids, triterpenoids, tetraterpenoids, poly terpenoids. These chemicals are phosphorylated intermediates of the non-mevalonate (or MEP pathway) and mevalonate pathway of isoprenoid biosynthesis (Figure 1). See Jomaa, H. et al. Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs. Science (New York,
N. Y. ) 285, 1573-1576 (1999); Hintz, M. et al. Identification of (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate as a major activator for human gammadelta T cells in Escherichia coli. FEBS letters 509, 317-322 (2001). These intermediate isoprenoids include but are not limited to (E)-4- hydroxy-3-methyl-but-2-enyl pyrophosphate (HMBPP), isopentenyl pyrophosphate (IPP), dimethyl-allyl-pyrophosphate (DMAPP). Bromohydrin pyrophosphate (BrHPP) and 2-methyl-3- butenyl-l -pyrophosphate (2M3B1PP) are examples of synthetic isoprenoids. See Espinosa, E. et al. Chemical synthesis and biological activity of bromohydrin pyrophosphate, a potent stimulator of human gamma delta T cells. The Journal of biological chemistry 276, 18337-18344, doi:l0.l074/jbc.Ml00495200 (2001); and Kobayashi, H. et al. Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study. Cancer immunology, immunotherapy: C// 56, 469-476,
doi:l0.l007/s00262-006-0l99-6 (2007).
3. SUMMARY OF THE DISCLOSURE
[0008] This disclosure provides a method for inducing expression of HIV viral antigen(s) in latently HIV-infected cells which comprises exposing the latently HIV-infected cells to a bisphosphonate so as to reverse latency and to induce the expression of the HIV viral antigen(s). The bisphosphonate may be an aminobisphosphonate. The aminobisphosphonate may be an alkyl aminobisphosphonate, a substituted alkyl aminobisphosphonate, a bisphosphonate with a nitrogen containing heterocycle, or a bisphosphonate containing a cyclic alkane or cycloaminoalkane. In some embodiments, the aminobisphosphonate is Alendronate (Fosamax™), Ibandronate (Boniva™ or Bonviva™), Neridronate (Nerixia™), Olpadronate, Pamidronate (APD/Aredia™), Risedronate (Actonel™), or Zoledronate (Zometa™ /Aclasta™).
[0009] The invention also provides a method of inducing expression of HIV viral antigens in latently HIV-infected cells in a subject which comprises administering to the subject a bisphosphonate so as to reverse latency and induce expression of the HIV viral antigens in the cells in the subject. The latently infected cells may be rCD4 cells.
[0010] The disclosure also provides a method to boost gd T cell functions and reverse viral latency in a subject infected with HIV which comprises administering to the subject a bisphosphonate.
[0011] In another embodiment, the disclosure provides for the use of an aminobisphosphonate as a latency reducing agent. The aminobisphosphonate may be Alendronate (Fosamax™), Ibandronate (Boniva™ or Bonviva™), Neridronate (Nerixia™), Olpadronate, Pamidronate (APD/Aredia™), Risedronate (Actonel™), or Zoledronate (Zometa™ /Aclasta™).
[0012] The present disclosure also provides a method for eliminating latently infected cells harboring quiescent HIV provirus that comprises reversing HIV latency by exposure to a bisphosphonate, and clearing these infected cells via the direct antiviral activity of gd T cells and/or adjuvant function over other effector cells such as CD8 T cells or Natural Killer (NK) cells.
[0013] In another embodiment, the disclosure provides a method of treating/curing a subject infected with HIV that comprises administering to the subject ex vivo expanded gd T cells and a bisphosphonate.
[0014] These methods further may comprise exposing the infected cells to a second HIV latency reversing agent, that may include but are not limited to an epigenetic modifier, an NFkB agonist, a PI3K Akt pathway inhibitor, a protein kinase C agonist, a TCR activator, a TLR agonist, a second mitochondrial-derived activator of caspases (SMAC) mimetic, an inhibitor of IAP (Inhibitor of Apoptosis Protein) family of proteins, or a stimulator of interferon genes protein (STING) agonists.
[0015] The expanded gd T cells and the bisphosphonate may be administered concurrently or sequentially.
[0016] In yet another embodiment, the disclosure provides a method of treating HIV infection in a subject, comprising: (a) isolating peripheral blood mononuclear (PBMC) cells from the subject; (b) culturing the isolated PBMC cells ex vivo with an effective amount of a bisphosphonate or antibodies and suitable cytokines/chemokines so as to expand gd T cells; (c) optionally genetically modifying the gd T cells before or after expansion, e.g., CAR T cells; (d) infusing the expanded gd T cells into the subject; and (e) administering to the subject a bisphosphonate so as to activate quiescent HIV pro virus, allowing elimination of HIV infection.
[0017] The method further may comprise administering to the subject in step (e) a second HIV latency reversing agent such as an epigenetic modifier, an NFkB agonist, a PI3K/Akt pathway inhibitor, a protein kinase C agonist, SMAC mimetic, a TCR activator, a STING agonist or a TLR agonist. An example of an epigenetic modifier LRA is a histone deacetylase (HD AC) inhibitor.
[0018] In most embodiments of the methods above, the subject is receiving ongoing, standard antiretroviral therapy (ART).
[0019] The PBMCs are expanded in the presence of the bisphosphonate for 5 to 30 days or 7 to 21 days. Alternatively, the bisphosphonate may be washed off after initial exposure of the cells to the drug.
[0020] In the methods disclosed herein, the expanded gd T cells and the bisphosphonate are administered concurrently or sequentially.
[0021] As used herein, the bisphosphonate may be Alendronate (Fosamax™), Ibandronate (Boniva™ or Bonviva™), Neridronate (Nerixia™), Olpadronate, Pamidronate (APD/Aredia™), Risedronate (Actonel™), or Zoledronate (Zometa™ /Aclasta™). The HDAC inhibitor may be belinostat (PXD101), entinostat (MS-275), mocetinostat (MGCD0103), panobinostat (LBH589), romidepsin or vorinostat (SAHA). Alternatively, the bisphosphonate may be used in conjunction with a TLR agonist, such as the TLR9 agonist Lefitolimod/MGNl703.
[0022] N-BPs are structurally related to pyrophosphates generated in the isoprenoid biosynthesis pathways and are shown herein to be both HIV latency reversing agents to reactivate latency and induce activation of gd T cell functions, including direct cytotoxic capacity and adjuvant functions over other effector cell populations. Other inhibitors of the mevalonate pathway may also be effective. Examples of terpenoids include but are not limited to (E)-4-hydroxy-3-methyl-but-2- enyl pyrophosphate (HMBPP), isopentenyl pyrophosphate (IPP), dimethyl-allyl-pyrophosphate (DMAPP), bromohydrin pyrophosphate (BrHPP) and 2-methyl-3-butenyl-l -pyrophosphate (2M3B1PP). Preliminary data indicates that HMBPP was effective as an HIV latency reversing agent. HMG-CoA inhibitors including statins may also be useful as HIV reversing agents. Non limiting examples of statins include atorvastatin, Lipitor ®; fluvastatin, Lescol®, Lescol® XL;
lovastatin, Mevacor®; mevastatin; pitavastatin, Livalo®; pravastatin, Pravachol®; rosuvastatin, Crestor®; simvastatin, Zocor®; simvastatin & ezetimibe, Vytorin®; lovastatin + niacin extended- release, Advicor®; atorvastatin + amlodipine, Caduet®; and simvastatin + niacin extended-release, Simcor®.
[0023] The disclosure also provides pharmaceutical compositions and uses as HIV latency reversing agents of a bisphosphonate and a second HIV latency reversing agent. Known HIV reversing agents are enumerated in the application, for example a histone deacetylase inhibitor such as vorinostat (SAHA).
[0024] In addition, the disclosure provides pharmaceutical compositions comprising an HMG- CoA reductase inhibitor and an HIV latency reversing agent such as a histone deacetylase. The disclosure also provides for pharmaceutical compositions comprising either (i) a synthetic analogue of a component of the mevalonate pathway, (ii) an inhibitor of the mevalonate pathway (beyond bisphosphonates or HMG-CoA reductase inhibitors), or (iii) an intermediate from the mevalonate pathway in combination with HIV latency reversing agent such as a histone deacetylase. These combination pharmaceutical compositions are useful as part of an HIV treatment and/or cure protocol.
4. BRIEF DESCRIPTION OF THE FIGURES
[0025] FIG. 1 : The mevalonate pathway produces famesyl pyrophosphate. Nitrogen- containing bisphosphonates (N-BP) inhibit the enzyme famesyl pyrophosphate synthase preventing farnesyl pyrophosphate groups to be synthesized. These groups are used by Famesyl transferase enzymes for prenylation downstream. Inhibition of the farnesyl pyrophosphate synthase induces accumulation of geranyl pyrophosphate and isopentenyl pyrophosphate, which are specifically recognized by gd T cells that become activated.
[0026] FIG.2A. Quantification of HIV gag RNA levels in HIV-infected suppressed donors.
A total of 18 donors were analyzed. Each graph represents one single donor. Each dot represents one replicate well containing lxlO6 rCD4 cells. Six to 15 wells were assayed per participant depending on cell availability. HIV gag cell-associated RNA (caRNA) levels were compared between untreated cells, the positive control (2pg/mL PHA and lOOU/mL IL-2), Vorinostat (335nM), and N-BPs PAM (25pg/mL and 2.5pg/mL) and Zol (ImM) in different experiments depending on cells availability.
[0027] FIG. 2B. Normalized levels of HIV gag RNA copies to the media condition. PAM
(DL2415) significantly induces HIV expression compared to the control, as well as positive controls PHA and IL-2 and SAHA. Wilcoxon signed rank test.
[0028] FIG. 2C-2D. N-BPs reactivate HIV from latency. N-BPs were used at concentrations that are comparable to the in vivo plasma concentrations reported for their use to treat bone-related diseases (PAM at 2.5pg/mL and Zol at ImM). Isolated rCD4 cells from nine HIV-infected donors on stable ART and suppressed for at least one year were assayed. Each dot represents one donor, which is the mean of 6-15 replicates of lxlO6 cells. FIG. 2C) PAM and Zol induced HIV gag caRNA copies/l05 resting CD4 cells compared to the untreated condition (p=0.004 and p=0.03, respectively). Mean HIV caRNA was comparable between the PHA and PAM and PHA and Zol (p>0.05 in both cases, Wilcoxon paired signed rank test). FIG. 2D) Fold change induction of HIV caRNA copies normalized to the untreated condition was comparable between the positive control (PHA and IL-2) and the conditions treated with PAM and Zol (p>0.05, Wilcoxon paired signed rank test).
[0029] FIG. 3A: PAM induces production of replication-competent HIV in cultures of isolated rCD4 cells. PHA reactivated latent HIV in 9 of the 10 patients analyzed by QVOA. SAHA induced HIV production in six of nine patients and finally PAM at 25pg/mL reactivated latent HIV in seven of the 10 patients while VOR (SAHA) reactivated in 6 out of 9 individuals.
[0030] FIG. 3B. PAM at 2.5pg/mL induce production of replication-competent HIV comparable to the positive control PHA and IL-2. rCD4 cells from seven HIV-infected donors on stable ART and suppressed for at least one year were assayed. Cells were cultured in limiting dilution from lxlO6 to O.lxlO6 cells to perform quantitative viral outgrowth assays (QVOA). Frequency of infection expressed as infectious units per million (IUPM) rCD4 cells is represented. IUPM cells was 0.291 after PAM treatment compared to 0.227 after treatment with the positive control PHA and IL-2. Both the positive control and PAM at 2.5pg/mL reactivated above the untreated condition (p=0.03 in both cases). Wilcoxon paired signed rank test.
[0031] FIG. 4A-4B: Toxicity of N-BPs to cell populations. Total PBMC or isolated rCD4 cells from HIV-infected participants were exposed to different concentrations of PAM. In parallel, controls with lOOU/mL IL-2 were ran. FIG. 4A) Percentage of 7-AAD in total PBMCs. No significant differences between media and increasing concentrations of PAM (DL-2415) were detected in any of the cell populations analyzed: total CD4 cells, CD8 cells, NK cells or gd T cells. FIG. 4B) Expression of CD95 in isolated rCD4 cells. PAM (DL-2415) is not toxic to rCD4 cells.
[0032] FIG. 5A: Effect of PAM (DL-2415) on cell proliferation. Representative histograms of one donor is shown. PAM does not promote proliferation of isolated rCD4 cells. PAM does not
promote proliferation of total CD4 or CD8 T cells. As expected, V52 cells proliferated in response to PAM and IL-2 (bottom histograms).
[0033] FIG. 5B: N-BPs do not induce proliferation of CD4, CD8 or gd T cells. Percentage of proliferation measured by carboxyfluorescein diacetate succinimidyl ester (CFSE) for varying concentration of PAM (upper graph) and Zol (lower graph). Percentage of CFSE positive cells (non proliferated) was comparable to the untreated condition for all concentrations analyzed. PAM at 2.5pg/mL and Zol at lOng/mL an lOOU/mL IL-2 were used as the positive control for V52 cell expansion. Bars represent the mean ±SEM of three to 5 different donors.
[0034] FIG. 5C. N-BPs do not promote activation of lymphocyte populations. Isolated PBMC were exposed to different concentrations of PAM (graphs on the left) and Zol (graphs on the right). PHA was used as the positive control, and untreated cells (media alone) were used as the negative control. Expression of activation markers CD69 and HLA-DR by flow cytometry was increased in the positive control, but activation levels remained comparable to the untreated condition in all other experimental conditions. Cells from three to five individuals were assayed in triplicate. Multiple t-test Holm-Sidak analysis p>0.05.
[0035] FIG. 6A-6C. N-BPs mechanism of action. RNA from isolated rCD4 cells was extracted and RNA-seq performed. FIG. 6A) The principal component analysis represents a multidimensional association showing that the greatest source of variation in gene expression is due to the treatment. A heatmap showed differentially expressed genes in the treated and the untreated conditions. Upregulated and downregulated were split according to the treatment (data not shown). FIG. 6B) Examples of pathways altered by PAM treatment analyzed by gene set enrichment using GSVA and curated gene modules (C2). Genes involved in the positive control, cholesterol biosynthesis pathway were upregulated in the untreated condition compared to the PAM-treated condition. Comparison of modules of genes involved in p53 DNA damage, methylation targets and HDAC7 targets between untreated and PAM-treated conditions is shown. FIG. 6C) Publicly available RNA-seq from HIV infected CD4+ T cell line and RNA-seq from PAM treatment showed that pathway coefficients correlated (r=0.44) suggesting that pathways are altered similarly.
[0036] FIG. 7A-7B:N-BPs reverse latency in vivo. ART-treated patients received the N-BP alendronate (Arm A) or placebo (Arm B). FIG.7A) Seven of the ten patients in arm A who received alendronate, showed an effect on HIV caRNA. In four of them the effect was a decrease compared to baseline, and in the other three, there was an increase compared to baseline. FIG. 7B) In the five patients analyzed that received placebo, HIV caRNA was comparable between all the time points analyzed. Wilcoxon signed rank test.
[0037] FIG. 8A-8C. Expansion of V52 cells after six days of culture. FIG.8A) Greater V52 cell frequency in uninfected donors. PBMC of uninfected (N=l0) and HIV-infected donors (N=l3) were stained for CD3 and V52 and analyzed by flow cytometry. As expected, uninfected individuals showed a statistically higher percentage of V52 cells compared to HIV-infected donors Data represent mean ±SEM (Mann-Whitney U-test, p<0.00l). FIG. 8B) Representative histograms showing V52 cell expansion. PBMC from uninfected (left histogram) or ART- suppressed HIV-infected donors (right panel) were incubated for six days using HMBPP+IL-2, PAM+IL-2, or IL-2 alone. FIG. 8C) V52 cells from HIV-infected individuals expand in response to Pamidronate (PAM) and IL-2. V52 cell fold change relative to basal cell numbers is represented. HIV-infected donors’ response to HMBPP was lower, not statistically significant after FDR adjustment, compared to uninfected individuals (FDR p=0.ll). Response to PAM and IL-2 was similar between uninfected and HIV-infected donors (FDR p=0.29). Response to HMBPP and PAM in uninfected donors was comparable (FDR p= 0.22), while response to HMBPP in HIV- infected donors was statistically lower (FDR p=0.04). Uninfected donors (n=9) are represented with grey circles and HIV-infected donors (n=ll) with squares. Uninfected and HIV-infected donors were compared using Mann Whitney U-test, *FDR-adjusted p<0.05. HMBPP, PAM and IL-2 conditions in uninfected donors and in HIV-infected donors were compared using Wilcoxon signed rank test, * FDR-adjusted p<0.05, ** FDR-adjusted p<0.005.
[0038] FIG. 9A-9B. Percentage of V52 cells after six days of culture. FIG. 9A) Basal and expanded V52 cell frequency. V52 cells frequencies from ART-suppressed HIV-infected donors achieve greater values when expanded with pamidronate (PAM)+IL-2. FIG. 9B) Detailed comparison of V52 cell numbers after exposure to HMBPP and PAM in HIV-infected donors. Each symbol shape represents one condition and each individual donor is represented by a different color. Mann Whitney U-test. *p<0.05, **p<0.005, ***p<0.0005.
[0039] FIG. 10A-10C. Expansion of V52 cells from ART -suppressed HIV-infected donors in response to pamidronate (PAM) FIG. 10A) PAM exposure significantly increase V52 cell frequency. V52 cells from suppressed HIV+ donors (N=2l) significantly expandeded in response to PAM. Patients treated in the acute infection (N=9) are represented with green triangles and patients treated in chronic infection (N=l2) are represented with purple squares. FIG. 10B) Decreased V52 cell numbers in donors treated in the chronic phase of the infection. HIV- infected donors treated in the chronic phase of the infection (N=l2) showed significantly reduced number of V52 cells (FDR p=0.007) compared to those treated in the acute phase of the infection (N=9). After PAM expansion, V52 cells remained significantly lower in donors treated in chronic
infection. Mean ±SEM. Mann-Whitney U-test, FDR p=0.02. FIG. 10C) Comparable expansion capacity between patients who initiated ART in the acute or chronic phase of HIV infection.
Fold change of V52 cell expansion with PAM was similar in patients treated in the acute and chronic infection. Mean ±SEM. Mann Whitney U-test.
[0040] FIG. 11A-11C: Phenotype of pamidronate (PAM)-expanded V52 cells in ART- suppressed HIV-infected donors. Phenotype of V 52 cells was analyzed by flow cytometry in eight HIV-infected individuals after expansion. Mean ±SEM is represented. FIG. 11A) Memory populations defined as central memory (TCM): CD45-/CD27+/CCR7+); transitional memory (TTM: CD45-/CD27+/CCR7-); effector memory (TEM: CD45-/CD27-/CCR7-). FIG. 11B) Expression of cytotoxic markers CD8, CD56 and CD16, and FIG. 11C) Expression of activation markers CD69, CD25 and HLA-DR, and exhaustion markers PD-l and CTLA-4.
[0041] FIG. 12A-12C. V52 T cells inhibit active HIV replication. FIG. 12A) Ex vivo isolated V52 T cells reduce HIV p24 production. HIV p24 production from autologous superinfected CD4 T cells was significantly reduced in the presence of V52 (N=8 for the 1:1 effectordarget ratio). Bars represent average viral production normalized to the condition where only superinfected CD4 cells were cultured. Ratios expressed as effector: target cells. FIG. 12B) Pamidronate (PAM)-expanded V52 T cells retain their capacity to inhibit viral replication. After 14 days of exposure to PAM, gd T cells were cocultured with autologous superinfected CD4 cells. V52 T cells (N=10 for the 1 : 1 effector: target ratio) significantly reduced HIV p24 production. FIG. 12C) Comparable inhibition capacity between basal and PAM-expanded V52 T cells. Data from basal HIV inhibition assays were compared to their respective inhibition capacity after PAM exposure. Inhibition capacity was similar in V52 cells (N=7 for the 1:1 effector: target ratio). Mean ±SEM is represented. Mann Whitney U-test. *p<0.05, **p<0.005, ***p<0.0005.
[0042] FIG. 13A) Examples of individual HIV p24 production by isolated V52 T cells expanded with pamidronate (PAM) compared to CD4 cells cultured alone. FIG. 13B) Comparison of inhibition capacity between basal and expanded V52 cells with CD8 T cells at 1:1 effector: target cell (N= 4, Mann-Whitney U-test).
[0043] FIG. 14A-14B. Cytotoxic assays. FIG. 14A) V52 cells degranulate in response to
PHA. CD107a production from V52 cells cocultured with PHA-activated HIV- superinfected CD4 cells is comparable to that produced after coculture with PHA-activated but not superinfected CD4 cells. FIG. 14B) MHC-blocking experiments. Expanded V52 cells were incubated with a pan- HLA monoclonal antibody prior to coculture with autologous HIV- superinfected CD4 cells.
[0044] FIG. 15A-15C. V52 cells degranulate in the presence of autologous HIV-infected
CD4 T cells. FIG. 15A) Flow cytometry plots showing an example of CD107a detection in
cocultures of expanded V52 cells with autologous CD4 cells (left) and with autologous JR-CSF- superinfected CD4 cells (right). FIG. 15B) Greater CD107a production in the presence of HIV- infected cells. CDl07a production was statistically higher when V52 cells were cocultured with HIV-superinfected CD4 cells compared to cocultures of autologous isolated CD4 cells (FDR p=0.006). CD 107 a production was the highest when V52 cells were cocultured with PH A- activated HIV-CD4 cells (FDR p=0.02) but without statistical differences compared to cells infected using polybrene. Mean ±SEM is represented. p=0.08, Wilcoxon matched-pairs signed rank test. FIG. 15C) Comparable degranulation capacity of V52 cells between donors treated in acute and chronic HIV infection. CDl07a production was not statistically different between acute and chronic patients. Both groups of patients showed statistically higher CDl07a expression in cocultures of V52 cells and superinfected CD4 target cells than in cultures of V52 cells cocultured with ex vivo isolated CD4 cells. Effector: target ratio (1:1). Mann Whitney U-test.
[0045] FIG. 16. gd T cells clear latently infected cells after latency reversal with vorinostat (VOR). Isolated resting CD4 (r-CD4) cells from ART-suppressed HIV-infected donors were reactivated with 0.5mM VOR. After washing, r-CD4 cells were cultured alone or with gd T cells, which were removed from the culture after 24 hours. The same number of replicate cultures of lxlO6 from each condition were then cultured in parallel for 19 days. VOR efficiently reactivated latent HIV in six (represented in the graph) of the eight patients analyzed in the condition where r- CD4 cells were cultured alone. Frequency of HIV recovery (number of positive wells for HIVp24 measured by ELISA) decreased significantly (p=0.03, Wilcoxon signed-rank test.) in cultures of r- CD4 cells in the presence of gd T cells, demonstrating that gd T cells can recognize and clear latently HIV infected cells upon latency reversal.
5. DETAILED DESCRIPTION OF THE DISCLOSURE
5.1. Definitions
[0046] While the following terms are believed to be well understood by one of ordinary skill in the art, the following definitions are set forth to facilitate explanation of the presently disclosed subject matter.
[0047] Throughout the present specification, the terms“about” and/or“approximately” may be used in conjunction with numerical values and/or ranges. The term“about” is understood to mean those values near to a recited value. For example,“about 40 [units]” may mean within ± 25% of 40 (e.g., from 30 to 50), within ± 20%, ± 15%, ± 10%, ± 9%, ± 8%, ± 7%, ± 6%, ± 5%, ± 4%, ± 3%, ± 2%, ± 1%, less than ± 1%, or any other value or range of values therein or there below.
Alternatively, depending on the context, the term“about” may mean ± one half a standard deviation, ± one standard deviation, or ± two standard deviations. Furthermore, the phrases“less than about [a value]” or“greater than about [a value]” should be understood in view of the definition of the term “about” provided herein. The terms “about” and “approximately” may be used interchangeably.
[0048] Nonlimiting examples of bisphosphonates are non-nitrogenous bisphosphonates are Etidronate (Didronel™), Clodronate (Bonefos™, Loron™) or Tiludronate (Skelid™). Examples of nitrogenous bisphosphonates are Alendronate (Fosamax™), Ibandronate (Boniva™ or Bonviva™), Neridronate (Nerixia™), Olpadronate, Pamidronate (APD/Aredia™), Risedronate (Actonel™), or Zoledronate (Zometa™ /Aclasta™).
[0049] "Disease" refers to any disease, disorder, condition, symptom, or indication.
[0050] "Host" preferably refers to a human. It also includes other mammals including the equine, porcine, bovine, feline, and canine families.
[0051] Non-limiting examples of latency reversing agents (LRAs) are an epigenetic modifier, an NFkB agonist, a PI3K/Akt pathway inhibitor, a protein kinase C agonist, a TCR activator or a TLR agonist. See Darcis et ah, 2017, Trends Immun 38(3) 217-228; Rasmussen and Lewin 2016 Curr Opin HIV AIDS 11:394-401; and Kim et al. 2018 Cell Host Microbe 23 14-26.
[0052] The epigenetic modifier may be (i) a bromodomain or BET inhibitor (e.g., CPI- 203, CPI-0610, 1-BET 151 (GSK1210151A), I-BET 762 (GSK525762), JQ1, LY294002, olinone, OTX- 015, TEN-010); (ii) a crotonylation agent, e.g., sodium crotonate or PEP005, see Jiang et al. 2018 “HIV latency is reversed by ACSS2-driven histone crotonylation” J Clin Invest, doi.org/l0.H72/JCI9807l published February 19, 2018 (iii) a histone deacetylase inhibitor (e.g., 4SC-202, Abexinostat (PCI-24781), ACY-1215, AR-42, Belinostat (PXD101), CG200745, Chidamide, CHR-2845 , CHR-3996, CUDC-101, Entinostat (MS-275), Givinostat (ITF2357), HBI- 8000, (a benzamide HDI), Kevetrin (selective for HDAC2), ME-344, Mocetinostat (MGCD0103), Panobinostat, Quisinostat (JNJ-26481585), Resminostat (4SC-201), Romidepsin, sulforaphane, Valproic acid, Vorinostat); (iv) a methylation inhibitor (e.g., 5-azacytidine, 5-aza-2-deoxycytidine (5-Aza-CdR), 5-fluoro-2-deoxycytidine, (-)-epigallocatechin-3-gallate, hydralazine, procainamid and zebularine); (v) a methyltransferase inhibitor, see Pechalrieu et al. 2017, Biochem Pharmacol 129 1-13, (e.g., 5-Aza-2'-deoxycytidine (5azadC), 5-Azacytidine (5azaC), DC_05 analogues, Dichlone, Flavonoid derivatives (Kazinol Q, chloro-nitroflavanones), Guadecitabine (SGI- 110), Indole derivatives, Isoxazoline and oxazoline derivatives, Laccaic acid A, MG98, Nanaomycin A, Procainamide conjugates, Propiophenone derivatives, Pyrrolopyridine derivatives, Quinazoline derivatives, RG108 analogues, SGI-1027, SW155246, Zebularine); (vi) a pTEF-b activator, see
Wang et al 2017 Sci Rep 7(9451) Aug. 25, 2017 (e.g., ingenol derivative, EK-16A).
[0053] Nonlimiting examples of NFkB agonists are the SMAC (second mitochondria-derived activator of caspases) mimetics (e.g., AZD5582 (Sampey et al. 2018, bioRxiv May 2, 2018), BV6, birinapant, LCL161).
[0054] Nonlimiting examples of a PI3K/Akt pathway inhibitors are disulfiram, mTor inhibitors (e.g., RAD rapamycin (sirolimus) and derivatives/analogs thereof such as everolimus or RAD001; ABT578, AP23573, AP23841, ascomycin (an ethyl analog of FK506), AZD08055, CCI-779, EX2044, EX3855, EX7518, INK-128, KU-0063794, OSI027, SAR543).
[0055] Nonlimiting examples of protein kinase C agonists are bryostatin, ingenol B/PEP005, prostratin).
[0056] Nonlimiting examples of a TLR agonist are TLR7 and TLR9 agonists (e.g., TLR9 agonist, Lefitolimod/MGNl703 or 1V270 or SD-101, see Sato-Kaneko et ah, 2017 JCI Insight 2(18) e93397).
[0057] gd T cells (gamma delta T cells) represent a small subset of T cells that possess a distinct T cell receptor (TCR) on their surfaces. A majority of T cells have a TCR composed of two glycoprotein chains called a- and b- TCR chains. However, in gd T cells, the TCR is made up of one g-chain and one d-chain. In humans they represent under 10% of total T cells) gd T cells are not MHC-restricted. As used herein, the gd T cells may be endogenous cells, e.g., native cells or expanded native cells from a patient. In other embodiments the gd T cells may be genetically engineered, e.g., CCR5 and/or CXCR4 knockouts. See Delhove and Qasim, 2017,“Genome-Edited T Cell Therapies” Curr Stem Cell Rep 3:124-136; Schumann et ah, 2015, "Generation of knock-in primary human T cells using Cas9 ribonucleoproteins". Proceedings of the National Academy of Sciences USA. 112 (33): 10437-10442; Zhang et al. 2017,“Gene editing in T cell therapy” J Genetics and Genomics 44 (2017) 415-422. In other embodiments, the gd T cells are adopted T cells. See Ruella and Kalos, 2014,“Adoptive immunotherapy for cancer.” Immunol Rev. 257(1): 14- 38; Pankrac et al., 2017,“Eradication of HIV-l latent reservoirs through therapeutic vaccination” AIDS Res Ther 14:45 DOI 10.1186/S12981-017-0177-4.
[0058] "Pharmaceutically acceptable salts" refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of the basic residues. The pharmaceutically acceptable salts include the conventional quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include, but are not limited to, those derived from inorganic and organic acids selected from l,2-ethanedisulfonic, 2-acetoxybenzoic, 2- hydroxyethanesulfonic, acetic, ascorbic, benzenesulfonic, benzoic, bicarbonic, carbonic, citric, edetic, ethane disulfonic, ethane sulfonic, fumaric, glucoheptonic, gluconic, glutamic, glycolic,
glycollyarsanilic, hexylresorcinic, hydrabamic, hydrobromic, hydrochloric, hydroiodide, hydroxymaleic, hydroxy naphthoic, isethionic, lactic, lactobionic, lauryl sulfonic, maleic, malic, mandelic, methanesulfonic, napsylic, nitric, oxalic, pamoic, pantothenic, phenylacetic, phosphoric, polygalacturonic, propionic, salicyclic, stearic, subacetic, succinic, sulfamic, sulfanilic, sulfuric, tannic, tartaric, and toluenesulfonic. Such conventional and non-toxic salts also include inorganic or organic bases such as lithium, magnesium, sodium, potassium, calcium, aluminum, zinc, arginine, lysine, benzathine, chloroprocaine, choline, diethanolamine, ethanolamine, ethylenediame, histadine, meglumine, procaine, and triethylamine. A detailed description of salt formation in pharmaceutically active compounds can be found in the following book: Stahl, P H, and Camille G Handbook of Pharmaceutical Salts: Properties, Selection, and Use. Ziirich: Verlag Helvetica Chimica Acta, 2011.
[0059] "Therapeutically effective amount" includes an amount of a compound of the present invention that is effective when administered alone or in combination to treat the desired condition or disorder. "Therapeutically effective amount" includes an amount of the combination of compounds claimed that is effective to treat the desired condition or disorder. The combination of compounds is preferably a synergistic combination. Synergy, as described, for example, by Chou and Talalay, Adv. Enzyme Regul. 1984, 22:27-55, occurs when the effect of the compounds when administered in combination is greater than the additive effect of the compounds when administered alone as a single agent. In general, a synergistic effect is most clearly demonstrated at sub-optimal concentrations of the compounds. Synergy can be in terms of lower cytotoxicity, increased antiviral effect, or some other beneficial effect of the combination compared with the individual components.
[0060] "Treating" or "treatment" covers the treatment of a disease-state in a mammal, and includes: (a) preventing the disease-state from occurring in a mammal, in particular, when such mammal is predisposed to the disease-state but has not yet been diagnosed as having it; (b) inhibiting the disease-state, e.g., arresting its development; and/or (c) relieving the disease-state, e.g., causing regression of the disease state until a desired endpoint is reached. Treating also includes the amelioration of a symptom of a disease (e.g., lessen the pain or discomfort), wherein such amelioration may or may not be directly affecting the disease (e.g., cause, transmission, expression, etc.).
[0061] Throughout the present specification, numerical ranges are provided for certain quantities. It is to be understood that these ranges comprise all subranges therein. Thus, the range“from 50 to 80” includes all possible ranges therein (e.g., 51-79, 52-78, 53-77, 54-76, 55-75, 60-70, etc.). Furthermore, all values within a given range may be an endpoint for the range encompassed thereby (e.g., the range 50-80 includes the ranges with endpoints such as 55-80, 50-75, etc.).
[0062] As used herein, the verb“comprise” as used in this description and in the claims and its conjugations are used in its non-limiting sense to mean that items following the word are included, but items not specifically mentioned are not excluded.
[0063] Throughout the specification the word“comprising,” or variations such as“comprises” or “comprising,” will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps. The present disclosure may suitably“comprise”,“consist of’, or “consist essentially of’, the steps, elements, and/or reagents described in the claims.
[0064] It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as "solely", "only" and the like in connection with the recitation of claim elements, or the use of a "negative" limitation.
[0065] Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Preferred methods, devices, and materials are described, although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure. All references cited herein are incorporated by reference in their entirety.
5.2. Pharmaceutically Acceptable Compositions
[0066] Provided herein are pharmaceutical compositions comprising a compound disclosed herein as an active ingredient, or a pharmaceutically acceptable salt, solvate or hydrate thereof in combination with a pharmaceutically acceptable vehicle, carrier, diluent, or excipient, or a mixture thereof.
[0067] The compound provided herein may be administered alone, or in combination with one or more other compounds provided herein. The pharmaceutical compositions that comprise a compound disclosed herein can be formulated in various dosage forms for oral, parenteral, and topical administration. The pharmaceutical compositions can also be formulated as modified release dosage forms, including delayed-, extended-, prolonged-, sustained-, pulsatile-, controlled-, accelerated- and fast-, targeted-, programmed-release, and gastric retention dosage forms. These dosage forms can be prepared according to conventional methods and techniques known to those skilled in the art (see, Remington: The Science and Practice of Pharmacy. 2lst Ed., Lippincott, Williams & Wilkins, Baltimore, M.D., 2006; Modified-Release Drug Delivery Technology, Rathbone et ah, Eds., Drugs and the Pharmaceutical Science, Marcel Dekker, Inc.: New York, N.Y., 2003; Vol. 126).
[0068] In one embodiment, the pharmaceutical compositions are provided in a dosage form for oral administration, which comprise a compound provided herein, e.g., a compound disclosed herein or
a pharmaceutically acceptable salt, solvate or hydrate thereof; and one or more pharmaceutically acceptable excipients or carriers.
[0069] In another embodiment, the pharmaceutical compositions are provided in a dosage form for parenteral administration, which comprise a compound disclosed herein or a pharmaceutically acceptable salt, solvate or hydrate thereof; and one or more pharmaceutically acceptable excipients or carriers.
[0070] In yet another embodiment, the pharmaceutical compositions are provided in a dosage form for topical administration, which comprise a compound disclosed herein or a pharmaceutically acceptable salt, solvate or hydrate thereof; and one or more pharmaceutically acceptable excipients or carriers.
[0071] The pharmaceutical compositions provided herein can be provided in a unit-dosage form or multiple-dosage form. A unit-dosage form, as used herein, refers to physically discrete a unit suitable for administration to a human and animal subject, and packaged individually as is known in the art. Each unit-dose contains a predetermined quantity of an active ingredient(s) sufficient to produce the desired therapeutic effect, in association with the required pharmaceutical carriers or excipients. Examples of a unit-dosage form include an ampoule, syringe, and individually packaged tablet and capsule. A unit-dosage form may be administered in fractions or multiples thereof. A multiple-dosage form is a plurality of identical unit-dosage forms packaged in a single container to be administered in segregated unit-dosage form. Examples of a multiple-dosage form include a vial, bottle of tablets or capsules, or bottle of pints or gallons. The pharmaceutical compositions provided herein can be administered at once, or multiple times at intervals of time. It is understood that the precise dosage and duration of treatment may vary with the age, weight, and condition of the patient being treated, and may be determined empirically using known testing protocols or by extrapolation from in vivo or in vitro test or diagnostic data. It is further understood that for any particular individual, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the formulations.
[0072] In one embodiment, the therapeutically effective dose is from about 0.1 mg to about 2,000 mg per day of a compound provided herein. The pharmaceutical compositions therefore should provide a dosage of from about 0.1 mg to about 2000 mg of the compound. In certain embodiments, pharmaceutical dosage unit forms are prepared to provide from about 1 mg to about 2000 mg, from about 10 mg to about 1000 mg, from about 20 mg to about 500 mg or from about 25 mg to about 250 mg of the essential active ingredient or a combination of essential ingredients per dosage unit form. In certain embodiments, the pharmaceutical dosage unit forms are prepared to provide about
10 mg, 20 mg, 25 mg, 50 mg, 100 mg, 250 mg, 500 mg, 1000 mg or 2000 mg of the essential active ingredient.
5.2.1. Parental Administration
[0073] The pharmaceutical compositions provided herein can be administered parenterally by injection, infusion, or implantation, for local or systemic administration· Parenteral administration, as used herein, include intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular, intrasynovial, intravesical, and subcutaneous administration·
[0074] The pharmaceutical compositions provided herein can be formulated in any dosage forms that are suitable for parenteral administration, including solutions, suspensions, emulsions, micelles, liposomes, microspheres, nanosystems, and solid forms suitable for solutions or suspensions in liquid prior to injection. Such dosage forms can be prepared according to conventional methods known to those skilled in the art of pharmaceutical science (see, Remington: The Science and Practice of Pharmacy, supra).
[0075] The pharmaceutical compositions intended for parenteral administration can include one or more pharmaceutically acceptable carriers and excipients, including, but not limited to, aqueous vehicles, water-miscible vehicles, non-aqueous vehicles, antimicrobial agents or preservatives against the growth of microorganisms, stabilizers, solubility enhancers, isotonic agents, buffering agents, antioxidants, local anesthetics, suspending and dispersing agents, wetting or emulsifying agents, complexing agents, sequestering or chelating agents, cryoprotectants, lyoprotectants, thickening agents, pH adjusting agents, and inert gases.
[0076] Suitable aqueous vehicles include, but are not limited to, water, saline, physiological saline or phosphate buffered saline (PBS), sodium chloride injection, Ringers injection, isotonic dextrose injection, sterile water injection, dextrose and lactated Ringers injection. Non-aqueous vehicles include, but are not limited to, fixed oils of vegetable origin, castor oil, com oil, cottonseed oil, olive oil, peanut oil, peppermint oil, safflower oil, sesame oil, soybean oil, hydrogenated vegetable oils, hydrogenated soybean oil, and medium-chain triglycerides of coconut oil, and palm seed oil. Water- miscible vehicles include, but are not limited to, ethanol, l,3-butanediol, liquid polyethylene glycol (e.g., polyethylene glycol 300 and polyethylene glycol 400), propylene glycol, glycerin, N- methyl-2-pyrrolidone, N,N-dimethylacetamide, and dimethyl sulfoxide.
[0077] Suitable antimicrobial agents or preservatives include, but are not limited to, phenols, cresols, mercurials, benzyl alcohol, chlorobutanol, methyl and propyl p-hydroxybenzoates, thimerosal, benzalkonium chloride (e.g., benzethonium chloride), methyl- and propyl-parabens, and sorbic acid. Suitable isotonic agents include, but are not limited to, sodium chloride, glycerin, and dextrose. Suitable buffering agents include, but are not limited to, phosphate and citrate. Suitable
antioxidants are those as described herein, including bisulfite and sodium metabisulfite. Suitable local anesthetics include, but are not limited to, procaine hydrochloride. Suitable suspending and dispersing agents are those as described herein, including sodium carboxymethylcelluose, hydroxypropyl methylcellulose, and polyvinylpyrrolidone. Suitable emulsifying agents include those described herein, including polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan monooleate 80, and triethanolamine oleate. Suitable sequestering or chelating agents include, but are not limited to EDTA. Suitable pH adjusting agents include, but are not limited to, sodium hydroxide, hydrochloric acid, citric acid, and lactic acid. Suitable complexing agents include, but are not limited to, cyclodextrins, including a-cyclodextrin, b-cyclodextrin, hydroxypropyl-b- cyclodextrin, sulfobutylether^-cyclodextrin, and sulfobutylether 7^-cyclodextrin (CAPTISOL®, CyDex, Lenexa, Kans.).
[0078] The pharmaceutical compositions provided herein can be formulated for single or multiple dosage administration· The single dosage formulations are packaged in an ampoule, a vial, or a syringe. The multiple dosage parenteral formulations must contain an antimicrobial agent at bacteriostatic or fungistatic concentrations. All parenteral formulations must be sterile, as known and practiced in the art.
[0079] In one embodiment, the pharmaceutical compositions are provided as ready-to-use sterile solutions. In another embodiment, the pharmaceutical compositions are provided as sterile dry soluble products, including lyophilized powders and hypodermic tablets, to be reconstituted with a vehicle prior to use. In one embodiment, the lyophilized nanoparticles are provided in a vial for reconstitution with a sterile aqueous solution just prior to injection. In yet another embodiment, the pharmaceutical compositions are provided as ready-to-use sterile suspensions. In yet another embodiment, the pharmaceutical compositions are provided as sterile dry insoluble products to be reconstituted with a vehicle prior to use. In still another embodiment, the pharmaceutical compositions are provided as ready-to-use sterile emulsions. The pharmaceutical compositions provided herein can be formulated as immediate or modified release dosage forms, including delayed-, sustained, pulsed-, controlled, targeted-, and programmed-release forms.
[0080] The pharmaceutical compositions can be formulated as a suspension, solid, semi-solid, or thixotropic liquid, for administration as an implanted depot.
5.2.2. Oral Administration Compositions
[0081] The pharmaceutical compositions provided herein can be provided in solid, semisolid, or liquid dosage forms for oral administration. As used herein, oral administration also includes buccal, lingual, and sublingual administration· Suitable oral dosage forms include, but are not limited to, tablets, fastmelts, chewable tablets, capsules, pills, troches, lozenges, pastilles, cachets, pellets, medicated chewing gum, bulk powders, effervescent or non-effervescent powders or
granules, solutions, emulsions, suspensions, wafers, sprinkles, elixirs, and syrups. In addition to the active ingredient(s), the pharmaceutical compositions can contain one or more pharmaceutically acceptable carriers or excipients, including, but not limited to, binders, fillers, diluents, disintegrants, wetting agents, lubricants, glidants, coloring agents, dye-migration inhibitors, sweetening agents, and flavoring agents.
[0082] Binders or granulators impart cohesiveness to a tablet to ensure the tablet remaining intact after compression. Suitable binders or granulators include, but are not limited to, starches, such as corn starch, potato starch, and pre-gelatinized starch (e.g., STARCH 1500); gelatin; sugars, such as sucrose, glucose, dextrose, molasses, and lactose; natural and synthetic gums, such as acacia, alginic acid, alginates, extract of Irish moss, panwar gum, ghatti gum, mucilage of isabgol husks, carboxymethylcellulose, methylcellulose, polyvinylpyrrolidone (PVP), Veegum, larch arabogalactan, powdered tragacanth, and guar gum; celluloses, such as ethyl cellulose, cellulose acetate, carboxymethyl cellulose calcium, sodium carboxymethyl cellulose, methyl cellulose, hydroxyethylcellulose (HEC), hydroxypropylcellulose (HPC), hydroxypropyl methyl cellulose (HPMC); microcrystalline celluloses, such as AVICEL-PH-101, AVICEL-PH-103, AVICEL RC- 581, AVICEL-PH-105 (FMC Corp., Marcus Hook, Pa.); and mixtures thereof. Suitable fillers include, but are not limited to, talc, calcium carbonate, microcrystalline cellulose, powdered cellulose, dextrates, kaolin, mannitol, silicic acid, sorbitol, starch, pre-gelatinized starch, and mixtures thereof. The binder or filler may be present from about 50 to about 99% by weight in the pharmaceutical compositions provided herein.
[0083] Suitable diluents include, but are not limited to, dicalcium phosphate, calcium sulfate, lactose, sorbitol, sucrose, inositol, cellulose, kaolin, mannitol, sodium chloride, dry starch, and powdered sugar. Certain diluents, such as mannitol, lactose, sorbitol, sucrose, and inositol, when present in sufficient quantity, can impart properties to some compressed tablets that permit disintegration in the mouth by chewing. Such compressed tablets can be used as chewable tablets.
[0084] Suitable disintegrants include, but are not limited to, agar; bentonite; celluloses, such as methylcellulose and carboxymethylcellulose; wood products; natural sponge; cation-exchange resins; alginic acid; gums, such as guar gum and Veegum HV; citrus pulp; cross-linked celluloses, such as croscarmellose; cross-linked polymers, such as crospovidone; cross-linked starches; calcium carbonate; microcrystalline cellulose, such as sodium starch glycolate; polacrilin potassium; starches, such as com starch, potato starch, tapioca starch, and pre-gelatinized starch; clays; aligns; and mixtures thereof. The amount of a disintegrant in the pharmaceutical compositions provided herein varies upon the type of formulation, and is readily discernible to those of ordinary skill in the art. The pharmaceutical compositions provided herein may contain from about 0.5 to about 15% or from about 1 to about 5% by weight of a disintegrant.
[0085] Suitable lubricants include, but are not limited to, calcium stearate; magnesium stearate; mineral oil; light mineral oil; glycerin; sorbitol; mannitol; glycols, such as glycerol behenate and polyethylene glycol (PEG); stearic acid; sodium lauryl sulfate; talc; hydrogenated vegetable oil, including peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, com oil, and soybean oil; zinc stearate; ethyl oleate; ethyl laureate; agar; starch; lycopodium; silica or silica gels, such as AEROSIL® 200 (W. R. Grace Co., Baltimore, Md.) and CAB-O-SIL® (Cabot Co. of Boston, Mass.); and mixtures thereof. The pharmaceutical compositions provided herein may contain about 0.1 to about 5% by weight of a lubricant.
[0086] Suitable glidants include colloidal silicon dioxide, CAB-O-SIL® (Cabot Co. of Boston, Mass.), and asbestos-free talc. Coloring agents include any of the approved, certified, water soluble FD&C dyes, and water insoluble FD&C dyes suspended on alumina hydrate, and color lakes and mixtures thereof. A color lake is the combination by adsorption of a water-soluble dye to a hydrous oxide of a heavy metal, resulting in an insoluble form of the dye. Flavoring agents include natural flavors extracted from plants, such as fruits, and synthetic blends of compounds which produce a pleasant taste sensation, such as peppermint and methyl salicylate. Sweetening agents include sucrose, lactose, mannitol, syrups, glycerin, and artificial sweeteners, such as saccharin and aspartame. Suitable emulsifying agents include gelatin, acacia, tragacanth, bentonite, and surfactants, such as polyoxyethylene sorbitan monooleate (TWEEN® 20), polyoxyethylene sorbitan monooleate 80 (TWEEN® 80), and triethanolamine oleate. Suspending and dispersing agents include sodium carboxymethylcellulose, pectin, tragacanth, Veegum, acacia, sodium carbomethylcellulose, hydroxypropyl methylcellulose, and polyvinylpyrrolidone. Preservatives include glycerin, methyl and propylparaben, benzoic add, sodium benzoate and alcohol. Wetting agents include propylene glycol monostearate, sorbitan monooleate, diethylene glycol monolaurate, and polyoxyethylene lauryl ether. Solvents include glycerin, sorbitol, ethyl alcohol, and syrup. Examples of non- aqueous liquids utilized in emulsions include mineral oil and cottonseed oil. Organic acids include citric and tartaric acid. Sources of carbon dioxide include sodium bicarbonate and sodium carbonate.
[0087] It should be understood that many carriers and excipients may serve several functions, even within the same formulation.
[0088] The pharmaceutical compositions provided herein can be provided as compressed tablets, tablet triturates, chewable lozenges, rapidly dissolving tablets, multiple compressed tablets, or enteric-coating tablets, sugar-coated, or film-coated tablets. Enteric-coated tablets are compressed tablets coated with substances that resist the action of stomach acid but dissolve or disintegrate in the intestine, thus protecting the active ingredients from the acidic environment of the stomach.
Enteric-coatings include, but are not limited to, fatty acids, fats, phenyl salicylate, waxes, shellac,
ammoniated shellac, and cellulose acetate phthalates. Sugar-coated tablets are compressed tablets surrounded by a sugar coating, which may be beneficial in covering up objectionable tastes or odors and in protecting the tablets from oxidation. Film-coated tablets are compressed tablets that are covered with a thin layer or film of a water-soluble material. Film coatings include, but are not limited to, hydroxyethylcellulose, sodium carboxymethylcellulose, polyethylene glycol 4000, and cellulose acetate phthalate. Hydrophilic polymer formulations have been widely used for improved oral availability such as ethylene oxides, hydroxy propyl methyl cellulose (HPC), poly (ethylene oxide) (PEO), polyvinyl alcohol (PVA), poly(hydroxyethylmethyl acrylate) methyl methacrylate (PHEMA), or vinyl acetate (PCT Pub. No. WO1999/37302 (Alvarez et al. ); Dimitrov & Lambov, 1999, Int J Pharm 189 105-111; Zhang et al., 1990, Proc Int. Symp Controlled Release Bioact. Mater. 17, 333, the contents of which are hereby incorporated by reference in their entirety). Film coating imparts the same general characteristics as sugar coating. Multiple compressed tablets are compressed tablets made by more than one compression cycle, including layered tablets, and press- coated or dry-coated tablets.
[0089] The tablet dosage forms can be prepared from the active ingredient in powdered, crystalline, or granular forms, alone or in combination with one or more carriers or excipients described herein, including binders, disintegrants, controlled-release polymers, lubricants, diluents, and/or colorants. Flavoring and sweetening agents are especially useful in the formation of chewable tablets and lozenges.
[0090] The pharmaceutical compositions provided herein can be provided as soft or hard capsules, which can be made from gelatin, methylcellulose, starch, or calcium alginate. The hard gelatin capsule, also known as the dry-filled capsule (DFC), consists of two sections, one slipping over the other, thus completely enclosing the active ingredient. The soft elastic capsule (SEC) is a soft, globular shell, such as a gelatin shell, which is plasticized by the addition of glycerin, sorbitol, or a similar polyol. The soft gelatin shells may contain a preservative to prevent the growth of microorganisms. Suitable preservatives are those as described herein, including methyl- and propyl parabens, and sorbic acid. The liquid, semisolid, and solid dosage forms provided herein may be encapsulated in a capsule. Suitable liquid and semisolid dosage forms include solutions and suspensions in propylene carbonate, vegetable oils, or triglycerides. Capsules containing such solutions can be prepared as described in U.S. Pat. Nos. 4,328,245; 4,409,239; and 4,410,545, the contents of which are hereby incorporated by reference in their entirety. The capsules may also be coated as known by those of skill in the art in order to modify or sustain dissolution of the active ingredient.
[0091] The pharmaceutical compositions provided herein can be provided in liquid and semisolid dosage forms, including emulsions, solutions, suspensions, elixirs, and syrups. An emulsion is a
two-phase system, in which one liquid is dispersed in the form of small globules throughout another liquid, which can be oil-in-water or water-in-oil. Emulsions may include a pharmaceutically acceptable non-aqueous liquid or solvent, emulsifying agent, and preservative. Suspensions may include a pharmaceutically acceptable suspending agent and preservative. Aqueous alcoholic solutions may include a pharmaceutically acceptable acetal, such as a di(lower alkyl) acetal of a lower alkyl aldehyde, e.g., acetaldehyde diethyl acetal; and a water-miscible solvent having one or more hydroxyl groups, such as propylene glycol and ethanol. Elixirs are clear, sweetened, and hydroalcoholic solutions. Syrups are concentrated aqueous solutions of a sugar, for example, sucrose, and may also contain a preservative. For a liquid dosage form, for example, a solution in a polyethylene glycol may be diluted with a sufficient quantity of a pharmaceutically acceptable liquid carrier, e.g., water, to be measured conveniently for administration.
[0092] Other useful liquid and semisolid dosage forms include, but are not limited to, those containing the active ingredient(s) provided herein, and a dialkylated mono- or poly-alkylene glycol, including, l,2-dimethoxymethane, diglyme, triglyme, tetraglyme, polyethylene glycol-350- dimethyl ether, polyethylene glycol-550-dimethyl ether, polyethylene glycol-750-dimethyl ether, wherein 350, 550, and 750 refer to the approximate average molecular weight of the polyethylene glycol. These formulations can further comprise one or more antioxidants, such as butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), propyl gallate, vitamin E, hydroquinone, hydroxycoumarins, ethanolamine, lecithin, cephalin, ascorbic acid, malic acid, sorbitol, phosphoric acid, bisulfite, sodium metabisulfite, thiodipropionic acid and its esters, and dithiocarbamates.
[0093] The pharmaceutical compositions provided herein for oral administration can be also provided in the forms of liposomes, micelles, microspheres, or nanosystems. Micellar dosage forms can be prepared as described in U.S. Pat. No. 6,350,458, the content of which is hereby incorporated by reference in its entirety.
[0094] The pharmaceutical compositions provided herein can be provided as non-effervescent or effervescent, granules and powders, to be reconstituted into a liquid dosage form. Pharmaceutically acceptable carriers and excipients used in the non-effervescent granules or powders may include diluents, sweeteners, and wetting agents. Pharmaceutically acceptable carriers and excipients used in the effervescent granules or powders may include organic acids and a source of carbon dioxide.
[0095] Coloring and flavoring agents can be used in all of the above dosage forms. The pharmaceutical compositions provided herein can be formulated as immediate or modified release dosage forms, including delayed-, sustained, pulsed-, controlled, targeted-, and programmed- release forms.
[0096] The pharmaceutical compositions provided herein can be co-formulated with other active ingredients which do not impair the desired therapeutic action, or with substances that supplement the desired action.
5.2.3. Topical Administration
[0097] The pharmaceutical compositions provided herein can be administered topically to the skin, orifices, or mucosa. The topical administration, as used herein, includes (intra)dermal, conjunctival, intracorneal, intraocular, ophthalmic, auricular, transdermal, nasal, vaginal, urethral, respiratory, and rectal administration·
[0098] The pharmaceutical compositions provided herein can be formulated in any dosage forms that are suitable for topical administration for local or systemic effect, including emulsions, solutions, suspensions, creams, gels, hydrogels, ointments, dusting powders, dressings, elixirs, lotions, suspensions, tinctures, pastes, foams, films, aerosols, irrigations, sprays, suppositories, bandages, dermal patches. The topical formulation of the pharmaceutical compositions provided herein can also comprise liposomes, micelles, microspheres, nanosystems, and mixtures thereof.
[0099] Pharmaceutically acceptable carriers and excipients suitable for use in the topical formulations provided herein include, but are not limited to, aqueous vehicles, water-miscible vehicles, non-aqueous vehicles, antimicrobial agents or preservatives against the growth of microorganisms, stabilizers, solubility enhancers, isotonic agents, buffering agents, antioxidants, local anesthetics, suspending and dispersing agents, wetting or emulsifying agents, complexing agents, sequestering or chelating agents, penetration enhancers, cryoprotectants, lyoprotectants, thickening agents, and inert gases.
[00100] The pharmaceutical compositions can also be administered topically by electroporation, iontophoresis, phonophoresis, sonophoresis, or microneedle or needle-free injection, such as POWDERJECT™ (Chiron Corp., Emeryville, CA), and BIOJECT™ (Bioject Medical Technologies Inc., Tualatin, OR).
[00101] The pharmaceutical compositions provided herein can be provided in the forms of ointments, creams, and gels. Suitable ointment vehicles include oleaginous or hydrocarbon vehicles, including lard, benzoinated lard, olive oil, cottonseed oil, and other oils, white petrolatum; emulsifiable or absorption vehicles, such as hydrophilic petrolatum, hydroxystearin sulfate, and anhydrous lanolin; water-removable vehicles, such as hydrophilic ointment; water-soluble ointment vehicles, including polyethylene glycols of varying molecular weight; emulsion vehicles, either water-in-oil (W/O) emulsions or oil-in-water (O/W) emulsions, including cetyl alcohol, glyceryl monostearate, lanolin, and stearic acid (see, Remington: The Science and Practice of Pharmacy. supra). These vehicles are emollient but generally require addition of antioxidants and preservatives.
[00102] Suitable cream base can be oil-in-water or water-in-oil. Cream vehicles may be water-washable, and contain an oil phase, an emulsifier, and an aqueous phase. The oil phase is also called the“internal” phase, which is generally comprised of petrolatum and a fatty alcohol such as cetyl or stearyl alcohol. The aqueous phase usually, although not necessarily, exceeds the oil phase in volume, and generally contains a humectant. The emulsifier in a cream formulation may be a nonionic, anionic, cationic, or amphoteric surfactant.
[00103] Gels are semisolid, suspension-type systems. Single -phase gels contain organic macromolecules distributed substantially uniformly throughout the liquid carrier. Suitable gelling agents include crosslinked acrylic acid polymers, such as carbomers, carboxypolyalkylenes, CARBOPOL®; hydrophilic polymers, such as polyethylene oxides, polyoxyethylene- polyoxypropylene copolymers, and polyvinylalcohol; cellulosic polymers, such as hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose phthalate, and methylcellulose; gums, such as tragacanth and xanthan gum; sodium alginate; and gelatin. In order to prepare a uniform gel, dispersing agents such as alcohol or glycerin can be added, or the gelling agent can be dispersed by trituration, mechanical mixing, and/or stirring.
[00104] The pharmaceutical compositions provided herein can be administered rectally, urethrally, vaginally, or perivaginally in the forms of suppositories, pessaries, bougies, poultices or cataplasm, pastes, powders, dressings, creams, plasters, contraceptives, ointments, solutions, emulsions, suspensions, tampons, gels, foams, sprays, or enemas. These dosage forms can be manufactured using conventional processes as described in Remington: The Science and Practice of Pharmacy, supra.
[00105] Rectal, urethral, and vaginal suppositories are solid bodies for insertion into body orifices, which are solid at ordinary temperatures but melt or soften at body temperature to release the active ingredient(s) inside the orifices. Pharmaceutically acceptable carriers utilized in rectal and vaginal suppositories include bases or vehicles, such as stiffening agents, which produce a melting point in the proximity of body temperature, when formulated with the pharmaceutical compositions provided herein; and antioxidants as described herein, including bisulfite and sodium metabisulfite. Suitable vehicles include, but are not limited to, cocoa butter (theobroma oil), glycerin- gelatin, carbowax (polyoxyethylene glycol), spermaceti, paraffin, white and yellow wax, and appropriate mixtures of mono-, di- and triglycerides of fatty acids, hydrogels, such as polyvinyl alcohol, hydroxyethyl methacrylate, polyacrylic acid; glycerinated gelatin. Combinations of the various vehicles may be used. Rectal and vaginal suppositories may be prepared by the compressed method or molding. The typical weight of a rectal and vaginal suppository is about 2 to about 3 g.
[00106] The pharmaceutical compositions provided herein can be administered ophthalmically in the forms of solutions, suspensions, ointments, emulsions, gel-forming solutions, powders for solutions, gels, ocular inserts, and implants.
5.3. Aerosol Administration
[00107] The pharmaceutical compositions provided herein can be administered intranasally or by inhalation to the respiratory tract. The pharmaceutical compositions can be provided in the form of an aerosol or solution for delivery using a pressurized container, pump, spray, atomizer, such as an atomizer using electrohydrodynamics to produce a fine mist, or nebulizer, alone or in combination with a suitable propellant, such as 1,1,1, 2-tetrafluoroethane or 1, 1,1, 2, 3,3,3- heptafluoropropane. There are many examples in the literature of metered dose inhalers (MDIs) or pressurized metered dose inhalers (pMDIs). See Kleinstreuer et al. 2015 World J Clin Cases 2(12) 742-756. The pharmaceutical compositions can also be provided as a dry powder for insufflation, alone or in combination with an inert carrier such as lactose or phospholipids; and nasal drops. Many pulmonary drugs are delivered by dry powder inhalers (DPIs) with differing arrangements such as single dose, multi-dose with the pharmaceutical composition in bulk, or multi-dose with individual blister packs. See Kleinstreuer et al. 2015; Weer and Miller 2015 J Pharm Sci 104 3259- 3288. For intranasal use, the powder can comprise a bioadhesive agent, including chitosan or cyclodextrin. As mentioned above, the pharmaceutical composition may be delivered by nebulizer such as an atomizer (jet nebulizer), an ultrasonic wave nebulizer, or a vibrating mesh nebulizer. See Kleinstreuer et al. 2015.
[00108] Alternatively, the pharmaceutical composition may be dissolved in glycerol, propane 1,2 diol gycol (PG), water or a mixture thereof and vaporized at relatively low temperature (>100 °C, typically 40-65 °C) in an e-cigarette. See Bertholon et al. 2013 Respiration 86 433-438; Brown and Cheng 2014 Tob Control May;23 Suppl 2:ii4- 10; and Famele 2015 Nicotine Tob Res 271-279; European Patent Appn. No. EP2641490A1 (Liu); European Patent Nos. EP1618803B1 and EP1736065B1 (Hon L., Best Partners Worldwide Limited); U.S. Appn. Nos. 20050016550 Al (Katase), 20110265806 (Alarcon and Healy), 20110277780A1 (Terry and Minskoff), 20130213418 Al (Tucker et al., Altria Client Service Inc.), 20130192621 (Li et al., Altria Client Service Inc.), 20130192623 (Tucker et al., Altria Client Service Inc.), 20130213419 (Tucker et al., Altria Client Service Inc.), 20130220315 (Conley, Fuma International); U.S. Patent Nos. 8,490,628 (Hon, Ruyan Investment Limited), 8,528,569 (Newton), 8,550,069 (Alelov).
[00109] Solutions or suspensions for use in a pressurized container, pump, spray, atomizer, or nebulizer can be formulated to contain ethanol, aqueous ethanol, or a suitable alternative agent for dispersing, solubilizing, or extending release of the active ingredient provided herein, a
propellant as solvent; and/or a surfactant, such as sorbitan trioleate, oleic acid, or an oligolactic acid.
[00110] The pharmaceutical compositions provided herein can be micronized to a size suitable for delivery by inhalation, such as about 50 micrometers or less, or about 10 micrometers or less. Particles of such sizes can be prepared using a comminuting method known to those skilled in the art, such as spiral jet milling, fluid bed jet milling, supercritical fluid processing to form nanoparticles, high pressure homogenization, or spray drying.
[00111] Capsules, blisters and cartridges for use in an inhaler or insufflator can be formulated to contain a powder mix of the pharmaceutical compositions provided herein; a suitable powder base, such as lactose or starch; and a performance modifier, such as l-leucine, mannitol, or magnesium stearate. The lactose may be anhydrous or in the form of the monohydrate. Other suitable excipients or carriers include dextran, glucose, maltose, sorbitol, xylitol, fructose, sucrose, and trehalose. The pharmaceutical compositions provided herein for inhaled/intranasal administration can further comprise a suitable flavor, such as menthol and levomenthol, or sweeteners, such as saccharin or saccharin sodium.
[00112] The pharmaceutical compositions provided herein for topical administration can be formulated to be immediate release or modified release, including delayed-, sustained-, pulsed-, controlled-, targeted, and programmed release.
5.4. Modified Release Formulations
[00113] The pharmaceutical compositions provided herein can be formulated as a modified release dosage form. As used herein, the term“modified release” refers to a dosage form in which the rate or place of release of the active ingredient(s) is different from that of an immediate dosage form when administered by the same route. Modified release dosage forms include delayed-, extended-, prolonged-, sustained-, pulsatile-, controlled-, accelerated- and fast-, targeted-, programmed-release, and gastric retention dosage forms. The pharmaceutical compositions in modified release dosage forms can be prepared using a variety of modified release devices and methods known to those skilled in the art, including, but not limited to, matrix controlled release devices, osmotic controlled release devices, multi-particulate controlled release devices, ion- exchange resins, enteric coatings, multilayered coatings, microspheres, liposomes, and combinations thereof The release rate of the active ingredient(s) can also be modified by varying the particle sizes and polymorphism of the active ingredient(s).
[00114] Examples of modified release include, but are not limited to, those described in U.S. Pat. Nos. 3,845,770; 3,916,899; 3,536,809; 3,598,123; 4,008,719; 5,674,533; 5,059,595; 5,591,767; 5,120,548; 5,073,543; 5,639,476; 5,354,556; 5,639,480; 5,733,566; 5,739,108; 5,891,474;
5,922,356; 5,972,891; 5,980,945; 5,993,855; 6,045,830; 6,087,324; 6,113,943; 6,197,350;
6,248,363; 6,264,970; 6,267,981; 6,376,461; 6,419,961; 6,589,548; 6,613,358; and 6,699,500, the contents of which are hereby incorporated by reference in their entirety.
5.4.1. Matrix Controlled Release Devices
[00115] The pharmaceutical compositions provided herein in a modified release dosage form can be fabricated using a matrix controlled release device known to those skilled in the art (see, Takada et al. in“Encyclopedia of Controlled Drug Delivery,” Vol.2, Mathiowitz Ed., Wiley, 1999).
[00116] In one embodiment, the pharmaceutical compositions provided herein in a modified release dosage form is formulated using an erodible matrix device, which is water- swellable, erodible, or soluble polymers, including synthetic polymers, and naturally occurring polymers and derivatives, such as polysaccharides and proteins.
[00117] Materials useful in forming an erodible matrix include, but are not limited to, chitin, chitosan, dextran, and pullulan; gum agar, gum arabic, gum karaya, locust bean gum, gum tragacanth, carrageenans, gum ghatti, guar gum, xanthan gum, and scleroglucan; starches, such as dextrin and maltodextrin; hydrophilic colloids, such as pectin; phosphatides, such as lecithin; alginates; propylene glycol alginate; gelatin; collagen; and cellulosics, such as ethyl cellulose (EC), methylethyl cellulose (MEC), carboxymethyl cellulose (CMC), CMEC, hydroxyethyl cellulose (HEC), hydroxypropyl cellulose (HPC), cellulose acetate (CA), cellulose propionate (CP), cellulose butyrate (CB), cellulose acetate butyrate (CAB), CAP, CAT, hydroxypropyl methyl cellulose (HPMC), HPMCP, HPMCAS, hydroxypropyl methyl cellulose acetate trimellitate (HPMCAT), and ethylhydroxy ethylcellulose (EHEC); polyvinyl pyrrolidone; polyvinyl alcohol; polyvinyl acetate; glycerol fatty acid esters; polyacrylamide; polyacrylic acid; copolymers of ethacrylic acid or methacrylic acid (EUDRAGIT®, Rohm America, Inc., Piscataway, N.J.); poly(2-hydroxyethyl- methacrylate); polylactides; copolymers of L-glutamic acid and ethyl-L-glutamate; degradable lactic acid-glycolic acid copolymers; poly-D-(-)-3-hydroxybutyric acid; and other acrylic acid derivatives, such as homopolymers and copolymers of butylmethacrylate, methylmethacrylate, ethylmethacrylate, ethylacrylate, (2-dimethylaminoethyl)methacrylate, and
(trimethylaminoethyl)methacrylate chloride.
[00118] In further embodiments, the pharmaceutical compositions are formulated with a non- erodible matrix device. The active ingredient(s) is dissolved or dispersed in an inert matrix and is released primarily by diffusion through the inert matrix once administered. Materials suitable for use as a non-erodible matrix device included, but are not limited to, insoluble plastics, such as polyethylene, polypropylene, polyisoprene, polyisobutylene, polybutadiene, polymethylmethacrylate, polybutylmethacrylate, chlorinated polyethylene, polyvinylchloride, methyl acrylate-methyl methacrylate copolymers, ethylene-vinyl acetate copolymers, ethylene/propylene copolymers, ethylene/ethyl acrylate copolymers, vinyl chloride copolymers
with vinyl acetate, vinylidene chloride, ethylene and propylene, ionomer polyethylene terephthalate, butyl rubber epichlorohydrin rubbers, ethylene/vinyl alcohol copolymer, ethylene/vinyl acetate/vinyl alcohol terpolymer, and ethylene/vinyloxyethanol copolymer, polyvinyl chloride, plasticized nylon, plasticized polyethylene terephthalate, natural rubber, silicone rubbers, polydimethylsiloxanes, silicone carbonate copolymers, and; hydrophilic polymers, such as ethyl cellulose, cellulose acetate, crospovidone, and cross-linked partially hydrolyzed polyvinyl acetate; and fatty compounds, such as carnauba wax, microcrystalline wax, and triglycerides.
[00119] In a matrix-controlled release system, the desired release kinetics can be controlled, for example, via the polymer type employed; the polymer viscosity; the particle sizes of the polymer and/or the active ingredient(s); the ratio of the active ingredient(s) versus the polymer, and other excipients or carriers in the compositions.
[00120] The pharmaceutical compositions provided herein in a modified release dosage form can be prepared by methods known to those skilled in the art, including direct compression, dry or wet granulation followed by compression, melt-granulation followed by compression.
5.4.2. Osmotic Controlled Release Devices
[00121] The pharmaceutical compositions provided herein in a modified release dosage form can be fabricated using an osmotic controlled release device, including one-chamber system, two- chamber system, asymmetric membrane technology (AMT), and extruding core system (ECS). In general, such devices have at least two components: (a) the core which contains the active ingredient(s); and (b) a semipermeable membrane with at least one delivery port, which encapsulates the core. The semipermeable membrane controls the influx of water to the core from an aqueous environment of use so as to cause drug release by extrusion through the delivery port(s).
[00122] In addition to the active ingredient(s), the core of the osmotic device optionally includes an osmotic agent, which creates a driving force for transport of water from the environment of use into the core of the device. One class of osmotic agents water-swellable hydrophilic polymers, which are also referred to as“osmopolymers” and“hydrogels,” including, but not limited to, hydrophilic vinyl and acrylic polymers, polysaccharides such as calcium alginate, polyethylene oxide (PEO), polyethylene glycol (PEG), polypropylene glycol (PPG), poly (2-hydroxy ethyl methacrylate), poly(acrylic) acid, poly(methacrylic) acid, polyvinylpyrrolidone (PVP), crosslinked PVP, polyvinyl alcohol (PVA), PVA/PVP copolymers, PVA/PVP copolymers with hydrophobic monomers such as methyl methacrylate and vinyl acetate, hydrophilic polyurethanes containing large PEO blocks, sodium croscarmellose, carrageenan, hydroxy ethyl cellulose (HEC), hydroxypropyl cellulose (HPC), hydroxypropyl methyl cellulose (HPMC), carboxymethyl
cellulose (CMC) and carboxyethyl, cellulose (CEC), sodium alginate, polycarbophil, gelatin, xanthan gum, and sodium starch glycolate.
[00123] The other class of osmotic agents is osmogens, which are capable of imbibing water to affect an osmotic pressure gradient across the barrier of the surrounding coating. Suitable osmogens include, but are not limited to, inorganic salts, such as magnesium sulfate, magnesium chloride, calcium chloride, sodium chloride, lithium chloride, potassium sulfate, potassium phosphates, sodium carbonate, sodium sulfite, lithium sulfate, potassium chloride, and sodium sulfate; sugars, such as dextrose, fructose, glucose, inositol, lactose, maltose, mannitol, raffinose, sorbitol, sucrose, trehalose, and xylitol, organic acids, such as ascorbic acid, benzoic acid, fumaric acid, citric acid, maleic acid, sebacic acid, sorbic acid, adipic acid, edetic acid, glutamic acid, p- toluenesulfonic acid, succinic acid, and tartaric acid; urea; and mixtures thereof
[00124] Osmotic agents of different dissolution rates can be employed to influence how rapidly the active ingredient(s) is initially delivered from the dosage form. For example, amorphous sugars, such as MANNOGEM™ EZ (SPI Pharma, Lewes, DE) can be used to provide faster delivery during the first couple of hours to promptly produce the desired therapeutic effect, and gradually and continually release of the remaining amount to maintain the desired level of therapeutic or prophylactic effect over an extended period of time. In this case, the active ingredient(s) is released at such a rate to replace the amount of the active ingredient metabolized and excreted.
[00125] The core can also include a wide variety of other excipients and carriers as described herein to enhance the performance of the dosage form or to promote stability or processing.
[00126] Materials useful in forming the semipermeable membrane include various grades of acrylics, vinyls, ethers, polyamides, polyesters, and cellulosic derivatives that are water-permeable and water-insoluble at physiologically relevant pHs, or are susceptible to being rendered water- insoluble by chemical alteration, such as crosslinking. Examples of suitable polymers useful in forming the coating, include plasticized, unplasticized, and reinforced cellulose acetate (CA), cellulose diacetate, cellulose triacetate, CA propionate, cellulose nitrate, cellulose acetate butyrate (CAB), CA ethyl carbamate, CAP, CA methyl carbamate, CA succinate, cellulose acetate trimellitate (CAT), CA dimethylaminoacetate, CA ethyl carbonate, CA chloroacetate, CA ethyl oxalate, CA methyl sulfonate, CA butyl sulfonate, CA p-toluene sulfonate, agar acetate, amylose triacetate, beta glucan acetate, beta glucan triacetate, acetaldehyde dimethyl acetate, triacetate of locust bean gum, hydroxylated ethylene-vinylacetate, EC, PEG, PPG, PEG/PPG copolymers, PVP, HEC, HPC, CMC, CMEC, HPMC, HPMCP, HPMCAS, HPMCAT, poly(acrylic) acids and esters and poly- (methacry lie) acids and esters and copolymers thereof, starch, dextran, dextrin, chitosan,
collagen, gelatin, polyalkenes, polyethers, polysulfones, polyethersulfones, polystyrenes, polyvinyl halides, polyvinyl esters and ethers, natural waxes, and synthetic waxes.
[00127] Semipermeable membrane can also be a hydrophobic microporous membrane, wherein the pores are substantially filled with a gas and are not wetted by the aqueous medium but are permeable to water vapor, as disclosed in U.S. Pat. No. 5,798,119. Such hydrophobic but water- vapor permeable membrane are typically composed of hydrophobic polymers such as polyalkenes, polyethylene, polypropylene, polytetrafluoroethylene, polyacrylic acid derivatives, polyethers, polysulfones, polyethersulfones, polystyrenes, polyvinyl halides, polyvinylidene fluoride, polyvinyl esters and ethers, natural waxes, and synthetic waxes.
[00128] The delivery port(s) on the semipermeable membrane can be formed post-coating by mechanical or laser drilling. Delivery port(s) can also be formed in situ by erosion of a plug of water-soluble material or by rupture of a thinner portion of the membrane over an indentation in the core. In addition, delivery ports can be formed during coating process, as in the case of asymmetric membrane coatings of the type disclosed in U.S. Pat. Nos. 5,612,059 and 5,698,220, the contents of which are hereby incorporated by reference in their entirety.
[00129] The total amount of the active ingredient(s) released and the release rate can substantially by modulated via the thickness and porosity of the semipermeable membrane, the composition of the core, and the number, size, and position of the delivery ports.
[00130] The pharmaceutical compositions in an osmotic controlled-release dosage form can further comprise additional conventional excipients or carriers as described herein to promote performance or processing of the formulation.
[00131] The osmotic controlled-release dosage forms can be prepared according to conventional methods and techniques known to those skilled in the art. See, Remington: The Science and Practice of Pharmacy, supra ; Santus and Baker, J. Controlled Release 1995, 35, 1-21; Verma et ak, Drug Development and Industrial Pharmacy 2000, 26, 695-708; Verma et ak, J. Controlled Release 2002, 79, 7-27, the contents of which are hereby incorporated by reference in their entirety.
[00132] In certain embodiments, the pharmaceutical compositions provided herein are formulated as AMT controlled-release dosage form, which comprises an asymmetric osmotic membrane that coats a core comprising the active ingredient(s) and other pharmaceutically acceptable excipients or carriers. See, U.S. Pat. No. 5,612,059 and WO 2002/17918, the contents of which are hereby incorporated by reference in their entirety. The AMT controlled-release dosage forms can be prepared according to conventional methods and techniques known to those skilled in the art, including direct compression, dry granulation, wet granulation, and a dip-coating method.
[00133] In certain embodiments, the pharmaceutical compositions provided herein are formulated as ESC controlled-release dosage form, which comprises an osmotic membrane that coats a core comprising the active ingredient(s), a hydroxylethyl cellulose, and other pharmaceutically acceptable excipients or carriers.
5.4.3. Multiparticulate Controlled Release Devices
[00134] The pharmaceutical compositions provided herein in a modified release dosage form can be fabricated as a multiparticulate controlled release device, which comprises a multiplicity of particles, granules, or pellets, ranging from about 10 pm to about 3 mm, about 50 pm to about 2.5 mm, or from about 100 pm to about 1 mm in diameter. Such multiparticulates can be made by the processes known to those skilled in the art, including wet-and dry-granulation, extrusion/spheronization, roller-compaction, melt-congealing, and by spray-coating seed cores. See, for example, Multiparticulate Oral Drug Delivery: Marcel Dekker: 1994; and Pharmaceutical Pelletization Technology; Marcel Dekker: 1989.
[00135] Other excipients or carriers as described herein can be blended with the pharmaceutical compositions to aid in processing and forming the multiparticulates. The resulting particles can themselves constitute the multiparticulate device or can be coated by various film forming materials, such as enteric polymers, water-swellable, and water-soluble polymers. The multiparticulates can be further processed as a capsule or a tablet.
5.5. DOSAGE
[00136] The pharmaceutical compositions that are provided can be administered for prophylactic and/or therapeutic treatments. An "effective amount" refers generally to an amount that is a sufficient, but non- toxic, amount of the active ingredient (i.e., a compound disclosed herein) to achieve the desired effect, which is a reduction or elimination in the severity and/or frequency of symptoms and/or improvement or remediation of damage. A "therapeutically effective amount" refers to an amount that is sufficient to remedy a disease state or symptoms, or otherwise prevent, hinder, retard or reverse the progression of a disease or any other undesirable symptom. A "prophylactically effective amount" refers to an amount that is effective to prevent, hinder or retard the onset of a disease state or symptom.
[00137] In general, toxicity and therapeutic efficacy of the compound disclosed herein can be determined according to standard pharmaceutical procedures in cell cultures and/or experimental animals, including, for example, determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50/ED50. Compositions that exhibit large therapeutic indices are preferred.
[00138] The data obtained from cell culture and/or animal studies can be used in formulating a range of dosages for humans. The dosage of the active ingredient typically lines within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage can vary within this range depending upon the dosage form employed and the route of administration utilized.
[00139] The effective amount of a pharmaceutical composition comprising a compound disclosed herein to be employed therapeutically or prophylactically will depend, for example, upon the therapeutic context and objectives. One skilled in the art will appreciate that the appropriate dosage levels for treatment, according to certain embodiments, will thus vary depending, in part, upon the molecule delivered, the indication for which the compound disclosed herein is being used, the route of administration, and the size (body weight, body surface or organ size) and/or condition (the age and general health) of the patient. A clinician may titer the dosage and modify the route of administration to obtain the optimal therapeutic effect. Typical dosages range from about 0.1 pg/kg to up to about 100 mg/kg or more, depending on the factors mentioned above. In certain embodiments, the dosage may range from 0.1 pg/kg up to about 150 mg/kg; or 1 pg/kg up to about 100 mg/kg; or 5 pg/kg up to about 50 mg/kg.
[00140] The dosing frequency will depend upon the pharmacokinetic parameters of the compound disclosed herein in the formulation. For example, a clinician will administer the composition until a dosage is reached that achieves the desired effect. The composition may therefore be administered as a single dose or as two or more doses (which may or may not contain the same amount of the desired molecule) over time, or as a continuous infusion via an implantation device or catheter. Treatment may be continuous over time or intermittent. Further refinement of the appropriate dosage is routinely made by those of ordinary skill in the art and is within the ambit of tasks routinely performed by them. Appropriate dosages may be ascertained through use of appropriate dose-response data.
[00141] In this disclosure, we demonstrate gd T cell targeting and elimination of reactivated HIV- infected resting CD4 T cells ex vivo. To our knowledge, our work is the first to comprehensively analyze the potential of gd T cells from ART-suppressed infected donors to clear persistent HIV infection in resting CD4 cells. We have performed ex vivo studies demonstrating cytotoxic and antiviral capacities of gd T cells to specifically target and inhibit viral replication. Further, using autologous systems we demonstrate the specific clearance of latently HIV-infected cells by gd T cells after latency reversal. This disclosure supports the use of gd T cells in combination with bisphosphonates in HIV cure strategies particularly for ART-suppressed infected individuals.
[00142] Current strategies aimed to cure HIV infection are based on combined efforts to reactivate the vims from latency and improve immune effector cell function to clear infected cells. These strategies are primarily focused on CD8 T cells and approaches are challenging due to insufficient HIV antigen production from infected cells and poor HIV-specific CD8+ T cell gd T cells represent a unique subset of effector T cells that can traffic to tissues, and selectively target cancer or virally-infected cells without requiring MHC presentation. We analyzed whether gd T cells represent a complementary/alternative immunotherapeutic approach towards HIV cure strategies.
[00143] gd T cells from HIV-infected virologically suppressed donors were expanded with the bisphosphonate pamidronate (PAM) and cells were used in autologous cellular systems ex vivo. These cells are i) are potent cytotoxic effectors able to efficiently inhibit HIV replication ex vivo, ii) degranulate in the presence of autologous infected CD4 T cells and iii) specifically clear latently infected cells after latency reversal with VOR.
[00144] This is the first proof of concept showing that gd T cells target and clear autologous HIV reservoir upon latency reversal. Our results open new insights of the immunotherapeutic use of gd T cells for current interventions in HIV eradication strategies.
[00145] The following Examples further illustrate the disclosure and are not intended to limit the scope. In particular, it is to be understood that this disclosure is not limited to particular embodiments described, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present disclosure will be limited only by the appended claims.
6. EXAMPLES
6.1. Aminobisphosphonates as Latency Reversing Agents [00146] BACKGROUND
[00147] The human immunodeficiency virus (HIV) infects CD4+ cells and integrates its viral genome into the host cell genome. Some of these cells enter a resting state where latent but replication-competent HIV remains invisible to current antiretroviral therapy (ART) and the immune system. This quiescent provirus within long-lived resting CD4 (rCD4) cells represent the main barrier to cure HIV infection, as demonstrated by HIV rebound when ART is interrupted. Current research efforts to cure HIV infection aim to get HIV out of latency using small molecule
HIV latency-reversing agents (LRAs) and inducing potent immune responses to eliminate infected
cells. Histone deacetylase (HD AC) inhibitors have been the most widely LRAs studied in different clinical studies (Archin et al., 2014). However, the effectiveness on single agent LRA use has shown modest efficacy in inducing reactivation sufficient to enable the immune system to target and clear infected cells (Martin and Siliciano, 2016). LRAs must reactivate the latent HIV without activating the cells and without disturbing functions from immune effector cells.
[00148] In addition to HDAC inhibitors, farnesyl transferase inhibitors (FTi) have also been reported to modestly induce the expression of latent HIV in cell model systems and in cells from patients. The magnitude of viral expression was substantially increased when delivered in combination with the HDAC inhibitor vorinostat (SAHA), currently undergoing several clinical trials worldwide. The discovery of FTi as LRAs was the result of an ultra-high throughput screen of 2.9 million compounds conducted in the presence of sub-optimal concentrations of SAHA (Hazuda D. HIV Persistence Workshop, Miami 2013). However, the specific mechanisms underlying HIV induction by FTi are poorly understood.
[00149] The enzyme famesyl transferase is required for prenylation, which transfers the farnesyl pyrophosphate (FPP) groups to proteins. These FPP groups are essential for several protein post- translational modifications such as prenylation. Protein prenylation is critical to the functions of a select group of proteins that have crucial functions in biological regulation, such as protein localization and regulatory capacity of cell signaling (Wang and Casey, 2016). FTi inhibit protein prenylation. These FPP groups are synthesized in the isoprenoid biosynthesis pathway also called the mevalonate pathway.
[00150] The mevalonate pathway, that produces FPP, can be manipulated using different drugs such as statins and bisphosphonates (BP) (FIG. 1). BP are a class of drugs currently approved for the treatment of several diseases involving bone density loss including treatment of osteoporosis, multiple myeloma, bone metastases lesions, and Paget’s disease, among others. BP can be divided into two classes: non-nitrogen-containing (Non-N-BP) class and nitrogen-containing class or aminobisphosphonates (N-BPs). Among the clinically available N-BPs that can be tested, we can find pamidronate, zoledronate, alendronate, ibandronate, risedronate, neridronate, and olpadronate.
Contrary to non-nitrogen-containing BPs that are metabolized in the cell, N-BPs are not metabolized, are more potent than their non-nitrogen containing counterparts, and function by inhibiting the enzyme famesyl pyrophosphate synthase (FDPS) in the mevalonate pathway (FIG.
1). Inhibition of the enzyme FPDS prevents the formation of FPP therefore protein prenylation is indirectly inhibited as well. Another indirect effect of the inhibition of the mevalonate pathway using N-BPs is the accumulation of the intermediate isopentenyl pyrophosphate (IPP), which in turn specifically activates V52 cells (Morita et al., 2007; Tanaka et ak, 1995; Wang et ak, 2011).
These V52 cells can be largely expanded in vitro using N-BPs to become potent cytotoxic effectors
against tumor cell lines (Poonia and Pauza, 2012). In addition, we have demonstrated that expanded V52 cells from ART- suppressed HIV-infected patients can be expanded in vitro using PAM. These expanded cells are i) potent cytotoxic effectors that inhibit active viral replication ex vivo, ii) degranulate in the presence of autologous infected CD4 T cells and iii) specifically target and eliminate latent HIV-infected cells after latency reversal with SAHA (Garrido et al., JCI Insight 2018 published June 21, 2018).
[00151] As N-BP inhibit the formation of FPP groups that are essential for protein prenylation, we hypothesized that N-BP may also reactivate HIV from latency. Induction of latent HIV by N- BP was analyzed using two different approaches: i) quantitation of HIV gag RNA copies in real time quantitative reverse PCR and ii) quantification of replication-competent HIV in quantitative viral outgrowth assays (QVOA). The use of N-BPs as LRA constitute a novel use of the clinically available N-BPs as a novel strategy towards HIV eradication.
[00152] Immunotherapy using ex vivo expanded gd T cells alone or in combination with N-BPs administration has been exploited in the oncology field (Kobayashi and Tanaka, 2015; Van Acker et ah, 2016; Zou et ak, 2017). We propose the use of N-BPs alone or in combination with other compounds classified as LRAs to reactivate the virus, and concomitant or subsequent adoptive transfer of ex vivo expanded gd T cells (autologous or allogeneic) as a novel approach to eliminate persistent HIV infection. Once activated, gd T cells also exert critical adjuvant functions to induce proper adaptive immune responses including induction of dendritic cell maturation and activation of HIV-specific T cell responses (Lafont et ak, 2014). Therefore, our strategy includes the novel use of N-BPs as LRAs and take advantage of the specific activation of gd T cell functions to eradicate persistent HIV infection.
[00153] Among the methods and uses disclosed herein are:
[00154] ex vivo expansion of gd T cells. PBMC from uninfected individuals will be isolated and gd T cells expanded in vitro using N-BPs and a combination of cytokines that will generate potent cytotoxic effector gd T cells, as per previously optimized protocols. Expansions will last at least 14 days, to obtain sufficient number of cells to analyze phenotype and ex vivo function.
[00155] ii) N-BP administration. ART-suppressed HIV-infected individuals will receive a dose of N-BPs alone or in combination with other LRAs, according to standard procedures to reactivate the latent virus. In an alternative embodiment, the methods and compositions may be used for treatment of acute HIV infection or patients that have not received ART therapy.
[00156] iii) Infusion of gd T cells. Previously expanded gd T cells will be infused concomitant to LRAs administration or as a two-step approach. The gd T cells may be administered with external
cytokines such as IL-2, IL-7 or IL-15. In some embodiments, the expanded gd T cells may be genetically engineered.
[00157] RESULTS
[00158] N-BPs induce HIV gag RNA production from isolated rCD4 cells. For HIV RNA analyses, 18 patients were analyzed. In each patient, a total of 24-72 million isolated rCD4 cells were studied using between 6-15 million cells per condition, depending on cell availability. Following in vitro exposure of isolated rCD4 cells to 25pg/mL PAM, in five out of the 11 patients analyzed, HIV gag RNA copies/lxlO5 cells were significantly quantified above the untreated control, the same patients whom showed positive HIV gag RNA copies using the positive control PHA and IL-2 (FIG. 2A). Importantly, in some patients HIV RNA expression levels induced by PAM were comparable to PHA control. The HDACi SAHA was also used as a control at the physiological concentration of 335nM in seven patients showing significant gag HIV expression in one patient. Altogether, in eleven patients following six hours of culture in media alone analyzed without stimulation, HIV gag RNA was quantifiable at a mean level of 70 HIV gag RNA copies, compared to 901 HIV gag RNA copies after PHA stimulation, 174 HIV gag RNA after VOR stimulation and 260 HIV gag RNA copies after 25pg/mL PAM stimulation. The lower concentration of 2.5pg/mL in two patients, induced a mean viral production of 149 HIV gag RNA copies compared to 97 HIV gag RNA copies after PHA and IL-2 stimulation and 92 gag HIV gag RNA copies after 25pg/mL PAM.
[00159] Overall, normalized RNA data to the untreated condition from 11 HIV-infected donors showed the capacity of PAM to induce latency reversal, measured as HIV gag RNA copies, from latent HIV in isolated rCD4 cells from durable suppressed individuals (FIG. 2B). As expected, the positive control PHA and IL-2 significantly induced HIV production compared to the untreated condition (p=0.004). In addition, compared to the untreated condition, PAM efficiently and significantly reversed latency in all patients (p=0.004), without statistical differences with the clinically used HDACi SAHA (p=0.2).
[00160] Ex vivo exposure of rCD4 cells to PAM 2.5pg/mL induces comparable HIV caRNA levels to that of a positive control
[00161] Next, as the exposure of 25pg/mL may translate into higher concentrations than what is achieved in the blood using FDA approved doses, in nine subsequent experiments we exposed isolated rCD4 cells to 2.5pg/mL showing that the lO-fold lower concentration effectively reversed latency compared to the untreated condition (FIG. 2C). After exposure of rCD4 cells to 2.5pg/mL
PAM, we detected a mean of 24.7 HIV gag copies in the untreated condition, 65.2 mean copies after PHA and IL-2 treatment, and 66.4 mean HIV RNA copies. Interestingly, mean HIV copy numbers were comparable between the PHA and IL-2 condition and the PAM at 2.5pg/mL
condition (p>0.05, Wilcoxon signed rank test). These HIV copy numbers were translated into a comparable fold change induction of HIV cell-associated RNA (caRNA) (FIG. 2D).
[00162] Finally, to corroborate that the capacity to reactivate latent HIV was translatable to other N-BPs, we tested whether ex vivo exposure to ImM Zol was capable of reversing HIV latency (FIG. 3A-3B). Untreated rCD4 cells showed a mean HIV gag RNA copies of 15.8, compared to a mean of 76.2 copies in the PHA condition, 52.9 copies when we used 2.5pg/mL PAM, 42.5 mean HIV RNA copies after exposure to ImM Zol. Our results demonstrate the capacity of Zol to reactivate HIV from latency. Comparison between the capacity to induce HIV caRNA of the positive control and N-BPs was comparable (p>0.05, Wilcoxon signed rank test).
[00163] Our results demonstrate that N-BPs are capable of inducing the production of HIV gag RNA from isolated rCD4 cells from HIV-infected donors on suppressive ART.
[00164] N-BPs induce replication-competent HIV production from isolated rCD4 cells in QVOA
[00165] To test whether PAM was inducing production of non-defective, replication-competent HIV, 12 HIV+ donors were analyzed. rCD4 cells were isolated, plated in limiting dilution and incubated in parallel with 2pg/mL PHA and lOOU/mL IL-2, 25pg/mL PAM, 335nM SAHA or 5U/mL IL-2 to perform QVOA. HIV latency was reversed and replication-competent vims produced in nine of 10 patients with a mean value of IUPM rCD4 cells of 0.426. SAHA induced viral production in six of nine patients tested with a mean IUPM value of 0.159. Finally, in cultures of rCD4 cells incubated with PAM, HIV was induced to produce replication-competent virus in seven of 10 patients with a mean IUPM rCD4 cells value of 0.180. The results are shown in FIG. 3A.
[00166] Ex vivo exposure of rCD4 cells to PAM 2.5pg/mL induce replication-competent HIV to levels comparable to the positive control
[00167] Following the rationale and experimental approach described in 00154, in seven additional experiments, we performed QVOA exposing the cells to 2.5pg/mL PAM. Our results show the capacity of PAM to produce replication-competent HIV from rCD4 cells with a similar frequency than the positive control PHA and IL-2 (FIG. 3B).
[00168] N-BPs are not toxic to immune cells
[00169] In order to analyze whether N-BPs are toxic to immune cells, dose response curves using PAM concentrations from 25pg/mL to 200pg/mL were performed to analyze the expression of 7- AAD in total CD4, CD8, gd and NK cells (FIG. 4A), and CD95 expression was used in rCD4 cells (FIG. 4B). Results show that N-BPs are not toxic even at the highest concentration of 200pg/mL to any of the populations analyzed.
[00170] N-BPs do not promote proliferation of rCD4 cells, total CD4 cells or CD8 cells
[00171] Proliferation analysis using CFSE assays demonstrate that N-BPs used at different concentrations, from 25mg/mL to 200pg/mL do not promote proliferation of rCD4 cells. PHA and IL-2 were used as the positive control, media alone as the negative control and 335nM SAHA as a comparator, as this HDACi do not promote proliferation either. Our results show that PAM did not induce proliferation of rCD4 cells at any of the concentrations analyzed (FIG. 5A-5B). As an additional control we tested the effect of PAM on V52 cells, that specifically induces expansion of V52 cells. As expected, our results demonstrate that PAM in combination with IL-2 significantly induces expansion of V52 cells. The results are shown in FIG. 5A-5B.
[00172] N-BPs do not promote activation of lymphocyte populations
[00173] We analyzed the expression of the activation markers CD69 and HLA-DR on total CD4 cells, CD8 T cells, gd T cells and rCD4 cells after exposure to different doses of the N-BPs PAM and Zol. PHA and IL-2 was used as the positive control and VOR was used to compare with N- BPs. As expected, PHA and IL-2 induced significant increase expression of both markers in all cell populations analyzed. Our results showed no increase on activation markers CD69 and HLA-DR expression after exposure to N-BPs compared to the untreated condition in total CD4 cells, CD8 cells and gd T cells (FIG. 5C).
[00174] N-BPs impact mRNA expression of genes implicated in chromatin regulation
[00175] In order to investigate the mechanism by which N-BPs induce reactivation of latent HIV, RNA-seq was performed on total RNA isolated from rCD4 cells from four of the same patients in whom caRNA experiments were assayed. Whole-transcriptome analysis with total RNA sequencing was performed in PAM-treated samples and compared to the untreated conditions. The principal component analysis demonstrated that treatment with PAM was the responsible for the largest source of gene expression variation (FIG. 6A). Results showed that 3,953 genes were differentially expressed (q- value <0.1 and base mean >10) showing a good split of downregulated and upregulated genes according to treatment (data not shown). Gene set enrichment analysis was performed using GSVA and curated modules (C2). First, the effect of N-BPS on cholesterol biosynthesis pathway was analyzed as our positive control and as expected, treatment with N-BPs decreased expression of genes related to this pathway (FIG. 6B). Example pathways regulated by N-BPs included DNA damage, cell cycle, metabolism and epigenetics. Comparison between untreated and PAM-treated conditions in DNA damage, methylation targets and HDAC7 targets are shown in figure 6B as examples. Interestingly, we found a positive correlation between the genes that are altered during HIV infection and those impacted by treatment with N-BPs (FIG. 6C). This result show that pathways are altered similarly and strongly suggest that N-BPs may have a specific function over HIV reactivation. Finally, we performed a comparison with the HDACi
vorinostat (SAHA) showing that 67% of the genes are altered with this treatment, showing the non specific effect over HIV reactivation (data not shown). The top ten genes that were significantly upregulated in the treated samples and showed greater than 2-fold upregulation compared to the untreated cells were as follows: LOC100507548 (3.17), RGS4 (2.60), PROKR2 (2.45), TACR3 (2.16), OPTC (2.15), KRTAP4-2 (2.14), RFPL3 (2.12), PRAMEF13 (2.11), SFTPA2 (2.04), BTNL8 (2.02). Importantly, some of these genes are involved in chromatin regulation and may have a critical role enabling HIV transcription. The current understanding of latency maintenance is that transcriptional silencing occurs through several complementary molecular mechanisms, including transcription initiation and elongation, and epigenetic silencing via histone deacetylases (HDACs) and histone methyltransferases Thus, N-BPs may be acting at the chromatin level to reverse HIV latency. Specifically, an example of the impact at the chromatin level is the downregulation of the expression of HDA7 targets and methyltransferases (FIG. 6B).
[00176] In vivo evidence of the capacity of N-BPs to reactivate the latent virus and to activate gd T cell’s functions as to eliminate infected cells.
[00177] About 67% of HIV-infected individuals suffer from osteopenia or osteoporosis1. See,
Brown, T. T. & Qaqish, R. B. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS (London, England) 20, 2165-2174, doi:l0.l097/QAD.0b0l3e3280l022eb (2006). A clinical trial was performed in 2004 to evaluate the safety and effectiveness of the oral N-BP alendronate in the treatment of HIV-associated osteopenia and osteoporosis. See McComsey, G. A. et al. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.
AIDS (London, England) 21, 2473-2482, doi:l0T097/QAD.0b0l3e3282ef96ld (2007). The study consisted of HIV-infected individuals receiving stable ART. One arm (Arm A) of the study received alendronate once weekly and vitamin D, and the other arm (Arm B) received placebo instead of alendronate and vitamin D. Authors reported that once weekly the N-BP alendronate was safe and effective in the treatment of decreased bone mineral density. In 2018 we contacted the AIDS
Clinical Trial Groups (ACTG) and obtained some frozen PBMCs and plasma of the HIV-infected individuals enrolled in that clinical trial. Following the same protocols used for the ex vivo analysis, we quantified HIV gag caRNA levels in total PBMCs at baseline (prior to treatment) and then at weeks 2, 24 and 48 during the treatment with alendronate. We analyzed ten individuals from Arm
A and five from Arm B. Seven of the ten patients from Arm A showed a significant effect of the alendronate treatment in vivo (FIG. 7A). Interestingly, in four of them, we measured a decrease in
HIV caRNA from basal to week 48, and in three of the seven, we detected an increase compared to the basal. We hypothesized that in the four individuals who experienced a decrease in caRNA compared to baseline, alendronate induced the activation of gd T cells. Activated gd T cells may
have exerted a direct cytotoxic function eliminating HIV-infected reactivated cells and/or adjuvant functions that included the induction of dendritic cells, and anti-HIV specific responses helping in the clearance of the infected cells. These results constitute the first proof of concept of the capacity of N-BPs to induce HIV from latency. In the placebo arm, HIV caRNA levels were comparable across the time-points in all individuals analyzed (FIG. 7B).
[00178] CONCLUSIONS
[00179] Our results demonstrate that N-BPs are novel LRAs capable of inducing HIV expression from latency. N-BPs are not toxic to immune cells, i.e., CD4 cells, CD8 cells, gd cells or NK cells, do not induce proliferation of infected cells and do not alter CD4 cell subpopulations, i.e., naive, TCM, TTM, TD (data not shown). We have identified N-BPs as LRAs to be used as a novel tool in HIV cure strategies. We propose that N-BPs can be used to reactivate latent HIV and these compounds may be used alone, in combination with other LRAs, or combined with immunotherapeutic strategies to augment immune capacity to eliminate the reactivated HIV. In this regard, this is of critical importance as V52 cells are potent effectors capable of targeting and eliminating infected cells (Garrido et al, JCI Insight 2018). The data disclosed herein also confirm the beneficial specific activation of V52 cells after incubation with N-BPs. Importantly, as demonstrated in HIV-infected patients treated for low bone mineral density often associated with HIV infection, N-BP can be safely used in combination with ART. Importantly, we were able to obtain samples from a clinical trial performed with the only objective to analyze the effect of one N-BP, alendronate, on bone density of HIV-infected individuals. Our results demonstrate that in vivo administration of N-BPs leads to the reactivation of the latent provirus and may induce cytotoxic functions from effector cells that lead to the killing of those reactivated cells. In summary, we have demonstrated that N-BPs are novel latency reversing agents and we propose their novel use in the field of HIV latency and persistence.
[00180] METHODS
[00181] Reagents
[00182] To test our hypothesis, we analyzed the ability of the N-BP pamidronate (PAM, Sigma- Aldrich) at two different concentrations: 25pg/mL and 2.5pg/mL to induce HIV reactivation from latency. The lower concentration translates into what has been predicted in plasma of cancer patients (2.6lpg/mL). Phytohaemagglutinin (PHA) was used as a positive control at a concentration of 2pg/mL for QVOA and at 5pg/mL for PCR experiments. VOR was used at the clinically relevant concentration of 335-500nM.
[00183] Donors
[00184] HIV-infected donors under suppressive antiretroviral treatment (ART) with undetectable plasma viral load (<50 copies/mL) for at least one consecutive year before inclusion were analyzed. Patients had initiated ART either in the acute or in the chronic phase of HIV infection.
[00185] Quantitative Polymerase Chain Reaction (qPCR)
[00186] qPCR constitutes the gold standard method to test latency reversal capacity. Isolated rCD4 cells are cultured in bulk using positive and negative controls: in the presence of positive controls PHA and IL-2 and VOR, untreated cells, or in the presence of the experimental condition: PAM at 25pg/mL or 2.5pg/mL for six hours. After six hours cells are washed and plated in replicates of lxlO6 cells. After further washes, cells are pelleted and stored at -80°C until RNA is extracted. Then, cDNA is synthesized using well-standardized protocols and gag HIV PCR performed using specific and validated primers to amplify Gag (Archin et al., 2012).
[00187] QVOA
[00188] HIV p24 protein production (replication-competent vims as measure of infectious particles production) in quantitative viral outgrowth assays (QVOA) after 24 hours of rCD4 cells exposure to PAM was analyzed. This assay has been extensively previously reported. Briefly, isolated rCD4 cells are maintained 24 hours in antiretrovirals to avoid de novo infection of potentially spontaneous reactivation. Then, cells are washed, they are counted and plated in limiting dilution. We performed 8 replicates at lxlO6, 8 replicates at 0.5xl06 and 10 replicates at O.lxlO6 of isolated rCD4 cells. Cells are exposed for 24 hours to positive controls PHA and IL-2 or VOR, PAM, and in parallel to 5U/mL IL-2 as a negative control. Then, cells are washed and PHA- activated PBMC-depleted of CD8 T cells are added at days 5 and 8 to the culture as targets of new infections to outgrowth the virus. After 15 days supernatants are harvested and HIVp24 ELISA performed, and confirmed at day 19 of culture. Then, using a previously well-established algorithm, the infectious units per million cultured cells (IUPM) are calculated.
[00189] Toxicity
[00190] The viability dye 7-Aminoactinomycin D (7-AAD) is a non-permanent dye that can be used to identify non- viable cells as it can penetrate in cells with non-intact membranes. Once inside the cell, 7-AAD binds to the DNA producing fluorescence that identifies cells as non-viable. 7- AAD was used to identify the toxic effect of PAM using the above-mentioned concentrations on PBMC after 6 and 24 hours of incubation. To analyze toxicity of PAM in rCD4 cells we used the expression of CD95 as a marker of apoptosis.
[00191] Cell activation
[00192] Using the same experimental conditions and controls, rCD4 cells and PBMC were incubated with different PAM concentrations for 6 or 24 hours, harvested, washed, stained with
monoclonal antibodies and analyzed by flow cytometry. The expression of the activation markers CD69 and HLA-DR was analyzed in subpopulations of PBMC (total CD4 cells and CD8 cells). For rCD4 cells CD69, HLA-DR and CD25 were used.
[00193] Cell proliferation
[00194] Cell proliferation was analyzed using carboxyfluorescein diacetate succinimidyl ester (CFSE)-based assays. CFSE is a fluorescent dye that covalently binds to amine residues and importantly, it halves in each cell division making this dye an excellent tracker for proliferation assays. In these assays, matched PBMC and rCD4 cells from HIV-infected donors are stained with CFSE following standard optimized protocols. After CFSE staining and washing, cells are cultured with the experimental condition for 6 and 24 hours. After washing, cells are cultured for five additional days to test the effect of PAM on proliferation. Controls for proliferation assays included 2pg/mL or 5pg/mL PHA and lOOU/mL IL-2, and 335nM VOR as positive controls, and 5U/mL and lOOU/mL as negative controls. In addition, we also included the effect of 25pg/mL and lOOU/mL IL-2 on V52 cells as a control, as these cells specifically proliferate in response to PAM and high IL-2 doses. Cells are then harvested and washed and stained with monoclonal antibodies to analyze specific proliferation in different T cell subpopulations that include: Total Lymphocytes (CD3+ cells), CD3+CD4+ cells, CD3+CD8+ cells, CD3+y5TCR+ cells, and CD3-CD56+ (NK) cells. This set of experiments included dose-response curve analysis using increasing PAM concentrations ranging from 0.5pg/mL to 200pg/mL (0.5, 1.5, 2.5, 5, 10, 12.5, 25, 50,100 and 200 pg/mL).
[00195] RNA sequencing
[00196] Isolated total RNA was quantified using a NanoDrop® Spectrophotometer. RNA Integrity Number (RIN) was then analyzed using the RNA6000 assay (Agilent) lpg of total RNA was converted to RNAseq libraries using the KAPA Stranded mRNA-Seq Kit (Illumina) and sequenced on an Illumina HiSeq 4000 using a 2x50bp configuration. Quality-control-passed reads were aligned to the human reference genome CGRh38/hg38 using STAR. See Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, and Gingeras TR. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29(1):15-21. Transcript abundance estimates for each sample were performed using Salmon, an expectation-maximization algorithm using the UCSC gene definitions. See Patro R, Duggal G, Love MI, Irizarry RA, and Kingsford C. Salmon provides fast and bias-aware quantification of transcript expression. Nat Methods. 2017;14(4):417- 9. Raw read counts for all RNAseq samples were normalized to a fixed upper quartile. See Bullard JH, Purdom E, Hansen KD, and Dudoit S. Evaluation of statistical methods for normalization and differential expression in mRNA-Seq experiments. BMC bioinformatics. 20l0;ll(l):94.
Differential gene expression analysis comparing treated (DL2415) versus untreated samples was performed using DESeq2 (4). See Love MI, Huber W, and Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biology. 2014;15(12):550. We run principal component analysis (PCA) to visualize sample-to-sample distances and examine the relationship between untreated and treated paired samples. See Venables WN, and Ripley BD. Modern Applied Statistics with S. Springer- Verlag New York; 2002.
6.2. REFERENCES (Section 6.1)
Archin, N.M., Liberty, A.L., Kashuba, A.D., Choudhary, S.K., Kuruc, J.D., Crooks, A.M., Parker, D.C., Anderson, E.M., Kearney, M.F., Strain, M.C., et al. (2012). Administration of vorinostat disrupts HIV-l latency in patients on antiretroviral therapy. Nature 487, 482-485.
Archin, N.M., Sung, J.M., Garrido, C., Soriano-Sarabia, N., and Margolis, D.M. (2014). Eradicating HIV-l infection: seeking to clear a persistent pathogen. Nat Rev Microbiol 12, 750-764.
Kobayashi, H., and Tanaka, Y. (2015). gammadelta T Cell Immunotherapy-A Review. Pharmaceuticals (Basel, Switzerland) 8, 40-61.
Lafont, V., Sanchez, F., Laprevotte, E., Michaud, H.A., Gros, L., Eliaou, J.F., and Bonnefoy, N. (2014). Plasticity of gammadelta T Cells: Impact on the Anti-Tumor Response. Frontiers in immunology 5, 622.
Martin, A.R., and Siliciano, R.F. (2016). Progress Toward HIV Eradication: Case Reports, Current Efforts, and the Challenges Associated with Cure. Annual review of medicine 67, 215-228.
Morita, C.T., Jin, C., Sarikonda, G., and Wang, H. (2007). Nonpeptide antigens, presentation mechanisms, and immunological memory of human Vgamma2Vdelta2 T cells: discriminating friend from foe through the recognition of prenyl pyrophosphate antigens. Immunological reviews 215, 59-76.
Poonia, B., and Pauza, C.D. (2012). Gamma delta T cells from HIV+ donors can be expanded in vitro by zoledronate/interleukin-2 to become cytotoxic effectors for antibody-dependent cellular cytotoxicity. Cytotherapy 14, 173-181.
Tanaka, Y., Morita, C.T., Tanaka, Y., Nieves, E., Brenner, M.B., and Bloom, B.R. (1995). Natural and synthetic non-peptide antigens recognized by human gamma delta T cells. Nature 375, 155- 158.
Van Acker, H.H., Anguille, S., Willemen, Y., Smits, E.L., and Van Tendeloo, V.F. (2016). Bisphosphonates for cancer treatment: Mechanisms of action and lessons from clinical trials. Pharmacology & therapeutics 158, 24-40.
Wang, H., Sarikonda, G., Puan, K.J., Tanaka, Y., Feng, L, Giner, J.L., Cao, R., Monkkonen, L, Oldfield, E., and Morita, C.T. (2011). Indirect stimulation of human Vgamma2Vdelta2 T cells through alterations in isoprenoid metabolism. Journal of immunology (Baltimore, Md. : 1950) 187, 5099-5113.
Wang, M., and Casey, P.J. (2016). Protein prenylation: unique fats make their mark on biology. Nature reviews. Molecular cell biology 17, 110-122.
Zou, C., Zhao, P., Xiao, Z., Han, X., Fu, F., and Fu, L. (2017). gammadelta T cells in cancer immunotherapy. Oncotarget 8, 8900-8909.
6.3. dg T Cells: Immunotherapeutic Approach for HIV Cure Strategies [00197] Introduction
[00198] Aminobisphosphonates (N-BP) such as pamidronate (PAM) and zoledronate (Zol) are drugs that modulate the isoprenoid metabolism indirectly augmenting IPP production and activating V52 cells (16). Once activated, V52 cells are potent cytotoxic effectors (20) against malignancies (17, 18) and HIV-infected cells (19-23). We and others have previously demonstrated that V52 T cells can inhibit active viral replication (20, 24). In addition, expanded V52 T cell immune adjuvant functions include induction of dendritic cell maturation and activation of HIV-specific T cell responses (25), which are of special interest as a future complementary use of gd T cells in adoptive cell transfer strategies. In this regard, a small clinical trial with ART-naive HIV-infected donors reported expansion of V52 cells, dendritic cell activation and, increased HIV-specific T cell responses after in vivo administration of Zol and IL-2 (26). Altogether, these studies suggest that gd T cells have potential in interventions aimed to eradicate HIV infection taking advantage of the knowledge generated from the cancer field (27-29).
[00199] Comparison of V52 cell expansion in HIV-infected and uninfected individuals
[00200] We compared different ex vivo experimental conditions to expand nd2 cells from ART- suppressed HIV-infected donors (N=l3) and uninfected donors (N=l0). In this first approach we expanded the cells for six days and conditions included i) HMBPP and IL-2; ii) PAM and IL-2; or iii) IL-2 alone. Basal nd2 cell percentages within CD3+ cells were analyzed by flow cytometry showing wide interindividual differences in uninfected individuals, and expected (30) profound depletion in HIV-infected donors (mean 4.0% vs 0.7%, respectively, FIG. 8A).
[00201] In uninfected individuals, HMBPP was a more potent inducer of nd2 cell expansion compared to PAM, while cells from HIV-infected donors expanded better after PAM treatment
(FIG.8B, FIG. 8C and FIG. 9A). Importantly, the fold change expansion induced by PAM in HIV-
infected donors was comparable to uninfected donors (FIG.8B, FIG. 8C). In HIV-infected donors, after six days of culture, a mean of 5.3% of the total CD3 cells present in the culture were V52 cells after HMBPP treatment, compared to 11.0% after PAM treatment (FIG 9B). In summary, PAM allows efficient V52 cell expansion in HIV-infected donors.
[00202] V52 T cells from ART-treated HIV-infected individuals successfully expand after exposure to PAM
[00203] Based on these results, in further experiments PBMC were exposed to 25 pg/mL PAM and 100 U/mL IL-2 for a total of 14 days, to increase V52 cell numbers. We expanded V52 cells from 21 ART-suppressed HIV-infected donors, to be used for different functional assays. Expansions were performed in the presence of antiretrovirals to avoid spread of infection. The average V52 cell expansion rate was 11.9% and was variable between subjects (FIG. 10A). As we previously reported (24) patients treated in the acute phase of the infection had greater basal V52 cell numbers compared to chronically treated patients (0.7% vs. 0.3%, p=0.007). After expansion, percentages of V52 cells from patients treated in the acute phase of HIV infection were also higher compared to patients treated in the chronic HIV infection (mean 15.0 vs. 6.8, p=0.02, FIG. 10B), but with comparable fold change expansion (p=0.56, FIG. 10C). Overall, mean fold expansion was 28.4, ranging from 1.7-fold to more than 124-fold increase. Altogether, V52 T cells from suppressed HIV-infected donors were successfully expanded in response to ex vivo exposure to PAM and IL- 2.
[00204] Phenotype of expanded V52 cells
[00205] The phenotype of expanded V52 cells after 14 days of exposure to PAM was analyzed in a subgroup of eight ART-treated suppressed HIV-infected donors (six patients treated in chronic infection and two patients treated in acute infection) by measuring the expression of markers of memory, cytotoxicity, activation and immune exhaustion by flow cytometry. V52 memory cell populations were defined as follows: Central Memory (TCM, CD45RA-/CD27+/CCR7+),
Transitional Memory (TTM, CD45RA-/CD27+/CCR7-) and Effector Memory (TEM, CD45RA-
/CD27-/CCR7-). The majority of expanded V52 cells expressed a TTM phenotype (65%), followed by TCM (23%) and finally by TEM (8%) (FIG. 11A). Cytotoxic markers including CD8, CD56 and CD16 were expressed by 37%, 32% and 45% of expanded V52 cells, respectively (FIG. 11B).
Altogether, 50% of the expanded V52 cells displayed a cytotoxic phenotype (V52+CD56+) and around 30% displayed an ADCC-like phenotype characterized by the expression of CD16.
Activation markers CD69, CD25 and HLA-DR were expressed in a mean of 37.2%, 14.8% and
16.6% V52 cells, respectively. The expression of the exhaustion markers PD-1 was observed in a mean of 19.8% and CTLA-4 was observed in 4.3% of the expanded V52 cells (FIG. 11C).
[00206] PAM-expanded V52 cells inhibit active HIV replication
[00207] We previously reported that gd T cells from uninfected donors are potent inhibitors of viral replication in vitro (24). To confirm and extend these results, we used an autologous cellular system to measure the capacity of ex vivo isolated V52 T cells from ART-suppressed HIV-infected donors to inhibit viral replication in CD4 T cells infected with the JR-CSF strain in vitro. A mean reduction of 85% in HIV p24 production was detected at 1 : 1 effector: target cell ratio, 64% at a 1 : 10 and 54% at 1:100 (FIG. 12A). HIV p24 production was significantly reduced at 1:1 and 1: 10 effectordarget cell ratio.
[00208] The capacity of PAM-expanded V52 T cells to inhibit HIV replication was demonstrated, using the same functional assays of viral inhibition. Our results show that PAM- expanded V52 cells retain their capacity to significantly inhibit viral replication (FIG. 12 B, FIG. 13A). Expanded nd2 cells at the 1:1 ratio showed a mean inhibition of viral replication of 71%, 57% at the 1:10 ratio, and 18% at 1: 100. To avoid inter-individual differences in the comparison of basal and expanded nd2 cells, we performed a side-by-side analysis using the same donors. Basal mean viral inhibition mediated by ex vivo nd2 T cells was comparable to that measured after expansion with PAM (FIG. 12C). We conclude that exposure of nd2 T cells to PAM and IL-2 for 14 days does not impair the antiviral function of these cells. Finally, in four patients, we compared the inhibition capacity of nd2 cells with that of CD8 T cells, showing comparable inhibition capacity between both cell types (FIG. 13B).
[00209] V52 T cells degranulate in the presence of HIV-infected CD4 cells
[00210] The ability of nd2 cells to target HIV-infected CD4 T cells was measured analyzing
CD107a expression. Total CD4 T cells from nine ART-suppressed HIV-infected individuals were isolated and superinfected with the HIV strain JR-CSF to act as targets in cocultures with autologous expanded nd2 cells. In preliminary experiments, isolated CD4 cells were activated with PHA prior to superinfection with JR-CSF. However, we observed that cytotoxic nd2 cells were activated when
CD4 cells were exposed to PHA, regardless of HIV superinfection (FIG 14A). Therefore, we used an alternative protocol to infect isolated CD4 cells using polybrene rather than PHA. We detected a significant increase of CD107a expression in expanded nd2 cells after co-culture with JR-CSF- infected-CD4 cells, but not when cultured with CD4 cells without superinfection or alone (mean=
13.2%, 8.5% and 8.3%, respectively, p= 0.006, FIG. 15A, FIG. 15B). Expression of CD107a was also statistically higher in the HIV-CD4 group activated with PHA (mean= 18.7%, p= 0.02) but compared to polybrene-infected targets, there were not significant differences (p=0.08). Finally, we determined if the state of HIV infection (acute or chronic) at the time of ART initiation, had an impact on gd T cell effector function. CD 107a expression was comparable in cells from acute and
chronic treated donors, suggesting that the cytotoxic function of V52 cells may be recovered after ART initiation (FIG. 15C). In summary, we demonstrate that expanded V52 cells specifically degranulate in the presence of HIV-infected CD4 cells.
[00211] gd T cells can efficiently clear latently HIV-infected cells upon latency disruption
[00212] gd T cells reduce the recovery of replication-competent HIV after reactivation of r-CD4 T cells with VOR. We made a modification to the previously reported latency clearance assay protocol used for CD8 T cells (8), which is itself a modification of viral outgrowth assays. This assay provides evidence of the capacity of effector cells to deplete r-CD4 cells producing replication-competent HIV following latency reversal. Our modification of the assay consisted on depleting gd T cells after 24 hours of coculture, and it is critical to allow evaluation of the specific clearance by gd T cells. This modification avoids measurement of unspecific effects over allogeneic uninfected cells added later to outgrowth the virus. Briefly, r-CD4 cells from eight ART- suppressed donors (six treated in chronic infection and two treated in acute infection) were isolated, exposed to VOR and co-cultured with or without autologous isolated expanded V52 T cells. After 24 hours of culture, gd T cells were depleted from the cultures, plated in replicates, and uninfected allogeneic CD4 cells were added to amplify replication-competent HIV. After 15/19 days of culture, viral outgrowth from r-CD4 cells cultured alone was detected in six out of eight HIV-infected donors, as measured by the number of HIV p24 positive wells. Interestingly, when gd T cells were present in the co-culture system, no virus was recovered in four donors, and viral recovery was reduced from 5 to 2, and 4 to 3 culture wells in the other two participants (FIG. 16). These results demonstrate that expanded V52 T cells can clear latently infected cells at the time of latency disruption by VOR.
[00213] DISCUSSION
[00214] Here we demonstrate the function, and ex vivo expansion capability of gd T cells from ART- suppressed HIV-infected individuals. These cells kill autologous HIV-infected CD4 T cells. In addition, V52 T cells were able to expand up to 120 fold in response to PAM/IL2 ex vivo and reduce up to 80% viral replication in autologous co-culture systems. Overall, this disclosure supports the important finding that gd T cell possess antiviral capabilities that are maintained in virologically-suppressed individuals. Further, such antiviral gd T cells can be expanded ex vivo to target latently infected cells induced to express HIV. The present work constitutes the first proof- of-concept showing that in the context of durable suppression of HIV infection, gd T cells are capable of eliminating HIV-infected targets, suggesting that gd T cells should be explored as a novel effector population to clear HIV infection from latent and active reservoirs.
[00215] As previously reported for the N-BP Zol (21), we show that PAM induces expansion of V52 cells in HIV-infected individuals. Although V52 cell numbers were higher in patients treated in the acute phase of the infection compared to chronic infection, expansion capacity was comparable between both groups. Unfortunately, due to the difficulty recruiting women (31) this disclosure only included men. However, we acknowledge that gender differences may exist given controversial findings in previous works according to gd T cell frequencies (32-34), that may potentially translate into functional differences. Current work is focused towards this end. PAM- expanded V52 cells were mostly in a transitional memory state, characterized by elevated IFN-g production (35, 36). This phenotype has also been reported both after in vitro exposure to different N-BP (37) and in vivo after Zol treatment in cancer patients (38). In addition, cytotoxic phenotype in gd T cells has been associated with the expression of CD16, CD56 and CD8 (34). Frequencies of expression of cytotoxic markers in expanded nd2 cells described herein are in accordance to those reported in cancer and HIV settings (25, 39, 40). Finally, although PD-l and CTLA-4 are well- known markers of immune exhaustion CD8 T cells (41), the significance of their expression on expanded nd2 cells remains to be elucidated (41).
[00216] PAM-expanded nd2 cells showed increased CD107a production after coculture with autologous HIV-superinfected CD4 cell targets compared to cocultures of autologous CD4 cells without superinfection, demonstrating specific degranulation triggered by HIV infection. CD107a production, although statistically significant, was not very high, suggesting the involvement of other pathways in HIV recognition (42). In addition, as only a fraction of the CD4 cells used as targets may be infected, CDl07a production may be potentially diminished compared to an assay were 100% of targets were activating gd T cells. Antigen recognition by the gd TCR is generally not restricted to major MHC molecules (14, 15), although gd T cell recognition of peptides loaded on MHC molecules has been reported (43). Interestingly, our MHC blocking experiments showed a moderate decrease of CD107a expression in nd2 cells that need to be further investigated (FIG 14A-14B). This disclosure also highlights the importance of carefully controlling for external factors in culture systems that might provide confounding results— such as the use of PHA to activate prior to infection, as cytotoxic nd2 cells were activated by cells treated with PHA independently of HIV infection. Even when isolated CD4 cells were rested for six to seven days after PHA activation, nd2 cells showed increased CD 107 a production, suggesting that PHA binding to glycosylated surface proteins produces long-term, and perhaps irreversible, changes at the surface of cells that are recognized by gd T cells.
[00217] To further analyze the role of gd T cells in a context more relevant to HIV eradication in vivo, we performed a modification of the previously reported latency clearance assay (8, 44). In
this assay, the capacity of effector cells to recognize latent HIV reactivated by latency reversal agents is evaluated. In our modified assay, we depleted gd T cells from the coculture before the addition of uninfected target cells to ensure specific clearance of r-CD4 infected cells. Our results demonstrate that gd T cells reduce viral recovery following latency reversal of r-CD4 cells with VOR. Immunotherapy with ex vivo expanded gd cells has been used in oncology with little toxicity and overall good tolerability (27). Of great significance for future strategies aimed to cure HIV, the use of haploidentical expanded nd2 cells from relatives in adoptive transfer strategies has been successful (45, 46). This type of intervention may be valuable for future use in HIV eradication strategies, as gd T cells can harbor replication-competent HIV (24). In this regard, supernatants from expansions showed a consistent negative HIV p24 detection. However, even if cells are expanded in the presence of antiretrovirals avoiding new rounds of infection, we still do not completely understand the overall importance of defective viruses that may be accumulating, and their modulating effector responses (47).
[00218] In summary, gd T cells from HIV-infected individuals retain their functionality after expansion and constitute an attractive immunotherapeutic alternative or complementary tool to current approaches aimed to cure HIV. Our work has opened novel and intriguing questions regarding the basic biology, function and specificities of gd T cells. Here, we show the first proof- of-concept of the potential clinical use of gd T cells in cellular therapy strategies for HIV cure.
[00219] METHODS
[00220] Participants
[00221] All HIV-infected donors included were on ART and virologically suppressed (<50 copies/mL) for at least one year prior to inclusion. Characteristics and inclusion criteria of these donors have been previously described (24, 48). HIV-infected donors treated in the acute phase of HIV infection started therapy within 45 days of the estimated date of infection. Buffy coats from uninfected donor volunteers were obtained from the New York Blood Center (Long Island City, NY, USA).
[00222] Isolation of cell populations
[00223] Peripheral blood mononuclear cells (PBMC) from HIV-infected individuals were isolated from leukapheresis products, and cells from uninfected individuals were isolated from buffy coats, all by ficoll-gradient centrifugation. nd2 cells and CD8 T cells were isolated by fluorescent activated cell sorting (FACS) using a FACSAria II (BD). PBMC were stained with monoclonal antibodies against CD3 (clone SK7), V52 (clone B6), CD4 (clone SK3), and CD8 (clone SK1) (all from Biolegend, San Diego, CA). nd2 T cells were defined as CD3+ nd2+ and CD8 T cells were defined by CD3+ ndT nd2 CD4 CD8+. CD4 T cells were isolated from the same
donor using a commercially available enrichment kit that contains antibodies against CD8, CD14, CD16, CD19, CD20, CD36, CD56, CD66b, CD123, TCR-g/d and glycophorin A (StemCell Technologies, Vancouver). Resting CD4 (r-CD4) cells were isolated using a custom StemCell Technologies cocktail that contained the following antibodies: CD8, CD14, CD16, CD19, CD20, CD36, CD56, CD123, ybTCR, Glycophorin A, CD66b, CD25, HLADR and CD69. Purity of the FACS-isolated populations and resting CD4 T cells was >99%, and magnetically isolated CD4 T cells showed a purity >96%.
[00224] Expansion of V52 cells
[00225] To compare V52 cell response to pyrophosphates and N-BP from HIV-infected and uninfected donors, lxlO6 PBMC were incubated in the presence of 100hM (E)-4-hydroxy-3- methyl-but-2-enyl pyrophosphate (HMBPP) (kindly provided by Dr. H. Jomaa, Justus-Liebig University, Giessen, Germany) and lOOU/mL IL-2, or 25pg/mL PAM and lOOU/mL IL-2, or lOOU/mL IL-2 alone. After six days, cells were stained with monoclonal antibodies against CD3 and V52 to analyze gd T cell frequency by flow cytometry. Briefly, cells were harvested, washed, resuspended in staining buffer, incubated on ice in the dark for 20 minutes and finally washed and resuspended in 2% paraformaldehyde solution. Acquisition and analysis was performed on the Attune NxT instrument (Applied Biosystems).
[00226] Fifty to 70 million PBMC from HIV-infected individuals were incubated in complete IMDM containing antiretrovirals (lOmM raltegravir and either lOmM abacavir or ImM efavirenz, depending on the patient’s regimen), 25pg/mL pamidronate (PAM, Sigma) and 200U/mL IL-2 during 14 days. Every three-four days, media containing lOOU/mL IL-2 was refreshed. HIV p24 quantification (ABLmc, Rockville, MA, USA) at days 7 and 14 was consistently under the limit of detection of the assay.
[00227] Phenotypic analysis of expanded V52 cells
[00228] At day 14 of expansion, an aliquot of PBMC was harvested, washed and resuspended in staining buffer to analyze the expression of different markers within expanded nd2 cells by flow cytometry i) Memory: CD45RA (clone HI100), CD27 (clone MT271) and CCR7 (clone G043H7); ii) cytotoxic: CD8 (clone SK1), CD56 (clone 5.1H11) and CD16 (clone 3G8); iii) activation: CD69 (clone FN50), CD25 (clone BC96) and HLA-DR (clone L243), and exhaustion: PD-l (clone EH12.2H7) and CTLA-4 (clone BNI3). Cells were stained for 20 min on ice in the dark, washed, fixed in a 2% paraformaldehide solution, acquired on FACS Aria II (BD) and analyzed using FlowJo v.lO.l.
[00229] HIV infection of isolated CD4 T cells
[00230] Isolated CD4 T cells from HIV-infected donors were super- infected with the viral strain JR-CSF using two different approaches i) CD4 cells were activated with 4pg/mL PHA and lOOU/mL IL-2 for 24h, washed twice and super-infected by spinoculation at 2500rpm for 2 hours. Cells were then extensively washed to remove free virions and then used for further experiments ii) Isolated CD4 cells were spinoculated at 2500rpm for 4 hours in the presence of 8 pg/mL polybrene. Cells were resuspended in complete media containing 20 U/mL IL-2 and without washing the virus were further cultured for 7 days. Then, cells were extensively washed, resuspended in suitable media and experiments were performed. As a control, isolated CD4 cells were mock infected following the same two approaches. Level of infection of isolated CD4 cells was routinely tested quantifying HIV p24 production in culture supernatants by ELISA. Results showed a consistent efficacy of infection with a mean of 264.1 ng/mL for cells activated with PHA and 128.9 ng/mL for cells infected with polybrene. HIV p24 production was below the limit of detection of the assay for non-superinfected CD4 T cells.
[00231] Viral inhibition assays
[00232] Viral inhibition assays using V52 cells from HIV-infected individuals as effectors, were performed as previously described for uninfected individuals (24), with some modifications. Fifty thousand infected CD4 T cells were co-cultured in triplicate at different effector: target ratios of 1 : 1 , 1:10 and 1:100, unless otherwise noted. Infected CD4 cells alone were also cultured in triplicate as control of HIV production. In some experiments, ex vivo isolated CD8 T cells were used as effector cells. Supernatants were harvested at day 7 and stored at -20°C until HIVp24 ELISA quantification (ABLinc., Rockville, MA, USA) was performed. Results are expressed as percent of viral inhibition normalized to HIV p24 production when target CD4 T cells were cultured alone.
[00233] Degranulation assays
[00234] CD 107 a was used as a functional marker of cytotoxicity. FACS -sorted expanded V52 T cells were co-cultured with JR-CSF-infected autologous CD4 cells as targets. CD4 T cells were infected following the two different approaches described above. At least 100,000 effector cells were co-cultured at a 1 : 1 ratio with CD4 target cells in 96-well plates for 5 hours in the presence of GolgiStop (BD) and the monoclonal antibody CDl07a (clone H4A3, BD). In some experiments, MHC expression was blocked by incubating the cells with a pan-HLA monoclonal antibody (clone W6/32, Biolegend). Cells were then harvested, washed with staining buffer, stained with V52-FITC (Biolegend) for 20 minutes on ice in the dark, washed twice, re-suspended in staining buffer and analyzed in the Attune Focusing Cytometer (Applied Biosystems).
[00235] Assays to analyze clearance of latent HIV after reactivation
[00236] These experiments are based on the latency clearance assay reported for CD8 T cells (8) and more recently for NK cells (44). Briefly, r-CD4 cells from HIV-infected donors were isolated as described above, and exposed to 0.5 mM VOR for 18 hours. After washing, r-CD4 cells were split into two conditions, one cultured alone and the other co-cultured with isolated expanded gd T cells at a 2: 10 ratio (gd cell:r-CD4 cell). After 24 hours of culture, gd cells were removed using a depletion magnetic bead-based kit according to manufacturer’s instructions (Miltenyi Biotech). The same treatment was applied to both conditions in parallel. This gd T cell depletion after the initial 24 hours of culture constitutes our modification of the original latency clearance assay reported for CD8 T cells, providing definitive proof that the effect observed at the end of the culture is due to clearance of the reactivated r- CD4 cells by gd T cells. After depletion, r-CD4 cells were plated at lmillion cells/well. Same number of wells (from 7 to 23 replicates) were assayed for the condition of r-CD4 cells alone and r-CD4 cells cocultured with gd T cells. As target cells to amplify viral signal, we added isolated PHA-activated total CD4 cells from uninfected donors at days three and eight of culture. Supernatants were harvested at day 15 and 19 by HIV p24 ELISA. Depletion of gd T cells after co-culture was analyzed by flow cytometry showing >99.9% efficacy. Results are expressed as number of positive wells for HIVp24, comparing cultures of r-CD4 cells with and without gd T cells.
[00237] Study approval
[00238] All patients provided written informed consent prior to inclusion in the study, and studies were approved by the UNC Institutional Review Board.
[00239] Statistics
[00240] Non-parametric tests were used. Comparison between different groups were performed using the Mann Whitney U-test and repeated measures within same groups were analyzed using Wilcoxon matched-pairs signed rank test. Where indicated, multiple comparisons were accounted for using FDR-adjusted p values (49). Statistical significance was considered for p<0.05.
6.4. REFERENCES (Sections 2.1 and 6.3)
1. Archin NM, Sung JM, Garrido C, Soriano-Sarabia N, and Margolis DM. Eradicating HIV- 1 infection: seeking to clear a persistent pathogen. Nat Rev Microbiol. 2014;12(11):750- 64.
2. Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, Taylor H, Hermankova M,
Chadwick K, Margolick J, Quinn TC, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature. 1997;387(6629):183-8.
3. Wong JK, Hezareh M, Gunthard HF, Havlir DV, Ignacio CC, Spina CA, and Richman DD. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science ( New York, NY). 1997;278(5341):1291-5.
4. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, Smith K,
Lisziewicz J, Lori F, Flexner C, et al. Latent infection of CD4+ T cells provides a
mechanism for lifelong persistence of HIV-l, even in patients on effective combination therapy. Nature medicine. 1999;5(5):512-7.
Siliciano JD, and Siliciano RF. Recent developments in the effort to cure HIV infection: going beyond N = 1. The Journal of clinical investigation. 2016;126(2):409-14.
Margolis DM, Garcia JV, Hazuda DJ, and Haynes BF. Latency reversal and viral clearance to cure HIV-l. Science ( New York, NY). 20l6;353(6297):aaf65l7.
Deng K, Pertea M, Rongvaux A, Wang L, Durand CM, Ghiaur G, Lai J, McHugh HL,
Hao H, Zhang H, et al. Broad CTL response is required to clear latent HIV-l due to dominance of escape mutations. Nature. 2015.
Sung JA, Lam S, Garrido C, Archin N, Rooney CM, Bollard CM, and Margolis DM. Expanded cytotoxic T-cell lymphocytes target the latent HIV reservoir. The Journal of infectious diseases. 2015;212(2):258-63.
Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, Mackey EW, Miller JD, Leslie AJ, DePierres C, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature. 2006;443(7l09):350-4. Shan L, Deng K, Shroff NS, Durand CM, Rabi SA, Yang HC, Zhang H, Margolick JB, Blankson JN, and Siliciano RF. Stimulation of HIV-l -specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity.
2012;36(3):491-501.
Morita CT, Jin C, Sarikonda G, and Wang H. Nonpeptide antigens, presentation mechanisms, and immunological memory of human Vgamma2Vdelta2 T cells:
discriminating friend from foe through the recognition of prenyl pyrophosphate antigens. Immunological reviews. 2007;215(59-76.
Jomaa H, Wiesner J, Sanderbrand S, Altincicek B, Weidemeyer C, Hintz M, Turbachova I, Eberl M, Zeidler J, Lichtenthaler HK, et al. Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs. Science (New York, NY).
1999;285(5433): 1573-6.
Hintz M, Reichenberg A, Altincicek B, Bahr U, Gschwind RM, Kollas AK, Beck E, Wiesner J, Eberl M, and Jomaa H. Identification of (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate as a major activator for human gammadelta T cells in Escherichia coli. FEBS letters. 2001;509(2):317-22.
Tanaka Y, Morita CT, Tanaka Y, Nieves E, Brenner MB, and Bloom BR. Natural and synthetic non-peptide antigens recognized by human gamma delta T cells. Nature.
1995;375(6527): 155-8.
Vavassori S, Kumar A, Wan GS, Ramanjaneyulu GS, Cavallari M, El Daker S, Beddoe T, Theodossis A, Williams NK, Gostick E, et al. Butyrophilin 3A1 binds phosphorylated antigens and stimulates human gammadelta T cells. Nature immunology. 2013;14(9):908-
16.
Wang H, Sarikonda G, Puan KJ, Tanaka Y, Feng J, Giner JL, Cao R, Monkkonen J, Oldfield E, and Morita CT. Indirect stimulation of human Vgamma2Vdelta2 T cells through alterations in isoprenoid metabolism. Journal of immunology (Baltimore, Md : 1950). 2011 ; 187(10):5099- 113.
Lo Presti E, Dieli F, and Meraviglia S. Tumor-Infiltrating gammadelta T Lymphocytes: Pathogenic Role, Clinical Significance, and Differential Programing in the Tumor Microenvironment. Frontiers in immunology. 2014;5(607.
Silva-Santos B, Serre K, and Norell H. gammadelta T cells in cancer. Nature reviews Immunology. 2015;15(11):683-91.
Wallace M, Bartz SR, Chang WL, Mackenzie DA, Pauza CD, and Malkovsky M. Gamma delta T lymphocyte responses to HIV. Clinical and experimental immunology.
1996; 103(2): 177-84.
Poccia F, Battistini L, Cipriani B, Mancino G, Martini F, Gougeon ML, and Colizzi V. Phosphoantigen-reactive Vgamma9Vdelta2 T lymphocytes suppress in vitro human
immunodeficiency virus type 1 replication by cell-released antiviral factors including CC chemokines. The Journal of infectious diseases. 1999;180(3):858-61.
Poonia B, and Pauza CD. Gamma delta T cells from HIV+ donors can be expanded in vitro by zoledronate/interleukin-2 to become cytotoxic effectors for antibody-dependent cellular cytotoxicity. Cytotherapy. 2012;14(2):173-81.
Fausther-Bovendo H, Wauquier N, Cherfils-Vicini J, Cremer I, Debre P, and Vieillard V. NKG2C is a major triggering receptor involved in the V [delta] 1 T cell-mediated cytotoxicity against HIV-infected CD4 T cells. AIDS (London, England ). 2008;22(2):2l7- 26.
Hudspeth K, Fogli M, Correia DV, Mikulak J, Roberto A, Della Bella S, Silva-Santos B, and Mavilio D. Engagement of NKp30 on Vdeltal T cells induces the production of CCL3, CCL4, and CCL5 and suppresses HIV-l replication. Blood. 2012;119(17):4013-6. Soriano-Sarabia N, Archin NM, Bateson R, Dahl NP, Crooks AM, Kuruc JD, Garrido C, and Margolis DM. Peripheral Vgamma9Vdelta2 T Cells Are a Novel Reservoir of Latent HIV Infection. PLoS pathogens. 20l5;l l(l0):el00520l.
Lafont V, Sanchez F, Laprevotte E, Michaud HA, Gros L, Eliaou JF, and Bonnefoy N. Plasticity of gammadelta T Cells: Impact on the Anti-Tumor Response. Frontiers in immunology. 20l4;5(622.
Poccia F, Gioia C, Martini F, Sacchi A, Piacentini P, Tempestilli M, Agrati C, Amendola A, Abdeddaim A, Vlassi C, et al. Zoledronic acid and interleukin-2 treatment improves immunocompetence in HIV-infected persons by activating Vgamma9Vdelta2 T cells. AIDS ( London , England). 2009;23(5):555-65.
Kobayashi H, and Tanaka Y. gammadelta T Cell Immunotherapy-A Review.
Pharmaceuticals (Basel, Switzerland). 2015 ;8(l):40-6l .
Zou C, Zhao P, Xiao Z, Han X, Fu F, and Fu L. gammadelta T cells in cancer
immunotherapy. Oncotarget. 20l7;8(5):8900-9.
Van Acker HH, Anguille S, Willemen Y, Smits EL, and Van Tendeloo VF.
Bisphosphonates for cancer treatment: Mechanisms of action and lessons from clinical trials. Pharmacology & therapeutics. 20l6;l58(24-40.
Poccia F, Boullier S, Lecoeur H, Cochet M, Poquet Y, Colizzi V, Fournie JJ, and Gougeon ML. Peripheral V gamma 9/V delta 2 T cell deletion and anergy to nonpeptidic mycobacterial antigens in asymptomatic HIV-l -infected persons. Journal of immunology (Baltimore, Md : 1950). 1996; 157(1):449-61.
Loutfy MR, V LK, Mohammed S, Wu W, Muchenje M, Masinde K, Salam K, Soje L, Gregorovich S, and Tharao W. Recruitment of HIV-Positive Women in Research:
Discussing Barriers, Facilitators, and Research Personnel's Knowledge. The open AIDS journal. 20l4;8(58-65.
Caccamo N, Dieli F, Wesch D, Jomaa H, and Eberl M. Sex-specific phenotypical and functional differences in peripheral human Vgamma9/Vdelta2 T cells. Journal of leukocyte biology. 2006;79(4):663-6.
Cairo C, Armstrong CL, Cummings JS, Deetz CO, Tan M, Lu C, Davis CE, and Pauza CD. Impact of age, gender, and race on circulating gammadelta T cells. Human immunology. 2010;71(10):968-75.
Ryan PL, Sumaria N, Holland CJ, Bradford CM, Izotova N, Grandjean CL, Jawad AS, Bergmeier LA, and Pennington DJ. Heterogeneous yet stable Vdelta2(+) T-cell profiles define distinct cytotoxic effector potentials in healthy human individuals. Proceedings of the National Academy of Sciences of the United States of America. 2016; 113(50): 14378- 83.
Dieli F, Poccia F, Lipp M, Sireci G, Caccamo N, Di Sano C, and Salerno A.
Differentiation of effector/memory Vdelta2 T cells and migratory routes in lymph nodes or inflammatory sites. The Journal of experimental medicine. 2003;l98(3):39l-7.
Fritsch RD, Shen X, Sims GP, Hathcock KS, Hodes RJ, and Lipsky PE. Stepwise differentiation of CD4 memory T cells defined by expression of CCR7 and CD27. Journal of immunology ( Baltimore , Md : 1950). 2005;l75(l0):6489-97.
Ferlazzo V, Sferrazza C, Caccamo N, Di Fede G, Di Lorenzo G, D'Asaro M, Meraviglia S, Dieli F, Rini G, and Salerno A. In vitro effects of aminobisphosphonates on
Vgamma9Vdelta2 T cell activation and differentiation. International journal of immunopathology and pharmacology. 2006;l9(2):309-l7.
Dieli F, Gebbia N, Poccia F, Caccamo N, Montesano C, Fulfaro F, Arcara C, Valerio MR, Meraviglia S, Di Sano C, et al. Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood. 2003;l02(6):23l0-l. Alexander AA, Maniar A, Cummings JS, Hebbeler AM, Schulze DH, Gastman BR, Pauza CD, Strome SE, and Chapoval AI. Isopentenyl pyrophosphate-activated CD56+
{ gamma} {delta} T lymphocytes display potent antitumor activity toward human squamous cell carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008;l4(l3):4232-40.
Urban EM, Li H, Armstrong C, Focaccetti C, Cairo C, and Pauza CD. Control of CD56 expression and tumor cell cytotoxicity in human Vgamma2Vdelta2 T cells. BMC immunology. 2009; 10(50.
Teigler JE, Zelinskyy G, Eller MA, Bolton DL, Marovich M, Gordon AD, Alrubayyi A, Alter G, Robb ML, Martin JN, et al. Differential Inhibitory Receptor Expression on T Cells Delineates Functional Capacities in Chronic Viral Infection. Journal of virology. 20l7;9l(23).
Pauza CD, Poonia B, Li H, Cairo C, and Chaudhry S. gammadelta T Cells in HIV Disease: Past, Present, and Future. Frontiers in immunology. 20l4;5(687.
Born WK, Zhang L, Nakayama M, Jin N, Chain JL, Huang Y, Aydintug MK, and O'Brien RL. Peptide antigens for gamma/delta T cells. Cellular and molecular life sciences :
CMLS. 20ll;68(l4):2335-43.
Garrido C, Abad-Fernandez M, Tuyishime M, Pollara JJ, Ferrari G, Soriano-Sarabia N, and Margolis DM. IL-15 STIMULATED NATURAL KILLER CELLS CLEAR HIV-l INFECTED CELLS FOLLOWING LATENCY REVERSAL EX VIVO. Journal of virology. 2018.
Wilhelm M, Smetak M, Schaefer-Eckart K, Kimmel B, Birkmann J, Einsele H, and Kunzmann V. Successful adoptive transfer and in vivo expansion of haploidentical gammadelta T cells. Journal of translational medicine. 20l4;l2(45.
Norell H, Moretta A, Silva-Santos B, and Moretta L. At the Bench: Preclinical rationale for exploiting NK cells and gammadelta T lymphocytes for the treatment of high-risk leukemias. Journal of leukocyte biology. 20l3;94(6): 1123-39.
Bruner KM, Murray AJ, Pollack RA, Soliman MG, Laskey SB, Capoferri AA, Lai J,
Strain MC, Lada SM, Hoh R, et al. Defective proviruses rapidly accumulate during acute HIV-l infection. Nature medicine. 20l6;22(9): 1043-9.
Archin NM, Vaidya NK, Kuruc JD, Liberty AL, Wiegand A, Kearney MF, Cohen MS, Coffin JM, Bosch RJ, Gay CL, et al. Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-l infection without accelerating the decay of latent infection. Proceedings of the National Academy of Sciences of the United States of America. 20l2;l09(24):9523- 8.
Benjamini Y, Drai D, Elmer G, Kafkafi N, and Golani I. Controlling the false discovery rate in behavior genetics research. Behavioural brain research. 200l;l25(l-2):279-84.
7. GENERALIZED STATEMENTS OF THE DISCLOSURE
[00241] The following numbered statements provide a general description of the disclosure and are not intended to limit the appended claims.
[00242] Statement 1: A method for inducing expression of HIV viral antigen(s) in latently HIV- infected cells which comprises exposing the latently HIV-infected cells to a bisphosphonate so as to reverse latency and to induce the expression of the HIV viral antigen(s).
[00243] Statement 2: The method of Statement 1, wherein the bisphosphonate is an aminobisphosponate.
[00244] Statement 3: The method of Statement 2, wherein the aminobisphosphonate is Alendronate (Fosamax™), Ibandronate (Boniva™ or Bonviva™), Neridronate (Nerixia™), Olpadronate, Pamidronate (APD/Aredia™), Risedronate (Actonel™), or Zoledronate (Zometa™ /Aclasta™).
[00245] Statement 4: A method of inducing expression of HIV viral antigens in latently HIV- infected cells in a subject which comprises administering to the subject a bisphosphonate so as to reverse latency and induce expression of the HIV viral antigens in the cells in the subject.
[00246] Statement 5: The method of Statement 4, wherein the latently infected cells are rCD4 cells.
[00247] Statement 6: The method of any of Statements 1-5, wherein the subject is receiving antiretroviral therapy (ART).
[00248] Statement 7 : A method to boost gd T cell expression and reverse viral latency in a subject infected with HIV which comprises administering to the subject a bisphosphonate.
[00249] Statement 8: The method of Statement 7, wherein the subject is receiving antiretroviral therapy (ART).
[00250] Statement 9: The use of an aminobisphosphonate as a latency reducing agent.
[00251] Statement 10: The use of Statement 9, wherein the aminobisphosphonate is Alendronate (Fosamax™), Ibandronate (Boniva™ or Bonviva™), Neridronate (Nerixia™), Olpadronate, Pamidronate (APD/Aredia™), Risedronate (Actonel™), or Zoledronate (Zometa™ /Aclasta™).
[00252] Statement 11 : A method for eliminating latently infected cells harboring quiescent HIV provirus that comprises exposing the infected cells with gd T cells and a bisphosphonate.
[00253] Statement 12: The method of Statement 11, further comprising exposing latently infected cells to a second HIV latency reversing agent.
[00254] Statement 13: The method of Statement 12, wherein the second HIV latency reversing agent is an epigenetic modifier, an NFkB agonist, a PI3K Akt pathway inhibitor, a protein kinase
C agonist, a SMAC (second mitochondria-derived activator of caspases) mimetic, a TCR activator or a TLR agonist.
[00255] Statement 14: The method of Statement 13, wherein the epigenetic modifier is a histone deacetylase (HD AC) inhibitor.
[00256] Statement 15: A method of treating/curing a subject infected with HIV which comprises administering to the subject ex vivo expanded gd T cells and a bisphosphonate.
[00257] Statement 16: The method of Statement 15, further comprising administering to the subject a second HIV latency reversing agent.
[00258] Statement 17: The method of Statement 16, wherein the HIV latency reversing agent is an epigenetic modifier, an NFkB agonist, a PI3K/Akt pathway inhibitor, a protein kinase C agonist, a SMAC (second mitochondria-derived activator of caspases) mimetic, a TCR activator, a TLR agonist, an inhibitor of LAP (Inhibitor of Apoptosis Protein) family of proteins, or a stimulator of interferon genes protein (STING) agonist.
[00259] Statement 18: The method of Statement 17, wherein the epigenetic modifier is histone deacetylase (HD AC) inhibitor.
[00260] Statement 19: The method of any of Statements 11-18, wherein the expanded gd T cells and the bisphosphonate are administered concurrently.
[00261] Statement 20: The method of any of Statements 11-18, wherein the expanded gd T cells and the bisphosphonate are administered sequentially.
[00262] Statement 21: The method of Statement 20, wherein the expanded gd T cells and the bisphosphonate are administered over a 24 hour period.
[00263] Statement 22: The method of any of Statements 11-21, wherein the ex vivo expanded gd T cells are ndΐ T-cells.
[00264] Statement 23: The method of any of Statements 11-21, wherein the ex vivo expanded gd T cells are nd2 T-cells.
[00265] Statement 24: The method of any of Statements 11-23, wherein the ex vivo expanded gd T cells are autologous cells.
[00266] Statement 25: The method of any of Statements 11-23, wherein the ex vivo expanded gd T cells are heterologous cells.
[00267] Statement 26: The method of any of Statements 11-25, wherein the bisphosphonate is Alendronate (Fosamax™), Ibandronate (Boniva™ or Bonviva™), Neridronate (Nerixia™), Olpadronate, Pamidronate (APD/Aredia™), Risedronate (Actonel™), or Zoledronate (Zometa™ /Aclasta™).
[00268] Statement 27: The method of any of Statements 14 or 18, wherein the HDAC inhibitor is belinostat (PXD101), entinostat (MS-275), mocetinostat (MGCD0103), panobinostat (LBH589), or vorinostat (SAHA).
[00269] Statement 28: A method of treating HIV infection in a subject, comprising: (a) isolating peripheral blood mononuclear (PBMC) cells from the subject; (b) culturing the isolated PBMC cells ex vivo with an effective amount of a bisphosphonate or antibodies and suitable cytokines so as to expand gd T cells; (c) or optionally genetically modifying the expanded gd T cells; (d) infusing the expanded gd T cells into the subject; and (e) administering to the subject a bisphosphonate so as to activate quiescent HIV provirus and treat the subject with HIV.
[00270] Statement 29: The method of Statement 28, further comprising administering to the subject in step (e) a second HIV latency reversing agent.
[00271] Statement 30: The method of Statement 29, wherein the second HIV latency reversing agent is an epigenetic modifier, an NFkB agonist, a PI3K/Akt pathway inhibitor, a protein kinase C agonist, a TCR activator, a TLR agonist, an inhibitor of LAP (Inhibitor of Apoptosis Protein) family of proteins, or a stimulator of interferon genes protein (STING) agonist.
[00272] Statement 31: The method of Statement 30, wherein the epigenetic modifier is a histone deacetylase (HDAC) inhibitor.
[00273] Statement 32: The method of any of Statements 28-31 , wherein the subject was receiving antiretroviral therapy (ART).
[00274] Statement 33: The method of any of Statements 28-32, wherein the PBMCs are expanded in the presence of the bisphosphonate for 5 to 30 days.
[00275] Statement 34: The method of any of Statements 28-33, wherein the PBMCs are expanded for 7 to 21 days.
[00276] Statement 35: The method of any of Statements 28-34, wherein the expanded gd T cells and the bisphosphonate are administered concurrently.
[00277] Statement 36: The method of any of Statements 28-34, wherein the expanded gd T cells and the bisphosphonate are administered sequentially.
[00278] Statement 37: The method of any of Statements 28-36, wherein the bisphosphonate is Alendronate (Fosamax™), Ibandronate (Boniva™ or Bonviva™), Neridronate (Nerixia™), Olpadronate, Pamidronate (APD/Aredia™), Risedronate (Actonel™), or Zoledronate (Zometa™ /Aclasta™).
[00279] Statement 38: The method of Statement 31, wherein the HDAC inhibitor is belinostat (PXD101), entinostat (MS-275), mocetinostat (MGCD0103), panobinostat (LBH589), or vorinostat (SAHA).
[00280] Statement 39: A pharmaceutical composition comprising a bisphosphonate and a second HIV latency reversing agent.
[00281] Statement 40: The pharmaceutical composition of Statement 39, wherein the second HIV latency reversing agent is an epigenetic modifier, an NFkB agonist, a PI3K/Akt pathway inhibitor, a protein kinase C agonist, a TCR activator, a TLR agonist, an inhibitor of IAP (Inhibitor of Apoptosis Protein) family of proteins, or a stimulator of interferon genes protein (STING) agonist.
[00282] Statement 41 : The pharmaceutical composition of Statement 40, wherein the epigenetic modifier is a histone deacetylase (HD AC) inhibitor.
[00283] Statement 42: A pharmaceutical composition comprising an HMG CoA inhibitor and an HIV latency reversing agent.
[00284] Statement 45: The pharmaceutical composition of Statement 42, wherein the HMG CoA inhibitor is a statin.
[00285] Statement 45: The pharmaceutical composition of Statement 44, wherein the statin is torvastatin, fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin or a combination thereof.
[00286] Statement 46: A pharmaceutical composition comprising either (i) a synthetic analogue of a component of the mevalonate pathway, (ii) an inhibitor of the mevalonate pathway (beyond bisphosphonates or HMG-CoA reductase inhibitors), or (iii) an intermediate from the mevalonate pathway, and an HIV latency reversing agent.
[00287] Statement 47: The pharmaceutical composition of Statement 46, wherein the synthetic analogue, inhibitor, or intermediate is (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMBPP), isopentenyl pyrophosphate (IPP), dimethyl-allyl-pyrophosphate (DMAPP), bromohydrin pyrophosphate (BrHPP) or 2-methyl-3-butenyl-l-pyrophosphate (2M3B1PP).
[00288] Statement 48: The pharmaceutical composition of any of Statements 42-47, wherein the HIV latency reversing agent is an epigenetic modifier, an NFkB agonist, a PI3K/Akt pathway inhibitor, a protein kinase C agonist, a TCR activator, a TLR agonist, an inhibitor of IAP (Inhibitor of Apoptosis Protein) family of proteins, or a stimulator of interferon genes protein (STING) agonist.
[00289] Statement 49: The pharmaceutical composition of Statement 48, wherein the epigenetic modifier is a histone deacetylase (HD AC) inhibitor.
[00290] Statement 50: The pharmaceutical composition of Statement 49, wherein the HDAC inhibitor is belinostat (PXD101), entinostat (MS-275), mocetinostat (MGCD0103), panobinostat (LBH589), or vorinostat (SAHA).
[00291] Statement 51: The use of the pharmaceutical composition of any of Statements 39-50 as an HIV latency reversing agent ex vivo.
[00292] Statement 52: The use of the pharmaceutical composition of any of Statements 39-50 as an HIV latency reversing agent when administered to a subject.
[00293] It should be understood that the above description is only representative of illustrative embodiments and examples. For the convenience of the reader, the above description has focused on a limited number of representative examples of all possible embodiments, examples that teach the principles of the disclosure. The description has not attempted to exhaustively enumerate all possible variations or even combinations of those variations described. That alternate embodiments may not have been presented for a specific portion of the disclosure, or that further undescribed alternate embodiments may be available for a portion, is not to be considered a disclaimer of those alternate embodiments. One of ordinary skill will appreciate that many of those undescribed embodiments, involve differences in technology and materials rather than differences in the application of the principles of the disclosure. Accordingly, the disclosure is not intended to be limited to less than the scope set forth in the following claims and equivalents.
[00294] INCORPORATION BY REFERENCE
[00295] All references, articles, publications, patents, patent publications, and patent applications cited herein are incorporated by reference in their entireties for all purposes. However, mention of any reference, article, publication, patent, patent publication, and patent application cited herein is not, and should not be taken as an acknowledgment or any form of suggestion that they constitute valid prior art or form part of the common general knowledge in any country in the world. It is to be understood that, while the disclosure has been described in conjunction with the detailed description, thereof, the foregoing description is intended to illustrate and not limit the scope. Other aspects, advantages, and modifications are within the scope of the claims set forth below. All publications, patents, and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference.
Claims
1. A method for inducing expression of HIV viral antigen(s) in latently HIV-infected cells which comprises exposing the latently HIV-infected cells to a bisphosphonate so as to reverse latency and to induce the expression of the HIV viral antigen(s).
2. The method of claim 1, wherein the bisphosphonate is an aminobisphosponate.
3. The method of claim 2, wherein the aminobisphosphonate is Alendronate (Fosamax™), Ibandronate (Boniva™ or Bonviva™), Neridronate (Nerixia™), Olpadronate,
Pamidronate (APD/Aredia™), Risedronate (Actonel™), or Zoledronate (Zometa™ /Aclasta™).
4. A method of inducing expression of HIV viral antigens in latently HIV-infected cells in a subject which comprises administering to the subject a bisphosphonate so as to reverse latency and induce expression of the HIV viral antigens in the cells in the subject.
5. The method of claim 4, wherein the latently infected cells are rCD4 cells.
6. The method of claim 4, wherein the subject is receiving antiretroviral therapy (ART).
7. A method to boost gd T cell expression and reverse viral latency in a subject infected with HIV which comprises administering to the subject a bisphosphonate.
8. The method of claim 7, wherein the subject is receiving antiretroviral therapy (ART).
9. The use of an aminobisphosphonate as a latency reducing agent.
10. The use of claim 9, wherein the aminobisphosphonate is Alendronate (Fosamax™), Ibandronate (Boniva™ or Bonviva™), Neridronate (Nerixia™), Olpadronate,
Pamidronate (APD/Aredia™), Risedronate (Actonel™), or Zoledronate (Zometa™ /Aclasta™).
11. A method for eliminating latently infected cells harboring quiescent HIV pro virus that comprises exposing the infected cells to gd T cells and a bisphosphonate.
12. The method of claim 11, further comprising exposing latently infected cells to a second HIV latency reversing agent.
13. The method of claim 12, wherein the second HIV latency reversing agent is an epigenetic modifier, an NFkB agonist, a PI3K/Akt pathway inhibitor, a protein kinase C agonist, a SMAC (second mitochondria-derived activator of caspases) mimetic, a TCR activator, a TLR agonist, an inhibitor of IAP (Inhibitor of Apoptosis Protein) family of proteins, or a stimulator of interferon genes protein (STING) agonist.
14. The method of claim 13, wherein the epigenetic modifier is a histone deacetylase
(HD AC) inhibitor.
15. A method of treating/curing a subject infected with HIV which comprises administering to the subject ex vivo expanded gd T cells and a bisphosphonate.
16. The method of claim 15, further comprising administering to the subject a second HIV latency reversing agent.
17. The method of claim 16, wherein the second HIV latency reversing agent is an epigenetic modifier, an NFkB agonist, a PI3K/Akt pathway inhibitor, a protein kinase C agonist, a SMAC (second mitochondria-derived activator of caspases) mimetic, a TCR activator, a TLR agonist, an inhibitor of IAP (Inhibitor of Apoptosis Protein) family of proteins, or a stimulator of interferon genes protein (STING) agonist.
18. The method of claim 17, wherein the epigenetic modifier is histone deacetylase (HD AC) inhibitor.
19. The method of claim 15, wherein the expanded gd T cells and the bisphosphonate are administered concurrently.
20. The method of claim 15, wherein the expanded gd T cells and the bisphosphonate are administered sequentially.
21. The method of claim 20, wherein the expanded gd T cells and the bisphosphonate are administered over a 24 hour period.
22. The method of claim 15, wherein the ex vivo expanded gd T cells are V51 T-cells.
23. The method of claim 15, wherein the ex vivo expanded gd T cells are nd2 T-cells.
24. The method of claim 15, wherein the ex vivo expanded gd T cells are autologous cells.
25. The method of claim 15, wherein the ex vivo expanded gd T cells are heterologous cells.
26. The method of claim 15, wherein the bisphosphonate is Alendronate (Fosamax™), Ibandronate (Boniva™ or Bonviva™), Neridronate (Nerixia™), Olpadronate,
Pamidronate (APD/Aredia™), Risedronate (Actonel™), or Zoledronate (Zometa™ /Aclasta™).
27. The method of claim 18, wherein the HDAC inhibitor is belinostat (PXD101), entinostat (MS-275), mocetinostat (MGCD0103), panobinostat (LBH589), or vorinostat (SAHA).
28. A method of treating HIV infection in a subject, comprising:
(a) isolating peripheral blood mononuclear (PBMC) cells from the subject;
(b) culturing the isolated PBMC cells ex vivo with an effective amount of a
bisphosphonate or antibodies and suitable cytokines so as to expand gd T cells;
(c) or optionally genetically modifying the expanded gd T cells;
(d) infusing the expanded gd T cells into the subject; and
(e) administering to the subject a bisphosphonate so as to activate quiescent HIV provirus and treat the subject with HIV.
29. The method of claim 28, further comprising administering to the subject in step (e) a second HIV latency reversing agent.
30. The method of claim 29, wherein the second HIV latency reversing agent is an epigenetic modifier, an NFkB agonist, a PI3K/Akt pathway inhibitor, a protein kinase C agonist, a TCR activator, a TLR agonist, an inhibitor of LAP (Inhibitor of Apoptosis Protein) family of proteins, or a stimulator of interferon genes protein (STING) agonist.
31. The method of claim 30, wherein the epigenetic modifier is a histone deacetylase
(HDAC) inhibitor.
32. The method of claim 28, wherein the subject was receiving antiretroviral therapy (ART).
33. The method of claim 28, wherein the PBMCs are expanded in the presence of the
bisphosphonate for 5 to 30 days.
34. The method of claim 33, wherein the PBMCs are expanded for 7 to 21 days.
35. The method of claim 28, wherein the expanded gd T cells and the bisphosphonate are administered concurrently.
36. The method of claim 28, wherein the expanded gd T cells and the bisphosphonate are administered sequentially.
37. The method of claim 28, wherein the bisphosphonate is Alendronate (Fosamax™),
Ibandronate (Boniva™ or Bonviva™), Neridronate (Nerixia™), Olpadronate,
Pamidronate (APD/Aredia™), Risedronate (Actonel™), or Zoledronate (Zometa™ /Aclasta™).
38. The method of claim 31, wherein the HDAC inhibitor is belinostat (PXD101), entinostat (MS-275), mocetinostat (MGCD0103), panobinostat (LBH589), or vorinostat (SAHA).
39. A pharmaceutical composition comprising a bisphosphonate and a second HIV latency reversing agent.
40. The pharmaceutical composition of claim 39, wherein the second HIV latency reversing agent is an epigenetic modifier, an NFkB agonist, a PI3K/Akt pathway inhibitor, a protein kinase C agonist, a TCR activator, a TLR agonist, an inhibitor of IAP (Inhibitor of Apoptosis Protein) family of proteins, or a stimulator of interferon genes protein (STING) agonist.
41. The pharmaceutical composition of claim 40, wherein the epigenetic modifier is a histone deacetylase (HDAC) inhibitor.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862687936P | 2018-06-21 | 2018-06-21 | |
US62/687,936 | 2018-06-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019246520A1 true WO2019246520A1 (en) | 2019-12-26 |
Family
ID=68984315
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2019/038469 WO2019246520A1 (en) | 2018-06-21 | 2019-06-21 | Aminobisphosphonates as latency reversing agents and combination treatments for hiv cure |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2019246520A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4132535A4 (en) * | 2020-04-06 | 2024-04-24 | Duke University | Compositions and methods for the treatment of infection-induced cardiomyopathy |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017007712A1 (en) * | 2015-07-04 | 2017-01-12 | Emory University | Use of trem-1 inhibitors for treatment, elimination and eradication of hiv-1 infection |
-
2019
- 2019-06-21 WO PCT/US2019/038469 patent/WO2019246520A1/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017007712A1 (en) * | 2015-07-04 | 2017-01-12 | Emory University | Use of trem-1 inhibitors for treatment, elimination and eradication of hiv-1 infection |
Non-Patent Citations (2)
Title |
---|
MARGOLIS DAVID M. ET AL.: "Latency reversal and viral clearance to cure HIV-1", SCIENCE, vol. 353, no. 6297, 2016, pages 1 - 17, XP055667286 * |
POCCIA FABRIZIO ET AL.: "Zoledronic acid and interleukin-2 treatment improves immunocompetence in HIV-infected persons by activating Vy9V52 T cells", AIDS, vol. 23, 2009, pages 555 - 565 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4132535A4 (en) * | 2020-04-06 | 2024-04-24 | Duke University | Compositions and methods for the treatment of infection-induced cardiomyopathy |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Goronzy et al. | Mechanisms underlying T cell ageing | |
Shu et al. | Epigenetic variability of CD4+ CD25+ Tregs contributes to the pathogenesis of autoimmune diseases | |
Bhutia et al. | Interferon-γ induces a tryptophan-selective amino acid transporter in human colonic epithelial cells and mouse dendritic cells | |
JP2016041744A (en) | INHIBITORS OF mTOR KINASE USED AS ANTI-VIRAL AGENTS | |
Schnekenburger et al. | Epigenetic alterations as a universal feature of cancer hallmarks and a promising target for personalized treatments | |
JP2014505076A (en) | Inhibitors of mTOR kinase as antiviral agents | |
WO2020028686A1 (en) | Targeting piezo1 for treatment of cancer and infectious diseases | |
WO2021142230A1 (en) | Methods to alter latency in ebv+ malignancies | |
van Duijn et al. | CD39 identifies a microenvironment-specific anti-inflammatory CD8+ T-cell population in atherosclerotic lesions | |
Samer et al. | Nicotinamide activates latent HIV-1 ex vivo in ART suppressed individuals, revealing higher potency than the association of two methyltransferase inhibitors, chaetocin and BIX01294 | |
Mangal et al. | Immunometabolism: an emerging target for immunotherapies to treat rheumatoid arthritis | |
WO2019246520A1 (en) | Aminobisphosphonates as latency reversing agents and combination treatments for hiv cure | |
Kell et al. | The central role of DNA damage in immunosenescence | |
US20170319619A1 (en) | Immunosuppressive blood cells and methods of producing the same | |
KR20140069271A (en) | Combination therapy for chemoresistant cancers | |
US20190218614A1 (en) | Clonal hematopoiesis and cytokine targets | |
US20220370509A1 (en) | Compositions and methods for treating or preventing crohn's disease | |
EP3492086A1 (en) | Use of epigenetic inhibitor 1-(beta-d-ribofuranosyl)-2(1h)-pyrimidinone (zebularine) for promoting wound healing, complex tissue and organ regeneration | |
JP4417273B2 (en) | Sperm activator and sperm deactivator | |
JP2023515010A (en) | miRNA-193a to promote immunogenic cell death | |
US20190269705A1 (en) | Methods and materials for treating graft versus host disease | |
EP3235511B1 (en) | Sulphonamide compounds for use in the treatment of hhv-8-associated diseases | |
Pervizaj-Oruqaj et al. | Viral Pneumonia Elicits a Lung Epithelial Repair Program in Transdifferentiating Alveolar Macrophages Characterized by Placenta-Expressed Transcript 1 (Plet1) Expression: Therapeutic Implications | |
WO2023049798A1 (en) | Hdac3 inhibitors for the treatment of langerhans cell histiocytosis and langerhans cell sarcoma | |
Shah et al. | STEM-07. DEFINING THE ROLE OF HUMAN ENDOGENOUS RETROVIRUS-K (HML-2) IN THE GLIOBLASTOMA STEM-CELL NICHE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19821732 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 19821732 Country of ref document: EP Kind code of ref document: A1 |